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The focus of this thesis is to assess the ability of an IgE-isotype tumour-specific 
antibody, MOO 8 IgE, to trigger cytotoxic immune responses against tumour cells. Currently, 
all tumour-specific antibodies approved by the FDA for treatment of cancer in patients, 
belong to IgG1 or IgG2 subclasses. It is proposed that IgE may be more effective than IgG in 
vivo, its potential having previously been underestimated due to poor performances in in vitro 
cytotoxicity assays. Results presented in this thesis suggest that IgE does in fact trigger 
effective immune responses against tumour cells both in vitro and in vivo. In vitro data has 
been obtained using a novel flow cytometric cytotoxicity / phagocytosis assay, the set-up of 
which is described. In vivo data has been obtained using a nude mouse xenograft model of 
ovarian cancer. The set-up of two new in vivo models is also described. These will be used 
to test efficacy and safety of IgE immunotherapy of cancer. 
The proposed in vivo efficacy of tumour-specific IgE antibodies is based largely on 
the location of IgE-receptor-expressing cells in the body and the extremely high affinity of the 
interaction between IgE and its receptor FcFRI, of - 1010 M-1. This high affinity interaction 
results in a binding half-life of IgE to FcFRI on mast cells in tissues in the order of weeks, 
compared to days for IgG. In allergic individuals, the effect of this tenacious retention of 
allergen-specific IgE on mast cells is a state of persistent hypersensitisation against allergen 
challenge. The IgE-FcFRI interaction is therefore a valid therapeutic target for blocking 
agents in allergy, a task made almost impossible however, by the large surface area of the 
interaction. The final aim of this thesis was to determine whether reducing the affinity of IgE 
binding to FcF_RI could have biological effects in vivo. The result was that a reduction in IgE- 
FcF_RI affinity of as little as 33-fold significantly reduced the intensity of passive cutaneous 
anaphylaxis in vivo. This result has major therapeutic implications for allergy. 
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Chapter 1: Introduction 
Work described in this Thesis has been performed as part of a novel, ongoing study 
into the proposal that tumour-specific antibodies of the IgE isotype could be used to initiate a 
powerful immune response towards turnour cells in cancer patients. The immune response 
triggered by IgE is most commonly encountered in the form of a futile, allergic response 
towards innocuous allergens, although it is also known to offer protection from parasite 
infection. For many years it has been clear that the interaction between IgE and one of its 
receptors, FcFRI, is of extremely high affinity (Metzger, 1986). As discussed below, this high 
affinity interaction confers on IgE the ability to bind FcERI tenaciously; this enables FcERl- 
expressing mast cells in tissues and basophils in blood to respond immediately to a specific 
multivalent allergen (or cell-bound turnour antigen) challenge. Results of experiments 
described in this Thesis suggest that the high affinity of this interaction may also make a more 
direct contribution to the intensity of the cellular response, triggered by antigen-induced 
FcF_RI cross-linking, as I have found a relationship between the affinity with which IgE binds 
FccRI and the intensity of the subsequent cellular response. To aid discussion of these 
experiments, I have introduced the IgE-system, cancer, and the immunotherapeutic treatment 
of cancer with monoclonal antibodies. To highlight the challenge faced by anti-cancer 
antibodies in their role as tools for manipulating the immune system to kill tumour cells, I 
also discuss the nature of the complex relationship that exists between cancer cells and the 
immune system. 
1.1 Cancer, 
It is very desirable that new approaches to cancer therapy be rapidly explored, as 
statistics provided by Cancer Research UK show that cancer causes more than one quarter of 
all deaths in the UK population (http: //www. statistics. gov. uk). For men, cancers of the lung, 
prostate, colon and oesophagus are the four main causes, and for women, it is lung, breast, 
bowel and ovary. 
1.1.1 The relationship between cancer and the immune svstem 
It is a slow process by which a normal cell transforms into a malignant one, 
potentially taking many years. A transformed cell may arise from a small population of 
rapidly dividing, genetically unstable cells, through the acquisition of mutation(s) that prevent 
it from being eliminated by the immune system (Hanahan and Weinberg, 2000). The 
immune-resistant nature of this tumour cell leaves it free to develop into a mass of tumour 
cells until its increasing size dictates that nutritional and oxygen supplies be increased or 
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causes damage to surrounding normal host tissue; these are stress signals which initiate an 
innate, followed by an adaptive, immune response (Dunn et al., 2002). This immune 
response may be unproductive for one of two reasons, despite, in some cases, expression of a 
unique tumour antigen. Firstly, a tumour may have already 'tolerised' T cells towards it; as 
tumour cells are essentially 'self, they do not send out distress signals or microbial immune- 
recognition patterns normally used by the immune system to recognise 'danger' (Matzinger, 
1998). In this way, tumour cells avoid stimulating expression of co-stimulatory signals on 
either themselves, or local professional antigen-presenting cells (Janeway et al., 4h edition). 
Co-stimulation is necessary to prevent T cell anergy or tolerance induction occurring upon 
interaction of a specific T cell receptor with tumour-antigen in the context of MHC. 
Alternatively, a tumour may be able to actively evade an immune response mediated towards 
it by one of a number of methods, discussed below. The immune system, therefore, 
inadvertently acts to select tumour cells with immune-resistant phenotypes. For a review of 
the process by which tumours develop under immunological pressure, see Dunn et al., 2002. 
Mechanisms used by turnour cells to avoid immune elimination (in addition to those 
used by normal host cells to avoid autoimmune attack) include methods for 'hiding' from, or 
actively manipulating immune responses. Examples include the loss or down-regulation of 
MHC class I antigens, in combination with mechanisms to inhibit NK cell function, loss of 
turnour antigen expression or the expression of defective death receptors. Alternatively, a 
tumour may secrete immunosuppressive cytokines that negatively affect maturation and 
function of immune cells, or induce apoptosis in tumour-specific activated T cells (for a 
review see Khong et al., 2002). The outcome of an unproductive anti-tumour immune 
response is often a tumour infiltrated with many components of an immune response, with 
which it has a dynamic relationship, as discussed below. 
1.1.2 Tumour-infiltratinR leukocytes 
A dominant tumour-infiltrating cell type is the macrophage. The relationship 
between tumour cells and tumour-associated macrophages JAMs) has recently been 
reviewed by Pollard, 2004; earlier reviews have been made by Mantovani et al., 1986 and 
1992, and by Bingle et al., 2002. Most TAMs are derived from peripheral blood monocytes, 
recruited from the circulation, although there is evidence for local macrophage proliferation 
(McBride, 1986). Paradoxically, although monocyte recruitment is mediated by the host as 
part of an anti-tumour immune response, it is also mediated by the tumour itself. Signals for 
monocyte recruitment include monocyte chernotactic protein-I (MCP-1) and macrophage 
colony stimulating factor (M-CSF) (Pollard, 2004; Mantovani et al., 1992). Other cell-types 
found infiltrating tumours include mast cells, eosinophils and neutrophils; these cell types 
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accumulate in response to both tumour- and TAM-derived chemoattractants, and are 
discussed below. 
In the majority of cases, macrophage infiltration is associated with poor prognosis. 
This highlights the success of the turnour in suppression of anti-turnour macrophage, 
functions. A tumour may create an immunosuppressive environment through secretion of IL- 
10 and TGF-pl. In addition, secretion of soluble CSF-I and IL-6 may occur; these cytokines 
can act together to block the maturation of TAMs into antigen-presenting dendritic cells 
(Pollard, 2004). Moreover, turnours may actually 'educate' TAMs to perform roles 
supportive in tumour growth and progression. For example, the release of stress-signals by 
turnour cells, e. g., hypoxia-inducible factor-2o: (HIF-2(x), has been shown to stimulate TAMs 
to 'help' the tumour, as they might help normal cells in distress. The HIF-(x2 signal triggers 
production of a wide variety of growth factors including those that aid directly in tumour 
growth, e. g., epidermal growth factor (EGF), and those which act indirectly, e. g., vascular 
endothelial growth factor (VEGF). VEGF enables angiogenesis to occur, allowing the tumour 
to satisfy its increased requirements for nutrients and oxygen, and thus increase in size 
(Pollard, 2004). An increase in tumour vasculature also facilitates the escape of metastatic 
cells. 
Turnour-associated eosinophilia has also been associated with both turnour- 
protective (Goldsmith et al., 1987; Kapp et al., 1983; Lowe et al., 1984a; Lowe et al., 1984b; 
Pretlow et al., 1983) and tumour-promoting (Chang et al., 1993; Elovic et al., 1990; Horiuchi 
et al., 1993; Wong et al., 1990) functions. The role of these tumour-infiltrating eosinophils is 
not fully understood, nor is the role of those eosinophils found infiltrating sites of allergic 
challenge or helminthic infections; it is clear, however, that eosinophils are highly cytotoxic 
and able to mediate significant host cell damage in all three disease states (Weller, 1991). In 
a number of animal models, it has been possible to manipulate eosinophils for tumour cell 
destruction: Tepper et al., 1989 and 1992, found tumour cells transfected to secrete IL-4 were 
significantly less turnourigenic than untransfected turnour cells, and the anti-turnour immune 
response was dependent upon the recruitment and infiltration of eosinophils. Perhaps also by 
an IL-4-dependent mechanism, Reali et al., 2001, showed that the specific targeting of 
turnours with IgE led to tumour rejection by a mechanism involving eosinophils. 
interestingly, a study involving subcutaneous treatment of small-cell lung carcinoma patients 
with recombinant human IL-2 resulted in marked peripheral eosinophilia (Rivoltini et al., 
1993); when purified, these eosinophils were shown to mediate significant IgGI-dependent 
tumour-cell death in an in vitro chromium-release assay. In contrast, eosinophils purified 
from the same patients before IL-2-therapy showed no significant IgGI-dependent tumour 
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cell killing. These results implicate eosinophils in the mechanism behind the survival 
advantage conferred by IL-2 therapy. 
Like macrophages and eosinophils, turnour-infiltrating mast cells have both positive 
and negative effects on tumour growth. Although classical mast cell degranulation as occurs 
in allergic disease might be detrimental to tumour growth, turnour-associated mast cells 
appear to have the capacity to 'selectively' degranulate. Selective degranulation may involve 
the release of mediators which aid in tumour growth (e. g., VEGF), and retention of those 
detrimental to tumour growth (e. g., IL-4) (a phenomenon reviewed in Theoharides and Conti, 
2004). 
1.2 Monoclonal antibodv theram for cancer 
1.2.1 The structure and function of antibodies 
Antibodies are one of three classes of specific antigen-recognition molecules in the 
immune system; the other two being the T cell receptor and the class I and 11 molecules of the 
major histocompatability complex (MHQ. Antibodies are produced by B cells; they may be 
tethered in B cell membrane where they act as the B cell receptor, or secreted by terminally 
differentiated B cells, termed plasma cells. A monomeric antibody is composed of two 
identical heavy chains, and two identical light chains. The heavy chains may be one of five 
different isotypes or subclasses therein, IgD, IgM, IgGl, IgG2, IgG3, IgG4, IgAl, IgA2, or 
IgE. The light chains may be either kappa or lambda class. The variable regions of each pair 
of heavy (VH) and light (VL) chains constitute the two identical antigen-binding sites. Each 
pair Of VH and VL, together with their adjacent CHI and CL domains constitute one of two Fab 
(Fragment antigen binding) regions of the antibody, which may be cleaved from the whole 
structure by papain digestion, or as one F(ab')2 unit by pepsin digestion. The remaining 
heavy chain constant domain pairs (CH2-CH3 for IgD, IgA and IgG or CH2-CH4 for IgE and 
IgM) constitute the Fc region (Fragment crystallisable). Heavy and light chains are cross- 
linked and stabilised by interchain disulphide bonds and non-covalent interactions. The five 
different antibody isotypes are shown schematically in Figure 1.1. 
As mentioned above, antigen binds within the cleft between the variable regions of 
each pair of heavy and light chains. The exquisite specificity of this region is determined by 
the amino acid sequence of three discrete, hypervariable, antigen-binding regions, termed 
complementarity-determining regions (CDRs) in each VH and VL region. The sequence of the 
CDRs, and thus their antigen specificity, is determined during lymphocyte development by a 
complex process of gene rearrangement. However, during an immune response, by the 
process of somatic hypermutation, a dividing B cell will produce progeny with mutations in 
these CDRs, some of which will confer the antibody with enhanced affinity binding to its 
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antigen. The amino acid sequence found between the CDRs provides the structural 
framework of the variable domains. Details of the development, structure and function of 
antibodies in the immune system can be found in Chapter 9 of Janeway et al., 4h Edition. 
IgG IgE 
Fab 









Figure LI: Schematic representation of the five different antibody isotypes found in the 
human body. Each Fab region contains three complementarity-determining regions that 
determine the antigen specificity of that antibody. The Fc region of each antibody mediates 
effector functions; one mechanism of Fc-mediated effector function is through binding to 
isotype-specific Fic receptors. The class of Fc-receptor to which an antibody binds, 
determines the cellular effector mechanisms available to that antibody isotype. 
An antibody is able to act in conjunction with cellular effectors by binding via its Fc- 
region to an isotype-specific Fc receptor expressed by the effector cell. Each antibody isotype 
binds to one or more specific Fe receptors. Each class of Fc receptor has a specific cellular 
expression profile and displays characteristic binding affinity for specific antibody. 
Classically, it is through the cross-linking and aggregation of two or more Fc receptors by 
specific antibody-antigen immune complexes that an Fc-receptor expressing cell becomes 
activated (Metzger, 1992). The signalling response initiated by receptor aggregation may 
trigger stimulatory or inhibitory responses depending on the nature of the signalling pathways ZI 
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with which an Fc receptor is linked. Although the final cellular response mediated by Fc 
receptor aggregation with specific antibody-antigen complexes will depend upon the cell type, 
effector functions may include ADCC, phagocytosis, endocytosis, release of inflammatory 
cytokines or other inflammatory mediators, and antigen presentation. Therefore, the isotype 
of an antibody dictates which Fc-mediated effector functions are harnessed. Table 1.1 details 
the properties of the Fc receptors to which IgG and IgE isotype antibodies bind. Table 1.1 
also indicates the relative affinities with which the different IgG subclasses bind Fcy- 
receptors. Antibodies of the IgG or IgM isotypes are also able to mediate effector functions 
by activating the classical pathway of complement; this is dependent upon the involvement of 
complement receptor-expressing phagocytes. 
Receptor Isoforin Specificity Affinity for Distribution on primary cell types 
monomeric 
antibody (M-') 
FcF-RI IgE 1010 )0. Mast cells, basophils, 
Langerhans cells, monocytes, 
eosinophils 
CD23 CD23a IgE 107 B-cells 
CD23b IgE 107 T cells, macrophages, NK 
cells, FDCs, IL-4 stimulated B 
cells and monocytes 
FcyRl IgGI =3>4 - 
101-109 Monocytes, macrophages and 
IFN-y-stimulated neutrophils 
and eosinophils 
Fc7Rll FcyRlla IgG I>I=2 < 101 Monocytes, macrophages, 
(stimulatory) neutrophils, Langerhans cells 
(eosinophils? ) 
FcyR f Ib IgGI >1 >2 >4 Monocytes, macrophages and 
(inhibitory) B cells (eosinophils? ) 
Fc'yRlll FcyRllla I=3>2=4 106 Macrophages, NK cells, 
(stimulatory) monocytes,, y8 T cells 
Table 1.1: Details of IgE and IgG Fc receptors. This table is adapted from Woof et al., 2004. 
Antibody affinities are taken from Ravetch and Kinet, 1991 and were determined using cell 
binding assays. 
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1.2.2 Back2round to monoclonal antibodv theravy for cancer 
In 1975, a letter written by K6hler and Milstein was published in Nature, reporting 
the technical feasibility of producing continuous cell lines from mice, expressing mouse 
antibodies of a single, chosen specificity. The advent of this hybridoma technology made real 
the possibility of generating large amounts of monoclonal tumour-specific antibody that could 
be used as a tool for the passive induction of a highly specific, anti-tumour immune response. 
This potential for highly selective tumour cell killing was a great advance on the 
indiscriminate cell killing of chemotherapy and radiotherapy. Since K6hler and Milstein's 
publication in 1975, many more technical barriers have been overcome and these mouse 
antibodies have been replaced by chimaeric or 'humanised' tumour-specific antibodies, to 
minimise the immunogenicity of therapeutic mouse antibodies in humans (the implications of 
which are discussed below, in section 1.2.4). Chimaeric antibodies are composed of human 
constant regions and murine variable regions, whereas a 'humanised' antibody is almost 
entirely human with only the CDRs of murine origin. 
Those anti-cancer antibodies that have been approved by the FDA for the treatment of 
cancer in humans are shown in Table 1.2; these antibodies can be divided into two broad 
categories. The first group includes those which rely on the manipulation of natural immune 
responses and or interference of tumour-antigen signalling pathways for their anti-tumour 
activity. The second group includes those which use the antibody as a vector for highly 
specific delivery of a toxic modality, to tumour cells. The potential mechanism by which an 
anti-cancer antibody of the former group may harness natural immune responses for tumour- 
cell killing, are discussed in section 1.2.3. Two important determinants of their success in 
immune manipulation are highlighted as being the nature of the tumour target antigen and the 
isotype of the antibody. However, the most effective isotype and specificity of an antibody 
reliant on immune manipulation for its activity may be quite different from those of a toxin- 
conjugate. For example, although a tumour-antigen that is intemalised might make an 
inappropriate target for an antibody attempting to cross-link the antigen-expressing tumour 
cell with a cytotoxic effector cell, this same antigen may be successfully manipulated for 
internalisation of a toxin-conjugate. Similarly, where an antibody of the IgGI isotype may 
effectively recruit cytotoxic effector cells by its high affinity binding to Fc receptors on these 
cell types, a toxin-conjugate of the same isotype may result in unwanted killing of these 
FcyR-expressing cells. 
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Antibody Isotype Nature Target Treatment for 
Name 
I 
Rituximab IgG I Chimaeric CD20 Non-Hodgkin's lymphorna 
Trastuzumab IgG I Humanised Her-2/neu Metastatic breast cancer 
Campath- IH IgG I Humanised CD52 Chronic lymphocytic leukaernia 
Cetuximab IgG I Chimaeric EGFR Metastatic colorectal carcinoma 
Gemtuzumab IgG4 Humanised toxin CD33 Relapsed acute myeloid 
leukaemia 
conjugate 
Tositumomab lgG2a Mouse CD20 Rituximab-failed, Non- 
Hodgkin's lymphoma 
radionuclide conjugate 
lbfitumomab IgGl Mouse CD20 Rituximab-failed, Non- 
Hodgkin's lymphoma 
tiuxetan radionuclide conjugate 
I 
Table 1.2: FDA-approved anti-cancer antibodies which directly target antigens expressed by 
tumour cells. The top four antibodies in this table are described in section 1.2.2 as belonging 
to 'group F and the remaining, lower three antibodies, as belonging to 'group 2'. This table 
combines data found in Glennie and van de Winkel, 2003, and Segota and Bukowski, 2004. 
1.2.3 Mode of anti-cancer antibody action: Influence of target antiRen and antibody isotype 
The original vision for anticancer antibodies was that they should be used as a precise 
way of exposing tumour cells to the immune system for killing. It was proposed that, 
following opsonisation, tumour cell killing would occur by Fc-mediated activation of 
complement pathways or recruitment of cytotoxic effector cells, as represented 
diagrammatically in Figures 1.2A and B, below. Although dependence on Fc-mediated 
tumour-cell killing mechanisms has been shown (Clynes et al., 1998), it was later realised that 
significant tumour cell death can be mediated independently of the antibody Fc region (Tutt et 
al., 1998), depending on the nature of the target antigen. Potential mechanisms by which an 
anti-cancer antibody may kill tumour cells independently of its Fc portion are shown 
diagrammatically in Figure 1.2C. These include, blocking the uptake of a vital growth factor 
in the case of growth factor receptor target antigens, or direct interference with cellular 
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signalling pathways to induce apoptosis or prevent proliferation. Anti-cancer antibodies that 
mediate a significant proportion of their function through Fc-independent mechanisms include 
Trastuzumab, Rituximab and anti-idiotype antibodies. Cross-linking of the target antigen of 
each of these antibodies, Her-2/neu, CD20 and the idiotype of the B cell receptor respectively, 
results in the generation of intracellular signals that negatively influence the survival of the 
cell (reviewed in Cragg and Glennie, 1999). Trastuzumab binding to Her-2/neu also leads to 
the blocking and down regulation of this receptor, preventing EGF uptake, which is critical 
for cell survival. 
Adding further weight to the importance of target antigen choice is the impact its 
properties have on the efficacy of Fc-mediated killing mechanisms. A high density of target 
antigen expression, and a high affinity of F(ab')2 binding to target antigen, have been shown 
to correlate with effective ADCC (Xia et al., 1993; Coney et al., 1994). The valency of a 
tumour antigen and whether or not it is internalised or shed will also impact on an antibody's 
efficacy; whether or not these factors impact positively or negatively may depend upon the 
properties of the antibody (e. g., its isotype and whether its functioning is dependent upon 
recruitment of natural immune effector mechanisms or the action of a conjugated toxic 
modality). The anatomical location of the tumour may also influence the type of immune 
response triggered, bearing in mind the selective distribution of the different antibody 
isotypes in the body (Janeway et al., 4th edition). 
The other critical determinant of anti-cancer antibody efficacy is its isotype. As 
discussed above, an antibody may be one of five different isotypes found in the human body, 
or subclasses therein, with each different isotype mediating a unique immune response. 
Rituximab, Trastuzumab, CAMPATH-IH and Cetuximab are all chimaeric IgGI antibodies 
(see Table 1.2). The dominance of the IgGI isotype among FDA-approved antibodies can be 
explained by the original theory that the mechanism of anti-cancer antibody action was 
dependent on recruitment of cellular effector mechanisms and complement activation. This 
theory was based on in vitro studies, which showed mouse IgG2a and rat IgG2b to be the 
most effective subclasses in mediating ADCC of turnour cell targets in vitro (Herlyn and 
Koprowski, 1982; Seto et al., 1983; Denkers et al., 1985; Hale et al., 1985 and Kaminski et 
al., 1986). These in vitro studies showing the efficacy of rat IgG2b, were supported by in 
vivo models (Dyer et al., 1989). Chimaeric or humanised IgGI antibodies were therefore 
chosen on the basis of their known ability to recruit cellular effectors, through their high 
affinity for FcyR expressed by cytotoxic effector cells (see Table 1.1). IgGl was 
subsequently shown to be the most effective IgG subclass in mediating ADCC of tumour cells 
by human effector cells by in vitro ADCC assays with human peripheral blood mononuclear 
cells (PBMC) as effectors (Steplewski et al., 1988). 
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Figure 1.2: Potential mechanisms by which a tumour-specific antibody may mediate tumour- 
cell death. In each case the tumour-specific antibody binds a turnour-associated antigen via 
its F(ab')2 regions. (A) The Fc regions interacts specifically with Fc receptors expressed by 
cytotoxic effector cells, such as NK cells or monocytes, to mediate ADCC of the tumour cell 
target. (B) Where an anti-tumour antibody is of the IgG or IgM isotype, the Fc region may 
activate the classical pathway of complement for tumour cell killing, or bind to complement- 
receptor expressing effector cells (such as macrophages) to mediate phagocytosis. (C) 
Depending on the nature of the tumour antigen, cross-linking of tumour antigens by F(ab')2 
regions may interfere with normal cell signalling to induce apoptosis, slow or stop cell growth 
or proliferation. Signalling through tumour antigen may be enhanced by cross-linking of 
antibody Fc regions, using a Fc-receptor-expressing cell as a multivalent platform upon which 
to cross-link. 
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1.2.4 Improving the clinical efficacy of anfi-cancer antibodies 
The early clinical trials with monoclonal antibodies were less successful than was 
hoped. The main problems were associated with the immunogenicity of mouse 
immunoglobulins in humans; this reduced their efficacy and prevented their repeated 
administration. The consequences of human anti-mouse immune responses (HAMA) are 
reviewed by Merluzzi et al., 2000. However, as mentioned in section 1.2.2, there have been 
developments in genetic engineering which have enabled this problem to be overcome. 
Murine antibody constant regions are now replaced with the equivalent human counterparts to 
make a human-mouse chimaeric antibody, or, all but the CDR regions are replaced by their 
human counterparts to make a 'humanised' antibody. It is now even possible to make a 
completely human tumour-specific antibody by phage display (Winter et al., 1994), or 
classical hybridoma. techniques that use transgenic mice containing human instead of the 
endogenous mouse genes (BrUggemann and Neuberger, 1996). In addition to their reduced 
immunogenicity, chimaeric and humanised. antibodies have an increased half-life in the 
circulation from the 1-2 days seen for mouse antibodies in humans, to the 2-3 weeks expected 
of human antibodies. This in turn, has increased their effective therapeutic dose, reducing the 
frequency and level of dosing required. Furthermore, as human antibody Fc regions interact 
more effectively than rodent antibodies with the natural defences of the human body (Winter 
and Milstein, 1991), a more effective immune response can be mediated. 
Once the problems associated with the use of mouse antibodies in humans were 
solved by chimerisation or humanisation, another problem became apparent; that is, the 
relatively poor penetration of these large immunoglobulin molecules into solid turnours 
(Carter, 2001). This is reflected in the fact that those anti-cancer antibodies that have been 
approved by the FDA are most successful in the treatment of turnouts of haernatopoietic 
origin, where such penetrative capacity is not required. One method of assisting antibody 
penetration into solid turnours is to remove the constant regions of an antibody, to make 
F(ab')2, Fab or single chain antibody variable region (scFv) fragments (Hudson and Souriau, 
2003). However, many benefits are lost by removing the Fc portion of an antibody. These 
include, a lower affinity for target antigen, a shorter half-life and a restriction in the range of 
effector functions that antibody is able to mediate; these fragments are therefore reliant on the 
tumour-target antigen being involved in a signalling pathway, which, when disrupted, 
negatively affects cell viability or proliferation. 
The efficacy of IgGI in the treatment of cancers of haernatopietic origin is in 
accordance with the known role of this antibody class in immunosurveillance and mediation 
of effector functions in the circulation. Indeed, each antibody isotype possesses unique 
properties that allow it to act more effectively at particular anatomical locations. For 
Chapter I 25 
example, IgA mediates its effector functions in mucosal secretions, which it is able to 
effectively penetrate by interaction of its dimeric IgA-J-chain complex with secretory 
component receptor on epithelial cells (Janeway et al., 4h edition). In contrast, IgE mediates 
its effector functions predominantly in solid tissues, which relates to the presence of Fcrr-Rl- 
expressing mast cells in this location, and the high affinity of IgE for FcF_RI; the reported role 
of CD23 in IgE transport may facilitate the entry of IgE into tissues, and this is discussed in 
more detail in section 1.4. Therefore, it may be that the isotype of tumour-specific antibody 
able to trigger the most effective anti-tumour immune response will vary according to the 
anatomical location of the tumour. Another factor likely to play an important role in the in 
vivo efficacy of anti-cancer antibodies, which was not directly assessed in the original 
experiments leading to the selection of the IgGI isotype, is the affinity of an antibody for its 
Fc receptor(s); this will dictate the half-life for which the antibody remains bound to its 
receptor(s) on effector cells in serum and tissue. Clearly, the efficacy of an anti-cancer 
antibody depends upon a multiplicity of properties deterinined by the target antigen, antibody 
isotype, anatomical location of the tumour, and the immune context of the interaction between 
effector and target cells. 
1.2.5 IgE isotype anti-cancer antibodies? 
IgE has the capacity to trigger a powerful cell mediated immune response involving a 
range of cytotoxic effector cell types which occurs most obviously towards innocuous 
allergens (Gould et al., 2003). Despite the well-recognised role of IgE in triggering such a 
powerful cell-mediated immune response, this isotype has rarely been included in 
comparisons of different isotypes of tumour-specific antibodies, in mediating specific target 
cell death. Where IgE has been included, it has performed less well than other isotypes in in 
vitro ADCC assays (BrUggemann et al., 1987; Gould et al., 1999). This poor performance of 
IgE in vitro, where the effector cell populations were PBMCs (and thus primarily 
lymphocytes and monocytes), most likely reflects the relatively low number of IgE-receptor- 
expressing effector cells in the circulation and the fact that, in the PBMC donors, who are 
frequently allergic and have high IgE levels, the IgE receptors expressed by the cells are 
already occupied with endogenous allergen-specific IgE (Karagiannis et al., 2003). It has 
been proposed that this naturally tissue-based IgE-mediated immune response might be 
manipulated for the killing of tumours of solid tissues in patients (Gould et al., 1999; Reali et 
al., 2001; Karagiannis et al., 2003). This is a particularly important area of cancer therapy to 
target, as the majority of human cancers are carcinomas arising from the epithelial cell layers 
(Rangarajan et al., 2003). The IgE-mediated immune response is described below, so that in 
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section 1.4 a more detailed rationale for the proposed use of IgE in cancer therapy can be 
made. 
1.3 The 12E-mediated immune response 
1.3.1 The IRE antibody 
IgE shares the basic architecture of all antibody isotypes (described in section 1.2.1) 
in having two identical heavy and two identical light chains, of epsilon and kappa or lambda 
class, respectively (Bennich and Johansson, 1968), linked by disulfide bonds and non- 
covalent interactions (see Figures 1.1 and 1.3). It is the presence of the CF-2 domain pair that 
principally distinguishes the IgE (and IgM) isotype from IgG, IgA and IgD. The equivalent 
position in IgG (between the F(ab)2 and Fc regions), where the CF-2 domains are found in 
IgE, is occupied by a flexible hinge region; this hinge region differs in length between each 
IgG subclass. The presence of the CF-2 domains in IgE has a profound impact on IgE's 
physical properties through their effect on the shape acquired by free IgE in solution and, 
consequently, the kinetics of IgE binding to its receptor FcF_RI (as discussed in section 1.3.3). 
In addition to FcF_RI, IgE is a ligand for both CD23 (FcERII) and epsilon-binding protein 
(EBP). The role of CD23 in the immune system has been extensively studied and is discussed 
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Figure 1.3: Schematic representation of IgE, IgE Fc and an IgE FcF, 3-4 fragment. The Fc 
region (filled rectangles) is composed of the CF2-4 domains of each of two heavy-chains. 
The F(ab')2 region (open rectangles) is composed of light-chain (variable (V], ) and constant 
(C,, ) domains) and heavy-chain variable regions (Vil) in addition to Cel domains. Inter-chain 
and intra-domain disulphide bridges are represented by black lines. 
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1.3.2 FcF-RI 
FcF-Rl is the IgE receptor best known for its role in the immediate activation of mast 
cells upon exposure to allergen in sensitised individuals. FccRI is a member of the 
immunoglobulin superfamily. The structure of FcERI may be tetrameric or trimeric. 
Tetrameric FccRI is composed of a single a-chain, single P-chain and a disulphide-linked y- 
chain dimer (Figure 1.4A). For trimeric FcF-RI expression, (x-chain associates with the 72- 
dimer in the absence of a P-chain (Figure IAB). For human and rat, but not mouse FcERl- 
expression, P-chain presence is dispensable and thus humans and rats express both isoforms, 
and mice only the tetrameric form (Blank et al., 1989; Miller et al., 1989). The necessity of 
P- for (x-chain expression in mice is thought to be due to the presence of an additional 
endoplasmic reticulum dilysine retention motif in the intracellular portion of mouse ot-chain 
which can only be masked by P, whereas human (x-chain has a single retention motif, 
effectively masked by steric hindrance upon assembly with y-chain alone (Blank et al., 1990; 
Letoumeur et al., 1995; Donnadieu et al., 2000). 
It is the cc-chain, a type I integral membrane protein, to which IgE binds. It consists 
of an extracellular sequence which is expressed as two immunoglobulin domain folds at the 
cell surface, in addition to a single transmembrane and a short cytoplasmic region. The P- 
chain spans the membrane four times such that the amino and carboxy termini are 
intracellular, with an aypical immuno-receptor tyrosine-based activation motif (ITAM) near 
the carboxy terminus (Donnadieu et al., 2003). The y-chain is a type I membrane protein 
consisting of a short extracellular portion and long intracellular tail containing an ITAM. The 
y2-subunit functions in signal transduction; where P-chain is present, it acts in synergy with 
the y2-dimer to amplify both y-chain signal transduction and FccRl cell-surface expression 
(Lin et al., 1996; Donnadieu et al., 2000). P-chain has no signalling capacity in the absence 
of the y2-dimer. The y-chain dimer also forms a limiting component of FcyRl and FcyRIII, 
and P-chain a dispensable component of FcyRIII (Ravetch and Kinet, 1991). 
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Figure IA Schematic representation of the structure of FcERI in (A) tetrameric and (B) 
trimeric isoforms. The (predominantly extracellular) IgE-binding (x-chain is composed of two 
immunoglobulin domains DI and D2. Both trimeric and tetrameric FcF'RI include a 7-chain 
dimer involved in signal transduction. Tetrameric FccRI additionally includes a single 
(predominantly cytoplasmic and transmembrane) P-chain, which functions to upregulate 
FcF-RI expression, and to amplify y-chain signalling. Inset shows ribbon representation of 
FcF, Rl ot-chain, based on crystal structures: this is provided for reference with section 2.1.2. 
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Tetrameric and trimeric FcERI isoforms have different cellular expression patterns, 
consistent between species and associated with different IgE-effector functions. Knowledge 
of species-specific differences in the cellular expression profile of FcF_RI is critical for 
successful modelling of the human IgE system in animals. In humans, rats and mice, 
tetrameric FcFRI is expressed only on mast cells and basophils; on these cell types it is 
abundant (-200 000 molecules / cell), reflecting the role of P in receptor amplification 
(Donnadieu et al., 2000). In humans, trimeric FccRI is expressed by monocytes (Maurer et 
al., 1994; Reischl et al., 1996), Langerhans cells (Wang et al., 1992), peripheral blood 
dendritic cells (Bieber et al., 1992) and platelets (Joseph et al., 1997). Where trimeric FcF_RI 
is expressed, it is at levels 10 - 100 fold lower than tetrameric FcCRI expression on mast cells 
and basophils (Donnadieu et al., 2000). Although eosinophils have been reported to express 
mRNA transcripts for 0, it is unclear whether it is transcribed into protein; trimeric FcF_R1- 
expression however, is confirmed (Gounni et al., 1994; Smith et al., 2000; Kayaba et al., 
2001). In rats, expression of trimeric FcERI has been demonstrated to occur on macrophages 
and eosinophils, as has an IgE-binding capacity of rat platelets (Dombrowicz et al., 2000). 
Thus, although its expression on Langerhans cells and monocytes has not yet been 
determined, the ability of rat cc and y2 to associate in the absence of P suggests trimeric FcF_RI 
expression on these cell types, as in humans, is likely. As mice do not express trimeric FcF_RI, 
expression of the high affinity IgE receptor is limited to those cell types able to express the 
tetrameric isoform i. e., mast cells and basophils. Tetrameric FcF'R1 is typically associated 
with the immediate cellular activation characteristic of mast cells and basophils in the acute 
phase of allergic reactions. Trimeric FcFRI, is known to have a role in antigen presentation, 
with internalisation of antigen-IgE complexes leading to presentation of antigen in the context 
of MHC class 11 at the cell surface (Novak et al., 2001). The effector functions that are 
triggered by cross-linking of FccRI expressed by different cell types are discussed in section 
1.3.5 and reviewed in Gould et al., 2003. 
1.3.3 The IgE-FcFRl interaction 
A defining feature of the interaction between IgE and FcF-RI is its extremely high 
affinity (Metzger et al., 1986). Cell binding assays have determined this to be in the order of 
-1010 M-1 (Ishizaka et al., 1986; Miller et al., 1989; Young et al., 1995; and Keown et al., 
1997). The crystal structures of IgE-Fc (Wan et al., 2002), FcF-RI (Garman et al., 2001) and 
an IgE-FcF, 3-4 fragment complexed with FcF-RI (Garman et al., 2000) have allowed the 
structural basis for this high affinity interaction to be understood in more detail. In brief, as 
demonstrated in Figure 1.5, the DI and D2 domains of FcF-RI (x-chain (Figure 1.4) are 
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essentially 'wedged' between the two CO domains of IgE. The generation of this high 
affinity interaction is discussed below and has been reviewed in detail in Wurzburg and 
Jardetzky, 2001, and Gould et al., 2003. 
7 DI FccRI (x-chain 
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Figure 1.5: (A) Schematic representation of the interaction between whole IgE and FcF-R1, 
showing that the interaction occurs between (predominantly D2 of) FcERI (x-chain and 
(predominantly the CO domains of) IgE-Fc. (B) Ribbon representation based on the crystal 
structure of the interaction between an IgE FcE3-4 fragment (shown schematically in Figure 
1.3) and FcERI (Y-chain. 
It can be seen from Table 1.3 below, that there is little difference between the overall 
affinities of whole IgE, IgE+c and an IgE FcF_3-4 fragment, for FcF_RL with neither CC4 
domain making direct contact with FccRI(x (although they are required for maintenance of the 
CE3 domains in a conformation suitable for receptor binding). it is the CP_3 domains which 
contribute the majority of the binding energy to the interaction. Indeed a large contact surface 
area has been shown to be involved in the interaction between CE3 and FccRIOC, involving 
twenty-two residues from IgE in total, making direct contacts with FcF-RI(X. Of those residues 
involved from each CF-3 domain, only four are common to both; these include H424, R334, 
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G335 and V336. The importance of the arginine residue at position 334 (in the C62-CF-3 
linker region) was identified by mutatagenesis studies, prior to elucidation of the crystal 
structure of the IgE-FcF-3-4: FcF-Rl(x complex, as being critical for high affinity binding of IgE 
to FccRI (Henry et al., 1997). Some direct contacts are also made between the CE2 domains 
and FcF-Rl(x (McDonnell et al., 2001). 
interaction KA (M-1) k. ff (s-') 
IgE-FcF, RI(x - ix 
109 (1010)* -2x 
10-4 (_10-7 in tissues) 
IgE Fc-FcFRloc -ix 109 -2x 
10-4 
IgE-FcF-3-4-FcF, RI(x -3x 108 -3x 
10-3 
IgG I -FcyRIll 5x 105 1 
Table 1.3: Kinetics (overall affinity, KA and off-rate, k. ff) for whole IgE, IgE-Fc, IgE FcC3-4 
binding to FaRlot, and comparison with IgGI binding to FcYRIII, the IgG FcR most 
homologous to FcCRI. Affinity constants are representative of comparable surface plasmon 
resonance (SPR) experiments (McDonnell et al., 2001 and Maenaka. et al., 2001). Each KA is 
a weighted average of the affinity of both phases of the biphasic interaction between IgE and 
FcF-RI. The affinity of whole IgE for FccRI shown in brackets and marked with a star 
represents that obtained in cell binding assays, which typically give higher affinities than 
SPR. 
It is proposed that for IgE to bind FcF-RI with full affinity it must undergo a dramatic 
conformational change upon receptor interaction. In solution, IgE adopts a compact and 
acutely bent structure, which, from comparison of the crystal structures of free IgE-Fc and the 
IgE-FcF-3-4: Fcr-RI complex, occludes receptor access to a number of residues required for 
direct interaction with FcFRI. This bent structure of uncomplexed IgE results from the two 
CF-2 domains, bending at the CF, 2-CF, 3 linker region, folding back asymmetrically against IgE- 
Fc, such that CE2 of heavy-chain A (indicated in Figure 1.6A) makes a number of direct 
contacts with CO and even CF-4 of heavy chain B; in addition, CE2 of chain B, also makes a 
few additional contacts with CO, but not CF-4, of chain A (Wan et al., 2002). The 
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conformational change, shown schematically in Figure 1.613, is proposed to involve the 
dissociation of CF-2 from these contacts with CF-3 and CF-4 and an opening out of IgE into a 












Figure 1.6: (A) schematic representation of an IgE FcF-2-4 fragment. (B) Domain structure of 
IgE FcF-2-4 showing the acute bend in the CF-2-3 linker region leading to the folding back of 
the CF, 2 domains (blue) against CO and CE4 domains (red and yellow)-, (C) Ribbon 
representation of the crystal structure showing the acute bend represented in (B). (D) 
Schematic representation of the conformational change that occurs in IgE upon interaction 
with FcFRI (green), allowing the D2 domain of FccRI a-chain to access all receptor-binding 
sites in IgE. Figure adapted from Wan et al., 2002. 
Chapter 1 33 
It is this conformational change in IgE which is thought to explain the biphasic 
binding kinetics seen in its interaction with FcF-RI, manifest as one slow and one fast 
association phase and one slow and one fast dissociation phase (Henry et al., 1997). It is 
proposed that the first phase of IgE's association with FcFRI represents the binding of one 
CO domain to FccRI(x, following which the conformational change in IgE occurs, allowing 
the binding of the second CO domain, which represents the second phase. It is the slow 
phase which is dominant in the dissociation of IgE from FcF-Rl, giving IgE its exceptionally 
slow off-rate of _1075 S-1 (shown in Table 1.3), and contributing to its exceptionally high 
affinity. As already mentioned and shown in Table 1.3, there is little difference in overall 
affinity between the binding of IgE Fc, which includes the CF-2 domains in addition to CO 
and CF, 4 domains, and IgE-FcF-3-4 to FcF-Rl(x. However, there is a difference in the kinetics 
of binding, with IgE-FcF, 3-4 showing a faster dissociation rate compared to IgE-Fc; it is due to 
compensatory differences in the on-rate (it is faster for IgE-FcE3-4), that the overall difference 
in affinity is not greater (Keown et al., 1997). This implicates the CF, 2 domains as having a 
role in slowing the confonnational change required for dissociation of IgE from FcF'RI, and 
thus stabilising the high affinity interaction. 
It is important to note that through the involvement of two non-identical (although 
overlapping) sites in the separate CO domains of IgE, binding to two distinct sites on 
FcF_RIoc, that binding of one IgE to more than one receptor is prevented. The use of two 
distinct sites means firstly, that two equivalent binding sites for Fcrc. Rlcc do not exist in IgE 
and secondly, that IgE binds FcF-RI(x asymmetrically, which sterically hinders access of the 
bound IgE to a second receptor. This 1: 1 stoichiometry (Keown et al., 1995 and 1997; Hunt 
et al., 2005) is an important property of the IgE-mediated immune response, as it prevents 
cross-linking of FcF_RI and thus cellular activation occurring in the absence of antigen. 
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1.3.4 Biological conseguences of the high affinity interaction between 12E and FcFRl 
The large surface area of interaction between IgE and FcFRl in combination with the 
extremely slow rate of IgE: FcFRl dissociation, together, make the interaction extremely high 
affinity. This high affinity interaction confers IgE, and thus the IgE-mediated immune 
response, with unique properties; the ability to bind FcERI in monomeric form, without the 
need to first complex with antigen, and to remain tenaciously bound for long periods of time. 
This creates an unusual situation for an antibody-mediated immune response, whereby FcF_Rl- 
expressing cells adopt the antigenic specificity of the prevalent IgE repertoire in the absence 
of antigen, such that cells are persistently sensitised for an immediate response upon antigen 
exposure and cross-linking of the receptor-bound IgE by allergen. Local synthesis of 
allergen-specific IgE contributes to this sensitisation (Smurthwaite et al., 2001). 
It has been calculated (using cell binding assays) that the half-life of IgE bound to 
FcF-RI expressed by cells in serum is approximately 16 hours (off-rate of - 10-5 s-1) (Young et 
al., 1995; Wan et al., 2002). In tissues, however, the diffusion of IgE would be restricted, and 
this is expected to slow the rate of dissociation of IgE from FcF-RI, to _10-7 s-1, increasing the 
half-life of binding to the order of weeks (calculated in Wan et al., 2002, from data in Geha et 
al., 1985). Indeed, IgE has been shown to remain in human skin for a half-life of 
approximately 13 days (Cass and Anderson, 1968). This restricted diffusion in tissues is also 
likely to lead to the re-binding of IgE to FccRI (and CD23) expressed by the same, or nearby, 
cells. Therefore, for the duration for which IgE persists in tissues, association, dissociation 
and re-association with FcFRl, is likely to occur. 
The IgG Fc receptor most homologous to FcF-RI, is FcyRIlI. IgG I binds FcyRIII with 
an affinity of 5x 10' M-', and a half-life of binding to cells in serum of only hours 
(determined in surface plasmon resonance experiments in Maenaka et al., 2001, comparable 
to those used to determine the kinetics of IgE binding to FcFRI, discussed above). As for IgE, 
restricted diffusion of IgG in the tissues is likely to increase the half-life of IgG binding to 
FcyRIII, to approximately one day (Wan et al., 2002), although it may persist in tissue for 
longer as a result of re-binding to Fcy receptors expressed by the same, or nearby cells, as is 
the case for IgE. It has been shown by Tada et al., 1975, that the half-life of rat IgE in rat 
skin, is 7.4 days, compared to only 2.4 days for rat IgG2a, 
The longer half-life of free IgG in serum, over IgE, can be explained by the ability of 
the former but not latter, to bind the neonatal Fc receptor, FcRn; this Fc receptor was first 
identified for its role in the gastrointestinal absorption of IgG from orally administered 
mothers milk into the systemic circulation of the neonate, as suggested by its name (Junghans, 
1997). However, in adults, FcRn is proposed to provide protection for IgG from degradation 
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(Lobo et al., 2004). The normal mechanism of antibody catabolism is involves the uptake of 
antibody into endosomes of catabolic cells by fluid-phase pinocytosis. The antibody is then 
subject to a decreasing pH in the endosome upon fusion with a lysosome, resulting in its 
proteolytic degradation. The affinity of FcRn for IgG-Fc has been shown to increase with 
decreasing pH; thus, a high affinity interaction between IgG and FcRn tethered to the inner 
leaflet of the endosome, protects the former from degradation. Subsequent fusion of the 
endosome with the plasma membrane and the associated return to physiologic pH allows the 
release of IgG from what is now cell surface FcRn, back into the extracellular medium. The 
role of FcRn in recycling of IgG, has been recently reviewed by Lencer and Blumberg, 2004. 
1.3.5 IlzE-FcF-Rl mediated effector functions in an allergic reaction 
As mentioned above, the IgE-FccRI interaction is central to the mediation of allergic 
immune responses. The basis of allergic disease is reviewed in Gould et al., 2003. An 
allergic immune response can only occur once an individual has produced allergen-specific 
IgE, in the 'sensitisation' phase; this requires Langerhans cells at the site of exposure to 
internalise allergen, migrate to local lymph nodes and present it to cognate T cells in the 
context of MHC class 11. Following this, allergen-specific T helper cells provide the co- 
stimulation necessary in the lymph node, but subsequently also at the site of allergen 
exposure, for mature allergen-specific B cells to differentiate to plasma cells producing 
allergen-specific IgE. This IgE binds to FcF_RI on mast cells 'sensitising' them towards 
subsequent challenge with the same allergen. Mast cells are the effector cells of the 
immediate response to allergen; their activities are said to 'orchestrate' the subsequent allergic 
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Figure 1.7: Allergic immune response. In the sensitisation phase, allergen is taken up by 
Langerhans cells which migrate to local lymph nodes and present antigen to cognate T cells. 
Activated T helper cells then produce IL-4, triggering B cells to switch and differentiate into 
IgE-producing plasma cells. Allergen-specific IgE binds to FcF_RI on mast cell and is cross- 
linked, aggregating FcF_RI, upon subsequent challenge with multivalent antigen: mast cell 
degTanulation results in symptoms, according to the site of allergen provocation, characteristic 
of the acute phase of the allergic reaction. In addition, eosinophils, amongst other cell types, 
are recruited, and these mediate the late phase of the allergic reaction. 
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When a sensitised individual is exposed to multivalent allergen, the allergen binds to, 
and cross-links, specific IgE bound to FcF_RI expressed by mast cells. It is this aggregation of 
two or more FcF_RI which activates the mast cell. In section 1.3.2,1 reported that mast cell 
and basophil FcFRI exists as a heterotetramer in the cell membrane, and I discussed the 
devolution of different functions to each of its subunits and reported that they include a role 
for the y2-dimer in signal initiation, after FcF_RI aggregation. Critically, however, no subunit 
of FcF_RI includes intrinsic kinase activity, making signial intitiation by FcERI aggregation, 
dependent upon recruitment of an extrinsic kinase. This is characteristic of all multichain 
immuno-recognition receptors, a group which also includes the antigen receptors of T cells 
and B cells, and other Fc receptors of the immunoglobulin superfamily (reviewed in Keegan 
and Paul, 1992). From in vitro studies with RBL-2H3 cells, it appears that initiation of 
signalling downstream of FcFRI aggregation depends on the (extrinsic) src-family kinase Lyn 
(Eiseman and Bolen, 1992; Yamashita et al., 1994; Pribluda et al., 1994), with one newly 
formed FcERI-aggregate requiring a minimum association of one molecule of Lyn to allow 
for transphoshorylation of tyrosines on apposed receptors (Yamashita et al., 1994). This brief 
introduction to FccRI signalling has been provided to facilitate discussion of work described 
in Chapter 7 of this Thesis. 
The immediate effect of signalling downstream of FccRI aggregation in mast cells is 
the fusion of intracellular granules with the mast cell membrane, and ensuing release of the 
granule contents into the extracellular space (Blank and Rivera, 2004). The contents of these 
granules include histamine, serotonin, proteases (chymase and tryptase), lipid mediators 
(prostaglandins and leukotrienes) and cytokines (IL-4). In addition to release of stored 
granule proteins, is the induction of transcription of IL-4 and IL-5, and chemokines, including 
eotaxin and RANTES. The physiological effects of mast cell activation include increased 
vascular permeability and contraction of smooth muscle, but are dependent upon the local site 
of allergen challenge: these effector functions represent the 'acute' phase of the allergic 
reaction, occurring within minutes of allergen challenge. When allergen is introduced directly 
into the blood stream of sensitised individuals, anaphylactic shock may occur; the 
consequences are severe and may be fatal (a recent review on the definition and management 
of systernic anaphylaxis can be found in Sampson et al., 2005). 
As well as mediating the acute phase of an allergic reaction, mast cell activation 
products also provide the signals for generation of the chronic, late, phase response, which 
manifests 4 to 8 hours after the initial reaction, and is dependent on the influx of T cells, 
monocytes, eosinophils and basophils; indeed eosinophil infiltration is a hallmark of allergic 
disease. The influx of these cell types is mediated by the IL-4, secreted from mast cells; this 
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serves to upregulate VLA-4 on the local epithelium, which interacts with the VCAM-I 
expressed by T cells, monocytes, eosinophils and basophils, to mediate their extravasation to 
sites of allergen provocation. Other non-specific chemoattractants present in allergic tissues 
include platelet-activating factor (PAF), complement factors, leukotrienes and IL-8. Both 
eotaxin and IL-5, secreted from mast cells, act as specific chernotactic signals for eosinophil 
recruitment from blood into tissues; eotaxin also acts on basophils. Local IL-5 and eotaxin 
production is enhanced by IL-4, IL-13 and IL-9, increasing eosinophil recruitment further 
(Dombrowicz and Capron, 2001). The specific inhibition of eosinophil apoptosis by IL-5 also 
contfibutes to tissue eosinophilia (Simon et al., 1995). 
In the eosinophil cytoplasm are granules containing major basic protein, eosinophil 
peroxidase, eosinophil-derived neurotoxin and eosinophil cationic protein (Seminario et al., 
1998). Eosinophil immediate cytotoxic effector functions, manifest in the late phase of the 
allergic reaction, are therefore also mediated predominantly by degranulation. Pro- 
inflammatory functions are also mediated through the synthesis and release of lipid mediators 
(PAF, leukotriene C4 and prostaglandin EA OXygen metabolites and cytokines, including IL-2 
and EFN-y(Wardlaw et al., 1995). Eosinophils may also act as immunoregulatory cells 
through expression and secretion of IL-10, IL-13, IL-4 and TGF-P. Furthermore, the ability 
of eosinophils, recruited to airways in allergic subjects, to home to regional lymph nodes 
following internalisation of IgE-antigen complexes, and present antigen to CD4' T-cells in the 
context of MHC class H in the presence of co-stimulation, has been demonstrated (reviewed 
in Shi, 2004). 
The pathogenesis of allergic reactions is enhanced by the involvement of several 
positive feedback loops (Gould et al., 2003). Firstly, the increased levels of allergen-specific 
IgE produced locally in response to allergen challenge and its binding to FcCRI, serves to both 
increase FcF_RI levels at the cell membrane by protecting it from proteolysis (Borkowski et 
al., 2001), and also to prolong the survival of these FcF-RI-expressing cells (reviewed in 
Kawakami and Galli, 2002). Increased levels of IgE bound to FccRI may also allow for 
enhanced FcFRI-dependent presentation of antigen by Langerhans cells, monocytes, 
eosinophils and mast cells, to cognate T cells, and consequently enhanced secretion of IL-4 
and IL-5 from T helper cells. Secretion of IL-4 has the effect of stimulating B cells to switch 
to production of IgE-isotype allergen-specific antibodies (Gould et al., 2003). IL-4 will also 
serve to increase the numbers of infiltrating eosinophils, T cells, monocytes and basophils 
(Figure 1.7). 
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1.3.6 CD23 
CD23 is the second of IgE's well-characterised receptors, and has been reviewed in 
Gould et al., 1997. CD23 is a 45 kDa type-11 integral membrane protein with a calcium- 
dependent (C-type) lectin-like domain at its extracellular C-terminus, giving it homology to 
members of the C-type lectin superfamily. This makes IgE the only immunoglobulin isotype 
to bind to a receptor that is not a member of the immunoglobulin superfamily. As shown in 
Figure 1.8A, CD23 is composed of a single polypeptide chain. Its C-type lectin domain 
'head' is separated from a single transmernbrane region by a 15 nm long, (x-helical coiled-coil 
stalk. The stalk of human CD23 is composed of three homologous repeats of 21 -amino acids, 
which together contain a periodic pattern of heptads, with hydrophobic residues at the first 
and fourth positions. This structure allows CD23 to oligomerise to form homodimers or 
homotrimers in the cell membrane (Beavil et al., 1992). In addition to IgE, CD23 interacts 
with complement receptors 2 (CR2 / CD21), 3 (CR3 / CD18 / CDI lb) and 4 (CR4 / CD18 / 
CD 11 c) and vitronectin (Gould et al., 1997). 
Although CD23 is typically referred to as the 'low affinity' receptor for IgE, the 
affinity of the interaction is actually quite high. The binding of IgE to a monomeric lectin 
domain head of CD23 occurs with an affinity of _ 106 M-1 (Gould et al., 1997). This 
affinity is increased to - 107 M-1 when IgE binds to CD23 in its native, homotrimeric form in 
the cell membrane (Gould et al., 1997). This increase in affinity is likely due to the specific 
binding of two different CD23 lectin domain heads to two non-identical sites in IgE, proposed 
to lie within the CO domains, and avidity effects conferred by the involvement of three 
polypeptide chains, each with IgE-binding capacity. The interaction between CD23 and IgE 
is unusual for ligand binding to a C-type lectin family member, as CD23 recognises protein 
and not carbohydrate moieties, in IgE (Gould et al., 1997). 
Two different isoforms of CD23 have been identified, CD23a and CD23b; these 
differ by 7 and 6 amino acids in their N-terminal cytoplasmic regions respectively, generated 
by the use of two alternative transcription-initiation sites and splicing of a short first exon to a 
common second exon. The primary impact of the sequence difference in the N-terminal tails 
of these isoforms appears to be on the intracellular trafficking properties of CD23a and 
CD23b; CD23a is associated with enodocytosis of IgE-coated particles, whereas CD23b is not 
efficiently intemalised, and is instead associated with phagocytosis of IgE-coated particles 
(Yokota et al., 1992). CD23a and CD23b have different cellular expression profiles; the 
former is expressed on mature activated (g'/8') B cells prior to heavy-chain class switching 
and differentiation to plasma cell. The latter is expressed on B cells and monocytes, 
following IL-4 stimulation, in addition to Langerhans cells, follicular dendritic cells, T cells, 
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and tissue eosinophils. CD23b expression has also been detected on airway (Campbell et al., 
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Figure 1.8: (A) The primary sequence of CD23. Sequences of both CD23a and CD23b, 
differing only by 6 and 7 amino acids, respectively, in their N-terminal, intra-cellular 
cytoplasmic regions, are shown. The sites of the (x-helical stalk, which can be cleaved by 
endogenous proteases, are shown in blue along with the sizes of the fragments released. The 
single N-glycosylation site is shown in green, and disuphide bonds in magenta. (B) Schematic 
representation of IgE binding to trimeric CD23 in the cell membrane. 
Chapter 1 41 
As for FcF-Rl, there are a number of differences between human, mouse and rat CD23 
structure and expression, which complicate the modelling of the human IgE system in 
rodents. Firsly, mouse CD23, but not rat CD23 (Beavil et al., 1992), contains an extra 21- 
amino acid heptad in the stalk region, not present in human CD23, explaining the larger size 
of mouse (49 kDa), compared to human CD23 (45 kDa; Conrad et al., 1990). Human IgE 
binds to human but not mouse or rat CD23, and rat IgE binds to mouse but not human CD23 
(Bettler et al., 1989). It is not known if mouse IgE is able to bind rat CD23. In addition, 
mouse CD23 does not bind to mouse CD21; the situation for rat CD23 binding rat CD21 is 
not known. This excludes a role for CD21 in the regulation of IgE levels in mice. 
Furthermore, the cellular expression of CD23 in mice appears to be more limited than in 
humans; this was originally thought to be due to expression of only the CD23a isoform, thus 
lin-ýting CD23 expression to B cells. However, the CD23b isoform has recently been found 
on mouse intestinal epithelial cells (Montangnac et al., 2005). Rat CD23 expression does not 
appear to be restricted in the same way, and indeed a functional, pro-inflammatory, role for 
CD23 expressed by rat macrophages has been shown (Bay6n et al., 1998), as has a role for rat 
CD23 expressed by intestinal epithelial cells (Ramaswamy et al., 1994). The closer likeness 
of rat FcF_RI (discussed above in section 1.3.2) and CD23 expression to humans may therefore 
make them better than mice for modelling of the human IgE system. 
1.3.7 CD23-mediated effector functions in the immune system 
The interaction of CD23 with ligands other than IgE confers it with many different 
functions in the immune system; these are discussed below. CD23 can also be cleaved from 
the cell membrane to release a 37 kDa soluble fragment, which can be digested further to 
form soluble IgE-binding fragments of 33,27,25 and 16 kDa, the latter consisting only of the 
lectin-domain head. The soluble fragments mediate further effector functions of CD23. 
CD23 is best known for its role in the feedback regulation of IgE synthesis. Feedback 
regulation of IgE synthesis is reviewed in Gould et al., 2001, and shown schematically in 
Figure 1.9. The feedback system is required to counteract the positive feedback loop of IgE 
synthesis: IL-4 and ligation of CD40 provide the signals for aB cell to switch to secretion of 
IgE isotype antibodies; IgE binds to mast cells allowing for their activation upon antigen 
challenge resulting in further IL-4 secretion and thus increased IgE secretion. The role of 
CD23 in negative feedback of IgE is highlighted by CD23-knockout mice, which overexpress 
IgE, whereas mice overexpressing CD23 are deficient in IgE (Lamers and Yu, 1995; Payet 
and Conrad, 1999). Binding of IgE to CD23 leads to down-regulation of IgE synthesis. Co- 
ligation of membrane IgE with CD23 on B cells by allergen-IgE complexes also has a role in 
downregulation of IgE synthesis. Soluble CD23 fragments and CD21 also serve to regulate 
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IgE synthesis, with binding of soluble CD23 fragments larger than 25 kDa to CD21 expressed 
by B cells up-regulating IgE synthesis. As CD23 is protected from proteolysis when IgE is 
bound, the binding of the excess IgE to membrane CD23 prevents the release of soluble CD23 
fragments, and thus these soluble CD23 fragments are unable to stimulate IgE synthesis 
further. 
sCD23 
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Figure 1.9: Bi-directional switch in IgE regulation by CD23: Interactions between IgE, 
CD23 and CD21 that lead to an increase in IgE synthesis, are shown on the fight-hand side of 
this diagram. These include the co-ligation of membrane IgE and CD21 by oligomeric 
soluble CD23 fragments. Interactions between IgE, CD23 and antigen that lead to a decrease 
in IgE synthesis are shown on the left-hand side of this diagram. These include the co- 
ligation of membrane IgE and CD23 by antigen-IgE complex in addition to the binding of 
secreted IgE (sIgE) to soluble CD23 fragments (sCD23), which compete with CD23 binding 
to membrane IgE. The binding of IgE to CD23 also provides protection from proteolysis of 
CD23 into soluble fragments, which would normally serve to upregulate IgE synthesis. 
The role of CD23 expressed by follicular dendritic cells in the apical light zone of the 
germinal centre in lymphoid tissue is the rescue of germinal centre B cells (centrocytes) from 
apoptosis; interaction of CD23 with CD21 on the B cell surface, induces expression of the 
Bcl-2 oncogene. This interaction may provide a second survival signal following the primary 
survival signal in the basal light zone, of a productive BCR interaction with antigen held as 
immune complexes on the surface of the FDC (Bonnefoy et al., 1993; Liu et al., 1991). 
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CD23 is not expressed by these germinal centre B cells but, as mentioned above, CD23a is 
expressed by mature, unswitched, B cells, where it has a role in the enhancement of IgE- 
dependent presentation of antigens to T cells. CD23 is non-covalently associated with the 
MHC class 11 antigen, human leukocyte antigen (HLA)-DR, in the B cell membrane. When 
an antigen-IgE complex binds to CD23, the antigen-IgE-CD23 complex and associated HLA- 
DR are internalised, the antigen digested and its peptides presented on the B cell surface in 
the context of HLA-DR, still in complex with CD23. The complexed CD23 is thought to 
have a role in stabilisation of the subsequent interaction between the B cell and cognate T 
cell, by interaction with CD21 on the T cell surface (Karagiannis et al., 2001). 
CD23 expressed by intestinal epithelial cells has been demonstrated to have a role in 
the fast transepithelial transport of free IgE and IgE-allergen complexes from the mucosal to 
the serosal side of the epithelium (Montagnac et al., 2005; Ramaswamy et al., 1994; Yang et 
al., 2000), where mast cells are activated. This function of CD23 is likely to be particularly 
important in the induction of food allergies through transport of IgE-antigen complexes 
formed in the intestinal lumen to FcF_RI expressed by mast cells in the underlying tissue, 
enabling a local hypersensitivity reaction to be stimulated. 
Finally, expression of CD23 on cells of the mononuclear phagocyte lineage 
implicates CD23 in the control of inflammation. Cross-linking of CD23 on IL-4-stimulated 
monocytes stimulates production of IL-6 (Paul-Eugene et al., 1992), IL-10 and TNF-(x 
(Borish et al., 1991) and superoxide anions (Kikutani and Kishimoto, 1990). Ligation of 
CD23 on the U937 monocyte cell line is also associated with the production of pro- 
inflammatory mediators, in addition to an increase in cell size, induction of oxidative 
metabolism and promotion of CD14 and LFA- I expression (Ouaaz et al., 1993). 
1.3.8 Epsilon-binding protein 
Epsilon-binding protein (F-BP) is a 31 KDa member of the soluble (S)-type lectin 
superfamily originally discovered in rat basophilic leukeamia cells by Liu et al., in 1985, as a 
protein with IgE-binding capacity. FBP, as an example of S-type mammalian lectins, is 
reviewed in Liu et al., 1993. The structure of F_BP conforms to the highly conserved two- 
domain structure of S-type mammalian lectins; the carboxy-tem-dnal domain contains 
consensus sequences shared by other P-galactoside-binding soluble lectins and the amino- 
terminal domain contains a highly conserved repetitive sequence. Human, rat and mouse F'BP 
are highly homologous. F_BP is secreted by mast cells and macrophages in response to 
inflammatory stimuli. One function of eBP in the allergic immune response is proposed to be 
the modulation of mast cell activation. It is through the ability of F_BP to self-associate to 
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form oligomers by which it is able to cross-link FcF-Rl, or IgE bound to FcF_RI, at the mast cell 
surface. This suggests that F_BP might contribute to the amplification of IgE-mediated 
inflammatory responses. However, the ability of FBP to bind cell surface glycoproteins 
means F_BP found in the extracellular medium may be expressed at the surface of cell types 
other than those from which it is secreted. Therefore, although the ability of EBP to bind both 
IgE and FcF_RI implicates it with a role in allergic immune responses, it is likely to have a 
broad spectrum of functions in the immune system. 
1.4 IRE and cancer 
In the sections above I have introduced cancer, its relationship with the immune 
system and treatment with tumour antigen-specific monoclonal antibodies. I have also 
described IgE, its receptors, FccRI, CD23, and FBP, and the allergic immune response. I now 
describe the features of this immune response which may make it a suitable arm of the 
immune system to be manipulated for tumour cell killing, particularly of solid-tissue-tumours. 
1.4.1 Rationale for use of tumour-sMcific IgE in cancer immunotherapy 
Throughout section 1.2,1 have emphasised the underlying causes of the high affinity 
interaction formed between IgE and FcF_Rl, and highlighted the biological consequence of this 
high affinity interaction as being a long half-life for which monomeric IgE remains bound to 
FcERL For cancer immunotherapy, an IgE isotype tumour-specific antibody may therefore be 
well-retained on effector cells such as mast cells, eosinophils and monocytes, leaving them 
primed to mediate an anti-tumour-immune response immediately upon exposure to tumour 
cells expressing specific antigen. The long half-life of the IgE-FcERI interaction should 
therefore reduce need for frequent treatment doses. Moreover, as mast cells are extremely 
sensitive to activation mediated through IgE-dependent cross-linking of FcFRI, with IgE- 
antigen-induced formation of FcFRl dimers shown to be sufficient for cellular activation 
(Segal et al., 1977), this suggests that the size of the treatment doses required would also be 
minimised. 
It is only possible to take advantage of this high affinity interaction for the treatment 
of cancers of solid tissues by virtue of the anatomical location of IgE receptor-expressing 
cytotoxic effector cells. Firstly, there is the presence of RERI-expressing mast cells 
throughout the tissues of the body and infiltrating turnours (as discussed in section 1.1.2). 
Mast cells initiate a powerful inflammatory immune response, as exemplified by their role as 
primary effector cells in allergic reactions, discussed in section 1.3.5. Furthermore, the 
effector mechanisms of mast cells are mediated in a highly specific manner, with localised 
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receptor aggregation causing localised degranulation (Lawson et al., 1978). This highly 
sensitive and specific route of mast cell activation may also be the answer to the killing of 
those few, but potentially fatal, malignant cancer cells that remain in minimal residual disease 
following surgery, or those metastatic cells, isolated and distant from primary tumour sites. 
In addition to mast cells with their well-recognised role in the allergic immune 
response and confinement to tissues, monocytes, macrophages and eosinophils are also 
potential cytotoxic, IgE-receptor-expressing effector cells (as discussed in section 1.3.5). The 
latter two cell types are found not only throughout tissues of the body, but actively infiltrating 
turnours of solid tissues and sites of inflammation, following receipt of specific signals to 
mediate their recruitment (as discussed in section 1.1.2). Those eosinophils and macrophages, 
resident within tissues, are perfectly positioned such that their sensitisation with tumour- 
specific anti-IgE antibody may trigger them to mediate a passive, specific, anti-tumour 
immune response. 
As mentioned in section 1.2.3, a major barrier to successful of treatment of solid 
turnours with and-cancer antibodies is their poor ability to penetrate such tissues. An intact 
IgG molecule has been shown to take 54 hours to move I mm into a solid tumour (Jain et al., 
1988). Also mentioned in section 1.2.3 is the fact that although penetration of solid tissues 
with antibody Fab fragments may be faster, 16 hours for movement of I mm (Jain et al., 
1988), the efficacy of this antibody fragment is reduced not only by its inability to recruit Fc- 
mediated effector mechanisms, but by their poor retention in the target tissue, making 
frequent dosing necessary. Use of IgE isotype antibodies may overcome this problem: it is 
well known that IgE is rapidly sequestered from the circulation to the tissues (Waldmann et 
al., 1976) until all IgE binding sites are occupied (Strober et al., 1978). The mechanism of 
this transport into tissues is likely to involve binding of monomeric IgE to FcF_R1 and CD23 
on cells in the circulation, enabled by the high affinity of the interactions, and then the 
movement of these cells into the tissues. Furthermore, CD23b expression has been 
demonstrated to occur on intestinal epithelial cells where it has a role in transcellular transport 
of free IgE (discussed in section 1.3.7). It therefore follows that a comparable process might 
operate to mediate the uptake of intravenous IgE, a potential route of exogenous tumour- 
specific IgE administration, into tissues containing turnour cells. 
Finally, treatment of cancer with IgE isotype tumour-specific antibodies may lead to 
the development of an acquired tumour-specific immune response. As mentioned in section 
1.3, both FcFRl expressed by Langerhans cells, eosinophils and monocytes, and CD23 
expressed by B cells, have a role in antigen presentation. Tumour antigen bound to tumour- 
specific IgE, itself bound to FccRI (or CD23 on B cells), may be internalised and 
subsequently presented in the context of MHC class 11 to cognate T cells. The inflammatory 
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environment created by the local activation of mast cells during MOvI8 IgE therapy, will 
hypothetically provide the signals for the expression of co-stimulatory molecules and 
stimulation of productive anti-tumour T cell responses. 
1.4.2 MOvI 8 IRE and its antigen: Folate binding protein 
The turnour-specific antibody used to assess the efficacy of IgE-isotype antibodies in 
mediating immune responses against tumour cells in this Thesis is MOvl8 IgE. MOvI8 IgE 
is a chimaeric IgE antibody specific for the ovarian carcinoma tumour-associated antigen, 
Folate Binding Protein (FBP) (Gould et al., 1999; Coney et al., 1991). The original MOvIg 
monoclonal antibody, murine MOvIg IgGl, was generated by immunisation of mice with a 
surgical specimen of ovarian cancer, as described in Miotti et al., 1987. The murine yl -heavy 
chains and K-light chains of this original MOvI8 IgG I antibody were switched for human yl- 
heavy chains and K-light chains to make chimaeric MOvI8 IgG (Coney et al., 1994) and, 
subsequently, the human yl-constant regions were switched for human F_ constant regions to 
make the chimaeric MOv 18 IgE (Gould et al., 1999). The affinity of MOv 18 IgE for FcF'Rl is 
as expected for native IgE at - 1010 M-1 (Gould et al., 1999). 
FBP is stably expressed on the cell surface of the majority of malignant as well as 
benign non-mucinous epithelial ovarian turnour cells. FBP is involved in the uptake of folate, 
from the extracellular environment and, accordingly, is also referred to as Folate Receptor 
(FR). The level of FBP expression has been shown to relate to clinical severity (Campbell et 
al., 1991; Toffoli et al., 1998), with high expression levels (- 106 molecules / cell) associated 
with poor prognosis (Coney et al., 1994), perhaps due to the proliferative advantage FBP 
expression confers (Bottero et al., 1993). The affinity of MOv 18 IgE for FBP is high at -4x 
109 M-1 (Gould et al., 1999). Expression of FBP on normal tissue is restricted to low levels, 
predominantly on adult oviduct epithelium and kidney proximal and distal tubules (Buist et 
al., 1985). Only weak reactivity of a radiolabelled MOvl8 IgG was seen with normal tissues 
in a Phase I study of intraperitoneal treatment of ovarian cancer patients with chimaeric 
MOv 18 IgG (Molthoff et al., 1997). 
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The enhanced in vivo activity of MOv 18 IgE over MOv 18 IgG has been reproduced 
in a second model, a nude mouse model, described in this Thesis (section 6.2) and 
Karagiannis et al., 2003. Also reported in this publication, is the in vitro immunofluorescence 
imaging of a population of PBMC from a non-allergic donor, acting as effector cells of 
MOvI8 IgE-mediated tumour cell death; monocytes were visualised as being the primary 
effector cells in this mixed population. Basophils were also frequently seen to be in contact 
with IGROV I tumour cells in the presence of MOv 18 IgE, but not anti-NP IgE. The role for 
monocytes was supported by immunohistochemical staining of tumour sections taken from 
HUA-tumour bearing nude mice, HUA is a human ovarian cancer xenograft expressing 
human FBP (described in detail in section 2.3.3 of this Thesis), which had been treated with 
human PBMC alone or PBMC plus MOvl8 IgE; monocytes were shown to be the primary 
infiltrating cells in the latter group. Furthermore, we demonstrated that a pure population of 
monocytes have the capacity to act as MOvl8 IgE-mediated effector cells in the killing of 
IGROV I tumour cells in vitro. 
Reali et al., 2001, provide another particularly important study addressing the 
potential for use of IgE in cancer therapy. In vivo models used in this study assess the 
efficacy of IgE in its ability to trigger passive and-tumour immune responses against syngenic 
mouse tumours in immunocompetent mice, and compare this to IgG. This model involved 
transplantion of C57BL/6 mice with the syngeneic tumour, MC38-CEA-2. Tumours were 
then targeted indirectly, with IgE. Treatment with tumour-targeted IgE conferred mice with a 
significant survival advantage over both untreated control mice, and, IgG-treated mice. 
Furthennore, experiments performed in this study also addressed whether or not the local 
inflammatory response accompanying tumour destruction, following treatment with tumour- 
specific IgE, has the capacity to initiate an active anti-tumour immune response. To this end, 
C57BU6 mice were inoculated with a low dose of MC38-CEA-2 tumour cells, which were 
pre-loaded with IgE. Control mice were inoculated in the same way, but tumour cells were 
IgE-negative. Subsequently, all mice were re-challenged with IgE-negative MC38-CEA-2 
tumour cells. What they found was that when mice were first 'vaccinated' with IgE-bearing 
tumour cells, they were conferred with significant protection from tumour growth resulting 
from tumour re-challenge; these mice survived significantly longer than mice 'vaccinated' 
with IgE-negative tumour cells. 
In the study reported by Reali et al., 2001, and described above, the protection 
conferred to C57BU6 mice by inoculation with IgE-bearing tumour cells, from tumour- 
growth occurring in response to re-challenge with the same tumour (not bearing IgE) at a later 
date, was shown to be dependent upon eosinophils, CD4' and CD8' T cells. Indeed, tumour- 
specific CTLs could be isolated from the spleens of protected mice, showing protection from 
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turnour growth, and used to elicit tumour cell killing in vitro. Turnour-specific CTLs could 
not be similarly isolated from mice bearing progressively growing tumours. IgE antibodies 
are already known to have a role in the capture and processing of antigen by professional 
antigen-presenting cells (Beiber et al., 1997). These data suggest that treatment of cancer 
with tumour-specific antibodies of the IgE isotype may lead to the generation of active, anti- 
tumour immunity. 
1.5 The aims of this Thesis 
The aims of this Thesis are two-fold. 
> The first is to assess the efficacy of MOvI8 IgE in triggering immune responses against 
turnours, both in vitro and in vivo, work described in Chapters 3 to 6 of this Thesis. 
> The second is to address how the affinity of the IgE-FcF-Rl interaction impacts on the 
intensity of IgE-mediated immune responses in vivo, work described in Chapter 7 of this 
Thesis. 
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Chavter 2: Materials and Methods 
2.1 Materials 
2.1.1 General Reagents 
Details of all the general reagents used for experimental work described in this 
Thesis, are tabulated below (Table 2.1). The supplier name and catalogue number is given for 
each product. Where relevant, the chemical formula and molecular weight is provided. 
Name, chemical formula, formula weight Supplier Catalogue # 
Acetic acid, glacial (CH3CO2H) Sigma A9967 
Acid citrate-dextrose Sigma C3821 
Acrylamide, 30% (w/v) acrylamide / 0.8% (w/v) NN, - Severn Biotech Ltd 20-2100-05 
methylenebis-acrylamide stock solution 
Ammonium Chloride, 53.49 Sigma A-215666 
Ammonium persulphate, (NH4)2S,, 08,228.2 Sigma A-3678 
Bovine Serum Albumin (BSA) Sigma A-2153 
CFSE, C291419NOII, 557.47 Molecular Probes C-1 157 
Coomassie brilliant blue R250, purified Electran 44418 2M 
D-Glucose, C61-11206,180.16 Sigma G7528-IKG 
DMEM Gibco 11966-025 
Dimethyl sulfoxide (DMSO) Sigma D2650 
Ethanol Sigma 45-983-6 
EDTA disodium saltý CjoH 14N208Na2.2H20,372.2 Sigma E-5134 
Evans blue dye Sigma E-2129 
Ficoll-PaqueTm PLUS Amersham Biosciences 17-1440-03 
Foetal Calf Serum Gibco 10106-169 
Formaldehyde Sigma F8775 
Formamide Sigma F7503 
Geneticin, 50 mg/ml Gibco 10131-027 
Glycerol Sigma G-6279 
Glycine, C, H5N02,75-07 Sigma G-7403 
Goat serum, normal Gibco 16210-072 
HEPES Sigma H-3375 
Histopaque@-1077, density = 1.077 0.001 Sigma 1077-1 
HT Supplement (50 x) Gibco 41065-012 
Hydrochloric Acid, HCL 2.0 N Sigma 251-2 
IGEPAL CA-630 Sigma 9036-19-5 
MACS CD16 MicroBeads Miltenyi Biotech 130-045-701 
MACS CS Depletion Columns Miltcnyi Biotech 130-041-305 
Magnesium Chloride, M902 FSA Laboratory Supplies NUO600 
Marvel, dried skimmed milk Premier International Foods, UK 
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2-mercaptoethanol, C2H60S, 78.13 Sigma M-7522 
Neuraminidase Sigma N2133 
NIP-BSA Biosearch Technologies N-5040-10 
NONIDET P-40 Sigma N-6507 
o-Phenylenediamine tablets, 5 mg per tablet Sigma P-6912 
Penicillin, Streptomycin, Glutamine Gibco 10378-016 
Percoll"A, density= 1,130 g/ml Amersharn Biosciences 17-0891-01 
Phosphate buffered saline, sterile Gibco 14190-094 
Phosphate-citrate buffer with sodium perborate capsule Sigma P-4922 
POIY-D-lysine, Iyophilised Sigma P-7405 
Potassium Chloride, KCI, 74.55 Sigma P-9333 
Potassium Phosphate, KH2PO4,136.1 Sigma P-0662 
Propidium Iodide Nucleic Acid Stain, I mg/ml in water Molecular Probes P-3566 
Protease inhibitor cocktail tablets Roche Diagnostics 1873580 
RAL 555 Kit Reactifs RAL 361550-0000 
Recombinant human IL-5 R&D Systems 205-IL 
Recombinant human IL-4 R&D Systems 204-EL 
RosetteSep! 'ý*' human monocyte enrichment cocktai i Stemcell Technologies 15028 
RPMI 1640 Gibco 31870-025 
Sodium Azide, NaN3,65.01 Sigma S-2002 
Sodium Chloride, NaCl, 58.44 Sigma S-9625 
Sodium Hydrogen Carbonate, NaHC03,84.01 BDH Chemicals 30151 
Sodium Pyruvate, 100 mM Gibco 11360-039 
Sucrose, C12H22011,342.3 Sigma S-7903 
TMED, N, N, N', N'tetramethylethylenediamine, C6H16N2 Sigma T-9281 
Trypsin-EDTA solution (10 x) Gibco 35400-027 
Trizma@ base, C4HIIN03,121.14 Sigma T1503-5KG 
Trypan blue solution, 0.4 % Sigma T8154 
Tween20 (polyoxyethylene(20)sorbitan monolaurate) Sigma P-5927 
Xanthine, sodium salt, 174.1 Sigma X-3672 
Table 2.1: Supplier details for 
2.1.2 AntiLb-odies 
All antibodies used in this project are described in Table 2.2 below. Antibodies 
specific for different epitopes of a single antigen have been used in some cases. Each 
antibody has been given a specific reference number to make clear which was used for which 
experiment. All antibodies are specific for human antigens unless specified otherwise. Table 
2.2 excludes details of chimaeric MOvl8 IgE, chimaeric MOvl8 IgG, human wild type anti- 
NP IgE and R334S anti-NP IgE, which were all produced in-house as described below, in 
section 2.2.2. Additional details of those antibodies against human IgE, FcFRI(x and CD23 
are given below Table 2.2. 
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Ref. # Specificity Conjugate Host Species Supplier and Code 
I CD14 PE Mouse, IgG2a, K Dako, R0864 
2 CD16 - Mouse IgGl, ic Dako, M7006 
3 CD23, BU38 - Mouse IgGl The Binding Site, AP271 
4 CD23, BU38 - Mouse IgG I Produced in-house (Dr. N. McCloskey) 
5 CD23, IDEC-152 - Monkey IDEC, 3002G990 
6 CD23, IDEC-152 F(ab')2 - Monkey IDEC 
7 CD23, Tu I - Mouse IgG3, ic SouthernBiotech, 9580-01 
8 CD32 - Mouse IgG I, ic Dako, M7190 
9 CD49d PE Mouse IgGl, K BD Pharmingen, 555503 
10 CD64 Mouse IgG I, ic Dako, M7218 
11 CD89 PE Mouse IgG 1, K BD Pharmingen, 555686 
12 Dual Negative FrFC Mouse IgG I Dako, X0949 
PE Mouse IgG2a 
13 FccRIct (15-11 3G6) - Mouse ascities Upstate Biotechnology, 05-491 
14 FcEM(x (15-1) - Mouse IgG Produced in-house (M. Corbett) 
15 FccRI(x (15A5) - Mouse IgGl Provided by Dr. A. Gilfillan, NIH 
16 IgE, 4.15 - Mouse IgG I, K Produced in-house (Dr. L. Smurthwaite) 
17 IgE HRP Polyclonal rabbit Dako, P 0295 
18 IgE FITC Goat Vector Laboratories, FI-3040 
19 IgE Biotin Goat Vector Laboratories, BA-3040 
(Reference 19 used with: Streptavidin- PE Dako, R 0438) 
20 IgE, (x-y fusion protein - Human IgG4 Produced in-house (Dr. S. Karagiannis) 
21 IgG FrFC Rabbit F(ab')2 Dako, 170315 
22 IgGl, Mouse PE Rat BD Pharmingen, 550083 
23 Isotype control PE Mouse IgG I, K Dako, X0955 
24 Isotype Control Mouse IgG I, K Dako, X 0931 
25 Isotype Control Mouse IgG3, ic BD Pharmingen, 556657 
26 Mouse immunoglobulins FTrC Goat F(ab')2 Dako, F0479 
27 MOPC 21 Mouse IgGl, ic Sigma 
Table 2.2: Details of antibodies used for experiments described in this Thesis. 
Anti-human IgE antibodies: Antibodies used against human IgE in this project, include 
those with reference numbers 16-20 in Table 2.2. Antibody number 16, anti-human IgE of 
clone 4.15 (Hassner and Saxon, 1984), was produced from the CIA-E-4.15 hybridoma. 
(ATCC: HB-235), and provided by Dr. Lyn Smurthwaite. 4.15 has been used to coat ELISA 
plates for the detection of human IgE (described in section 2.3.1, below). 4.15 binds to an 
epitope between amino acids 218 and 301 in the Cc2 domains, of lgE-Fc (information 
available in the ATCC specification sheet for the CIA-E-4.15 hybridoma). The HRP- 
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conjugated polyclonal rabbit anti-human IgE antibody from Dako, code P 0295 (Table 2.2; 
reference 17) was used as a detection antibody in the same anti-human IgE ELISAs. 
The FITC-conjugated goat-anti-human IgE antibody from Vector (Table 2.2; 
reference 18) has been used to detect endogenous IgE, MOv 18 IgE and anti-NP IgE, bound to 
IgE receptors on (both primary and U937) monocytes (Chapter 3). An equivalent goat anti- 
human IgE antibody (Table 2.2; reference 19, also from Vector Laboratories) conjugated to 
biotin, was used in combination with streptavidin-PE, to detect IgE (again endogenous, 
MOvI8 IgE and anti-NP IgE) bound to IgE receptors on eosinophils (Chapter 3). The 
purpose of using the biotin-streptavidin-PE detection method instead of FITC was to amplify 
the signal from the low level of IgE receptors expressed by eosinophils; an anti-human IgE 
antibody directly conjugated to PE was not available. 
The structure of the anfi-IgE construct, a-y fusion protein (reference number 20, in 
Table 2.2), is that of an IgG4 antibody with its two Fab arms, each replaced with a soluble 
fragment (the IgE-binding, extracellular region) of the FcF-RI(X chain: IgG4-Fc-(sFcERIa)2, as 
described in Shi et al., 1997. When (x-, y fusion protein is amine coupled to Sepharose beads 
(via its Fc region), the extremely high affinity (and specificity) of the FcERI(x: IgE interaction 
can be exploited for the specific isolation of IgE antibodies from cell culture supernatants, as 
indeed has been its role in this project (protein purification by affinity chromatography is 
described in section 2.3). oc-y fusion protein itself is purified from cell culture supernatants 
using a standard Protein G-Sepharose column. 
Antibodies against FcdUcc: Those antibodies with specificity for FcCRI cc-chain, which 
were used in this project, include 15-1 (Table 2.2; reference numbers 13 and 14) and 15A5 
(Table 2.2; reference number 15). Antibody 15-1 was originally described in Wang et al., 
1992, and 15A5 in Riske et al., 1991. What 15-1 and 15A5 have in common, is that they both 
bind to a site in FceRlcc, which is overlapping with, but non-identical to, the IgE binding site. 
The site in FCERI to which IgE binds includes the B-C, C'-E and F-G loops of the D2 domain 
of FcFRl cc-chain (shown in Figure 1.4). The 15-1 binding site has been localised to residues 
110-120 of the BC loop (Rigby et al., 2000). The 15-1 binding site was originally thought to 
also involve direct interactions with valine 155 and tryptophan 156 in the FG loop 
(Nechansky et al., 1998). However, Rigby et al., 2000 suggest mutation of these residues to 
leucine and alanine, respectively, are likely to have prevented 15-1 binding through an 
indirect effect on the conformation of the BC loop and not through direct disruption of the 
FccRl(x: 15-1 interaction. The site in FcF-Rl(x to which 15A5 binds has also been localised to 
D2, specifically, within residues 125-140 (Riske et al., 1991). The consequence of 15-1 and 
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15A5 binding to sites in FcF-RI(x which are cross-reactive with the IgE binding site, is that IgE 
is unable to bind receptors to which antibody is pre-bound, and likewise, 15-1 and 15A5 are 
unable to bind receptors to which IgE is bound. Therefore, 15-1 and 15A5 can only directly 
detect those FcF_Rl unoccupied by IgE. The affinities of the 15-1 and 15A5: FcF-Rl 
interactions are similar to IgE: FcF-Rl. 15-1 has a slightly slower off-rate than IgE (Nechansky 
et al., 200 1) and 15A5 a slightly faster off-rate (Riske et al., 199 1). 
Antibodies against CD23: Anti-human CD23 antibodies used in this project include clone 
BU38 (Table 2.2; references 3 and 4), clone TO (Table 2.2; reference 7) and IDEC-152 
(Table 2.2; reference 5). Two different supplies of BU38 were used; one was made in house 
and kindly provided by Dr. Natalie McCloskey and the other was purchased from a 
commercial source (The Binding Site). BU38 recognises the lectin domain of CD23 (Gabriel 
Grundy, PhD Thesis), blocking IgE binding. The anti-human CD23 antibody, Tul (Southern 
Biotechnology), also blocks binding of IgE to CD23, but the site in which TO binds to in 
CD23 to mediate this effect has not been characterised. It is not reported in the available 
literature regarding IDEC-152, to which epitope of CD23 IDEC-152 binds; however, it is 
known to be cross-reactive with the IgE binding site (Mavromatis and Cheson., 2001; 
Rosenwasser et al., 2003; Mavromatis et al., 2004, and personal communication with IDEC 
Pharmaceuticals). 
2.1.3 Buffers and Solutions 
Suppliers and details of the chernicals used in the recipes listed below are detailed in 
Table 2.1. Ultrapure water was obtained from a MilliQ UF Plus machine supplied by Triple 
Red (Thame, UK) and used at a purity of 18.2 mfj / cm. Buffers and solutions were prepared 
as follows: 
APS: APS was prepared as a 10 % (w/v) solution in MilliQ water. 
Carbonate coating buffer: 15 mM sodium carbonate, (1.59 9/ litre), 35 MM sodium 
hydrogen carbonate, (2.93 9/ litre) prepared in I litre MilliQ water and pH adjusted to 9.6. 
Coomassie blue stain: 0.05% Coomassie brilliant blue R was dissolved in methanol, 
distilled water and acetic acid mixed at a 5: 5: 1 ratio. 
Coomasssie destain: 0.05 % methanol 7.5 % acetic acid in deionised water. 
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FACS Buffer: PBS supplemented with 5% normal goat serum. 
FACS Fix: FACS buffer supplemented with I% paraformaldehyde. 
Fekete solution (Fekete, 1938): A bleaching solution used for the identification of turnour 
metastases on rodent lung tissue. This is composed of 70 % ethanol, 15 % MilliQ water, 10 
% formaldehyde and 5% glacial acetic acid. 
Glycine: 2M glycine (15 g/ litre of MilliQ water), pH adjusted to 2.5. 
Lysis Buffer A: For lysis of red blood cells in granulocyte pellets during eosinophil 
purification. 155 mM ammonium chloride, (8-29 g/ litre), 10 mM NaHC03, (0.84 g/ litre) 
and 0.1 mM EDTA (0.37 g/ litre) prepared in I litre MilliQ water. Filter sterilised and pH 
adjusted to 7.4. 
Lysis Buffer B: For homogenisation of mouse ear tissue. To make 50 ml, 2.5 ml 2M NaCl 
(100 mM), 0.5 ml IM Hepes (10 mM), 0.075 ml IM MgC12 (1.5 mM), 0.5 ml IM KCI (10 
mM) in addition to 12.5 ml 100 % glycerol (25 %) and 0.25 n-d 100 % NP40 (0.5 %) were 
added to 33.675 ml MilliQ water. The MilfiQ water included a protease inhibitor cocktail 
prepared by dissolving one 'complete' tablet in 2 ml of MilliQ water to make a 25 times stock 
solution of which 1.407 ml was included in the 33.675 n-d of MilliQ water. 
MACS Buffer: 2 mM EDTA (0.74 9/ litre) and 0.5 % BSA (5 g) dissolved in I litre of PBS. 
OPD Buffer: 0.05 M phosphate-citrate buffer was made by dissolving the contents of one 
phosphate-citrate buffer capsule into 100 ml of milliQ water. OPD buffer was made by 
dissolving I o-Phenylenediamine tablet into 10 mls of phosphate-citrate buffer. 
Percoll, density = 1.082 g/ ml: Percoll was made to a density of 1.082 g/ ml for density 
gradient fractionation of whole blood for eosinophil isolation. First, a 90 % solution of 
percoll was made by diluting 9 parts percoll with I part sodium chloride 9% (9 g NaCI / 100 
ml MilliQ water, filter sterilised). For the percoll d=1.082, to make 100 ml, 66.3 ml of 
percoll 90 % was mixed with 33.7 ml sodium chloride 0.9 % (0.9 g NaCI / 100 ml MilliQ 
water, 0.2 gm filter sterilised). 
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Phosphate Buffered Saline: 0.14 M NaCI, 2.7 mM KCI, 1.5 mM KH2PO4,8.0 mM 
Na2HP04 pH 7.4 in MiIIiQ water. 
Phosphate Buffered Saline-(Tween): PBS with the addition of 0.05 % Tween 20 (0.5 ml 
litre PBS). 
Run buffer for gel filtration: Standard buffer used in both preparative and analytical gel 
filtration. 0.5 M Tris-HCI, 250 mM NaCI 0.05 % NaN3; degassed and 0.2 gm filtered pH 7.2. 
Run buffer for SDS-PAGE: A IN stock solution was made by dissolving 30 g Tris and 
144g Glycine in 100 nil 10 % SDS. One part stock solution was added with 9 parts MilliQ 
water immediately before use. 
Sample buffer: A5x stock solution was made by making 3.125 ml IM Tris (pH 6.8), 5 ml 
Glycerol and 0.25 g SDS and I ml P-mercaptoethanol to 10 ml with water. 20 gl sample was 
mixed with 5 gl sample buffer to make a final buffer concentration of I x. 
Selection media A: Used in the selection of J558L cell colonies, successfully transfected 
with R334S anti-NP IgE heavy chain. This selection media is composed of 84 ml DMEM, 4 
ml HT supplement (50x), 4 ml Xanthine (12.5 mg / ml; made in 0.2 M NaOH), 8 MI 
Mycophenolic Acid (250 gg / ml; made in 0.1 M NaOH) and 0.6 ml HCI (2 N). 
Selection media B: Used in the selection of J558L cell colonies, successfully transfected 
with R334S anti-NP IgE heavy chain. This selection media is composed of 92 ml DMEM, 2 
ml HT supplement (50x), 2 mI Xanthine (12.5 mg / ml; made in 0.2 M NaOH), 4 ml 
Mycophenolic Acid (250 gg / ml; made in 0.1 M NaOH) and 0.3 n-d HCI (2 N). 
Tris Buffered Saline: A 10 x TBS stock was made by dissolving 48.46 g of Trizma base 
(200 mM) with 116.88 9 of Sodium Chloride (I M) and 20 g of Azide (I %) in 2 litres of 
water. The pH was reduced to 8.2.200 ml of stock solution was diluted with MilliQ water to 
2 litres immediately before use and the pH of 8.2 confirmed. 
Tris: IM tris was made by dissolving 121.14 g of Trizma base in I litre of MilliQ water and 
adjusting the pH to 8.2. 
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2.1.4 Animals 
All animals were housed in a specific pathogen-free facility at room temperature, 
excluding nude mice, which were housed in sterile isolators at 20 T (La Calhene, Ltd., 
United Kingdom). All animals had continuous access to food and water. 
Balb/c mice: Balb/c mice were purchased from Iffa-Credo, France. All mice were 8-12 
weeks old at the start of experiments, and of either gender. 
Nude mice: Female nulnu mice from a colony of mixed genetic background (purchased by 
Frances Balkwill, Translational Oncology, St. Bartholomew's Hospital, Charterhouse Square, 
London) were used at 8-12 weeks old. Nude mice are bom athymic (and free of hair). This 
phenotype results from a nonsense mutation in the winged-helix-nude gene which encodes a 
member of the forkhead / winged-helix transcription factor family. Expression of whn is 
restricted to epithelia] cells of the thymus and skin, where it normally functions to direct cell- 
fate decisions, maintaining the balance between growth and differentiation. Without the 
thymic microenvironment, developing T cells are unable to make the cellular interactions they 
need to undergo positive or negative selection and the effect of the whn defect is therefore an 
almost complete absence of T-cells (T cells are not completely absent, as some are able to 
mature in the periphery). 
Human FcdU transgenic (hFcCRITg) mice: The generation of hFcF'RITg mice, mutant for 
the murine FcERI (x-chain gene and carrying a transgene for human FcF_RI (X-chain, is 
described in detail in Dombrowicz et al., 1996 and 1998. In brief, transfected human (x-chain 
associates with mouse FcF_RI P-chain and y2-dimer or y2-dimer alone, to form complete 
tetrarneric or trimeric FcF_RI complexes at the cell surface. Receptors have been demonstrated 
to be functional in vitro by the triggering of an intracellular calcium influx and serotonin 
release in IL-3-cultured BMMCs from hFccRI transgenic mice but not control animals, when 
loaded with human anti-NP IgE and cross-linked by NIP-BSA. Functionality in vivo has been 
demonstrated by passive induction of cutaneous and systemic anaphylaxis following 
sensitisation with human IgE and subsequent antigen challenge. 'Humanisation' of these 
mice is conferred not only through expression of a form of FcF_Rl which binds to human IgE, 
but by a move from a tissue-specific distribution of FcFRI characteristic of mice (tetrameric 
FcERI on mast cells and basophils) to a tissue-distribution characteristic of humans 
(tetrameric FcF_RI on mast cells and basophils in addition to trimeric FcFERI on monocytes, 
eosinophils, langerhans cells and platelets) (Dombrowicz et al., 1998). This is a consequence 
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of both transfection of the human FcFRl promotor (Dombrowicz et al., 1996) and the fact that 
the y-subunit alone is sufficient for expression of human but not mouse (x-chain, which also 
requires the presence of P-chain (Ra et al., 1989), as discussed in section 1.3.2. Expression of 
hFcF-Rl(x was checked prior to my receipt of the mice by Southern blot (as described in 
Dombrowicz et al., 1996). 
Wistar Albino Glaxo (WAG) rats: Female inbred rats of strain WAG/RijHsd were 
purchased from Harlan, France. All rats were used between 10 and 12 weeks of age. 
2.2 Tissue culture 
All tissue culture was perfomed under sterile conditions in a laminar flow hood 
(Howorth, Crowthome Hi-tec. ). Cells were grown in a humidified atmosphere at 37 T in 5 
% C02 (in a Nuaire DH Autoflow incubator, Triple Red Ltd. ). All culture media was 
supplemented with 10 % FCS (not heat inactivated), 2 MM L-glutamine, penicillin (5000 U/ 
ml) and streptomycin (100 gg / ml) unless otherwise specified. For storage, aliquots of 10 x 
106 cells were prepared to a total volume of 1 ml using 950 gl of freezing media (90 % FCS 
and 10 % cell-specific standard culture media) plus 50 gl DMSO and kept in liquid nitrogen 
after a progressive shift of temperature. 
2.2.1 Culture of cell lines 
The relevant phenotypic characteristics of the cell lines described below are discussed 
in more detail in Chapter 3 of this Thesis. In this section, details of the origin and 
maintenance of each cell line are given. In all cases, cell lines were maintained for a 
maximum of 100 passages. To passage, adherent cell lines were detached by removal of 
media, rinsing of the monolayer in PBS, followed by incubation in the minimal amount of 
Trypsin-EDTA necessary to cover the monolayer, for the minimal amount of time possible at 
37 T in 5% C02- When all cells were detached (as judged by light microscopy), they were 
washed in the culture media in which they were normally grown (as were cells which grew in 
suspension). Washing of all cell lines involved centrifugation for 5-8 minutes at 1200 rpm 
in a Sorval RT 6000D centrifuge, fitted with a HIOOOB rotor. After centrifugation, 
supernatant was poured off and the cells reconstituted at the required split ratio, or specific 
concentration. 
U937 monocyte cell line: The U937 monocyte cell line was originally derived (as reported 
in Sunstrom and Nilsson, 1976) from the pleural effusion of a patient with histiocytic 
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lymphoma. The wild type myelomonocytic U937 cell line used in this Thesis was kindly 
provided by Dr. J. -P. Kinet. U937s were grown in the standard culture media described 
above, and maintained at a density between Ix 105 -2x 106 cells / n-J. Where U937 
monocytes were cultured in IL-4, this involved supplementation of the standard culture media 
with 320 U/ ml of recombinant human IL-4, four days prior to use of the U937 monocytes in 
an experiment (this protocol for IL-4 culture of U937 monocytes was optimised for maximal 
upregulation of CD23 expression, by Dr. Sophia Karagiannis). 
IGROV1 tumour cell line: The human ovarian cancer cell line IGROV I (136nard et al, 
1985) was used as the standard turnour-target in in vitro killing assays. The IGROV I cell line 
originates from a stage III ovarian carcinoma of a 47-year-old woman. Histological analysis 
of the original tumour diagnosed it to be a glandular and polymorphous ovarian epithelioma 
with multiple differentiations, primarily endometrioid, with some serous clear cells and 
undifferentiated foci. Since establishment in tissue culture, the IGROVI cell line has been 
maintained in monolayer where it exhibits a 20-hour doubling time and retains its epithelial 
morphology. IGROVI cells were maintained in RPMI 1640 with standard additives and 
passaged as described above thrice weekly, at a ratio of 1: 3 or 1: 4. 
For some experiments (indicated where relevant), it was required that IGROV I cells 
be killed. This was perforned using the Dako fixation / permeabilisation kit, according to the 
manufacturer's instructions. This involved treatment of a pellet of IGROVI cells (up to I 
million, in no more than 500 gl of FACS buffer), with 50 gl of 'Buffer A' for 30 minutes at 4 
T. Cells were then washed once in FACS buffer, and 50 [il of 'Buffer B' was added to the 
pellet, again for 30 minutes at 4 T. 
C26 cells: The Balb/c colon carcinoma cell line C26 was maintained in Dulbecos Modified 
Eagles Medium with standard additives. C26 cells grow as an adherent monolayer. C26 cells 
transfected to express human FBP, and termed C26tFR, were cultured in the same media as 
for wild type C26 cells, additionally supplemented with 0.8 mg / nil G418. C26tFR cells 
were grown in the absence of G418 for 5 days prior to injection into mice. Cells were split 
approximately 1: 6 every 3 days by standard trypsinisation, as described above. Both wild 
type and C26tFR cells were kindly provided by Dr. S. Canevari. 
CC531 cells: Dr. S. Canevari also kindly provided the CC531-turnour cell line, which was 
originally derived from a chemically induced adenocarcinorna of the colon of a WAG rat 
(Marquet et al., 1984). Wild type CC531 cells were grown in RPMl 1640 with standard 
additives. For the purposes of work described in Chapter 6 of this Thesis, Dr. S. Canevari 
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also kindly provided CC531 cells transfected to express human FBP, termed CC53ltFR. 
Three different clones of CC5 31 tFR were received, clones 2,11 and 16, each expressing FBP 
at high, medium and low levels, respectively. Transfected CC531 cells were grown in the 
same medium as wild type cells, additionally supplemented with 0.4 mg / ml G418. Wild 
type and FBP-transfected CC531 clones were split approximately 1: 6 every 3 days by 
standard trypsinisation as described above. The normal appearance of CC531 cells is of 
visibly granular adherent cells, with some cells in suspension. 
2.2.2 Hybridoma culture 
Culture media for all hybridoma cell lines was supplemented with standard additives 
and grown in a hurnidified atmosphere at 37 OC in 5 0/0 C02, as described above. When a total 
volume of 250 n-d was reached by culture in flasks, cells and media were transferred to roller 
bottles in which they were grown for up to two weeks. During roller bottle growth, cells were 
gassed with sterile 5 0/0 C02 in air for one minute every other day. Cell counts were carried 
out regularly by haernocytometer using 2% w/v trypan blue. Supernatant was harvested by 
centrifugation at 10 000 rpm (in a Sorval RC-5B Plus centrifuge fitted with fixed-angle rotor) 
for ten minutes to remove cell debris. Supernatant was subjected to 0.2 gm filtration and 
stored at 4 OC after supplementation with sodium azide to a final concentration of 0.05 % to 
inhibit bacterial growth. Purification of antibodies from hybridoma supernatants is described 
in section 2.3.1. 
JW8 hybridoma: The cell line JW8, secreting wild type, human anti-NP IgE, was kindly 
provided by Dr. A Neuberger (Bruggemann et al., 1987). This consisted of the J558L ; ý- 
light chain-secreting mouse myeloma permanently transfected with the construct for human 
anti-NP IgE heavy chain. Cells were grown in Dulbecco's Modified Eagles Medium with 
standard supplements and kept between 3 and 9x 10-5 cells / ml. 
R334S hybridoma: Human anti-NP IgE mutated in the CF, 3 domain of each heavy chain by 
substitution of the arginine residue at position 334 for serine (R334S NIP IgE), was 
constructed by Dr. Jianguo Shi for the purpose of work described in Chapter 7 of this Thesis. 
Dr. J. Shi used the following protocol: Wild type human anti-NP IgE heavy chain construct 
was transformed into Eschefichia coli (XLI-blue) and the plasmid DNA was purified with 
QIAGENTM purification kit and mapped with restriction enzymes according to the 
manufacturer's instructions. The DNA was then sequenced using a reverse primer, IgE-S2 
(5' cca ggt cag gtt cag g 3', between amino acid residues 369-374). Using the obtained 
sequence, two primers (R334S-FOR and R334S REV) were designed and synthesised by 
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MWG-biotec. The mutant R334S was generated using Quickchange XL site-directed 
mutagenesis kit (Stratagene) according to the manufacturers instructions. The colonies 
obtained were screened and mapped. Two of the positive colonies were sequenced to judge 
the site of mutagenesis. The R334S human anti-NP IgE heavy chain construct was 
transfected into J558L cell line (a human X light chain-secreting mouse myeloma). 
Transfection was performed by electroporation; IX 107 cells were washed and resuspended in 
a final volume of 0.7 ml of ice cold PBS and 15 4g of linearised R334S anti-NP IgE was 
added to the cells and mixed well in a 0.4 cm electroporation cuvette (Bio-Rad). 
Electroporation was performed with two 0.1 second pulses of 1500 V at a capacity of 3 ý117. 
The samples were left on ice for 30 minutes then diluted in 70 nil of DMEM and plated in 
seven 96-well flat-bottomed plates at 100 gl / well. After 24 hours of growth, 'selection 
media A' was added, which was replaced after 5 days with 'selection media B' (the details of 
which are described in section 2.1.3). Four positive colonies were obtained. After ELISA 
and western blotting analysis, one colony was selected due to its faster growth rate and higher 
production of R334S anti-NP IgE. J558L cells expressing the R334S anti-NP IgE protein 
were grown in DMEM with standard supplements and kept between 3 to 9x 105 cells / in]. 
Chimaeric MOv18 IgGl: The construction of chimaeric MOvl8 IgG was originally 
described in Coney et al., 1994. SP2/0 cells transfected to express chimaeric MOvI8 IgG 
were grown in Iscove's Modified Dulbeccos Medium supplemented in addition to standard 
additives, with I mM pyruvate. The concentration of FCS in the media was reduced during 
culture firstly to 5% by splitting 1: 1 in serum free media, then 1: 1 again in 5% low IgG FCS, 
so that the final concentration of regular FCS and low IgG FCS is each at 2.5 %, reducing the 
IgG which is not MOvI8 IgG in the supernatant. 
Chimaeric M008 IgE: Construction of the chimaeric MOvI8 IgE expression vector and its 
transfection into the murine melanoma cell line SP2/0 is described in Gould et al., 1999. To 
express chimaeric MOvl8 IgE, SP2/0 cells were cultured in Iscove's Modified Dulbeccos 
Medium, supplemented in addition to standard additives, with I mM pyruvate. Chimaeric 
MOv 18 IgE is described in more detail in Chapter 3 of this Thesis. 
2.2.3 Isolation and culture Of VrimM cells 
Isolation of primary cells: Primary monocytes and peripheral blood mononuclear cells 
(PBMC) which were to used as effector cells in in vitro assays of tumour cell killing were 
purified from the peripheral blood of donors with no history of allergic symptoms. Those 
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monocytes to be used as effector cells in in vivo assays of M008-mediated turnour cell 
killing were purified from human volunteers whose atopic status was determined on the basis 
of negative skin prick tests for II aeroallergens, and total serum IgE levels of 30 - 150 ng / 
mi, with allergen specific IgE levels, below 0.3 IU / ml. The reasoning for selection of non- 
atopic donors is discussed in Chapter 3. Any donor was used for eosinophil donation, 
regardless of atopic status. As standard, blood was venous and treated immediately with I ml 
of acid citrate-dextrose (ACD) per 10 n-d whole blood. 
Peripheral blood mononuclear cells: To isolate an enriched population of mononuclear cells 
from whole peripheral blood, ACD-treated blood was diluted 3 parts blood to 5 parts PBS and 
8 parts of this diluted blood was layered onto 3 parts Histopaque-1077. For gradient 
separation of PBMC, the layered blood was centrifuged at 2000 rpm for 20 minutes at room 
temperature, with the brake off. Buffy coat, containing the PBMC, was transferred to a new 
sterile tube using a Pasteur pipette and washed by resuspension in PBS and centrifugation at 
1500 rpm for 10 minutes at room temperature, following which the cell pellet was 
resuspended to 10 million cells in I ml PBS. Lyophilised neuraminidase was made to I n-d in 
PBS to make a stock solution of 10 neuraminidase units per ml PBS. Aliquots of 30 gl 
containing 0.3 units were then made and stored at - 20 T. PBMC were incubated with one 
aliquot of neuraminidase per I ml cell suspension for 30 minutes at 37 OC, as was previously 
determined to be optimal (Karagiannis et al., 2003). The purpose of neuraminidase treatment 
was to digest the carbohydrate groups (sialyl Lewis x), shown to be present on the cell 
membrane which, likely through their proximity to FcF-RI, sterically hinder IgE binding 
(Wank et al., 1983 and Reischl et al., 1996). After neuraminidase incubation, PBMC were 
washed once in the solution in which they were to be finally resuspended, and centrifuged at 
1200 rpm for 10 minutes at room temperature. 
Monocytes: For each " of ACD-treated whole blood, 10 gl of 100 mm EDTA (I mM final) 
and 50 gl RosetteSepTm human monocyte enrichment cocktail was added. This preparation 
was left to stand for 20 minutes at room temperature in sterile conditions. RosetteSepTm 
cocktail includes antibodies against cells expressing CD2, CD3, CD8, CD19, CD56 or 
CD66b, and anti-glycophorin A for red blood cells. Unwanted cells are cross-linked to red 
blood cells, creating tetrameric antibody complexes that increase their density relative to 
monocytes and allow their separation. The blood preparation was then diluted 1: 1 with PBS 
and subjected to gradient separation by layering at a ratio of 4 parts blood/PBS n-tix onto 3 
parts Ficoll, followed by centrifugation at 2000 rpm for 20 minutes with the brake off, at 
room temperature. The buffy coat, containing predominantly monocytes was isolated and 
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transferred to a new sterile tube, using a Pasteur pipette. This monocyte preparation was 
washed twice by resuspension in a solution of PBS containing 2% FCS and I mM EDTA and 
centrifugation at 1500 rpm for 10 minutes. The supernatant was poured off and the cell pellet 
made to I nil with PBS and counted; cells were resuspended to 10 million per n-J PBS. One 
freshly-thawed aliquot of neuraminidase, containing 0.3 U, as described above, was added per 
1 ml monocyte suspension, and the suspension was incubated for 30 minutes at 37 T. 
Following neuraminidase incubation, for in vitro killing assay use, monocytes were washed in 
RPMl containing 10 % FCS and 2 MM L-glutamine, penicillin (5000 U/ ird) and streptomycin 
(100 Rg / ml), in which they were also resuspended. For injection into nude mice, monocytes 
were washed and resuspended in PBS. Monocyte preparations isolated in this way were on 
average 70 - 80 % pure as judged by FACS analysis of the proportion of cells staining 
positive for CD14 (a monocyte marker) in the final cell population. 
Eosinophils: Throughout the eosinophil purification procedure, cell preparations and buffers 
were kept at 4 OC, which kept eosinophils inactive and thus prevented them from 
degranulating. Whole blood diluted 1: 1 with sterile PBS was layered at a 2: 1 ratio onto a 
Percoll gradient (density 1.082 g/ ml) and centrifuged at 2000 rpm for 20 minutes with the 
brake off at room temperature. The granulocyte pellet containing mainly neutrophils and 
eosinophils was harvested and transferred into a clean falcon tube to avoid contamination by 
mononuclear cells adhering to the tube sides. Erythrocytes were depleted with a 25 minute 
hypotonic saline lysis. This involved a 15 minute incubation of no more than 10 ml of 
granulocyte pellet reconstituted to a total volume of 50 ml with lysis buffer A, followed by 
centrifugation of the cell / lysis buffer suspension for 8 minutes at 1500 rpm, and replacement 
with fresh lysis buffer for a further 10 minute incubation. The granulocyte pellet was washed 
once in ice cold PBS and resuspended to 1x 106 cells / ml in MACS buffer followed by 
incubation for 30 minutes with 8 gl of anti-CD16-coated immunomagnetic beads per I 
million granulocytes, at 4 OC. CD16 (FcyRIII) is expressed at high levels on neutrophils but is 
absent on - 94 % of eosinophils (Seminario et al., 1999). Neutrophils were then removed by 
passage of the cells through the field of a permanent magnet. After isolation, a cytospin was 
performed and eosinophils were established to be a n-dnimum of 95 % pure by RAL 555, May 
GAinwald Giemsa staining kit, and at least 99 % viable by trypan blue exclusion. 
Culture of primary cells: Where indicated, eosinophils were cultured for 4 days at I million 
cells per I ml of RPMl 1640 medium containing standard culture media supplements. Flasks 
(25 CM2) containing 5 nil cells were additionally supplemented with 2.5 ng / ml of 
recombinant human IL-5, either alone or in combination with either 10 gg / ml anti-NP IgE or 
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MOvI8 IgE. This concentration of IgE was chosen based on work described in Kayaba et al., 
2001, which demonstrated that this was the minimal amount of IgE required for maximal 
upregulation of FcF-Rl. IL-5 was included in all eosinophil culture as, without it, the number 
of cells viable after 4 days of culture was less than 50 %, as judged by trypan blue exclusion. 
2.3 Methods 
2.3.1 Protein Methods 
Antibody purification: Antibodies produced in-house included MOv 18 IgE, MOv 18 IgG, 
wild type anti-NP IgE and R334S anti-NP IgE. Individual hybridoma cell lines were grown 
as described in section 2.2.2. All antibodies were purified from cell culture supernatants by 
affinity chromatography. Purification of wild type and R334S anti-NP IgE for use in in vivo 
passive cutaneous anaphylaxis experiments also included a second step of gel filtration, using 
HPLC (analytical and preparative). Affinity chromatography and HPLC was always 
performed with the help of either Dr. Andrew Beavil or Dr. James Hunt. 
Affinity chromatography: Purification of IgG isotype antibodies (MOv 18 IgG and 15.1) was 
performed using a Protein G column, purchased in a ready-to-use form from Amersham 
Biosciences. The specific ligand used for purification of IgE isotype antibodies (MOv 18 IgE, 
wild type and R334S anti-NP IgE) was the a-7 fusion protein, amine coupled to Sepharose 
beads and packed into a glass column. The structure of (x-y fusion protein is described in 
section 2.1.2, and originally in Shi et al., 1997. All affinity chromatography steps described 
below were performed using automated peristaltic pump apparatus passing fluid over the 
column at a rate of 0.5 nil / minute. The first step involved repeated cycling of the pH 
adjusted supernatant (pH 8.6) over the column to allow for binding of antibody to ligand until 
column saturation. Unbound material was removed by thorough washing of the column with 
TBS, pH 8.6. Captured antibody was eluted using 0.2 M glycine, pH 2.5, and the eluate 
immediately neutralised by addition of IM Tris, pH 8. The column was re-equilibrated by 
cycling of TBS. 
Gel filtration: The purpose of the additional gel filtration step in both wild type and R334S 
anti-NP IgE purification, was to ensure these preparations were free of aggregated material to 
avoid activating cells in the absence of antigen in passive cutaneous anaphylaxis experiments, 
described in Chapter 7. Gel filtration provides a suitable method for removing aggregated 
protein by separating proteins on the basis of size. Aggregated molecules and other 
contaminants larger than the monomeric antibody pass more quickly through the porous bead 
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matrix, allowing them to be separated from the pure monomeric antibody fraction which 
travels more slowly, due to transient trapping in smaller pores of the matrix. Gel filtration 
was perforned on a Gilson HPLC system using a Superdexým 200 column (Amersharn 
Pharmacia Biotech), which is suitable for separation of proteins with molecular weights 
between 10 - 600 kDa. 
Final preparations: Eluted protein was concentrated using 80 ml Centricon Plus-80 
centrifugal filter units (Millipore) containing ultrafiltration membranes with a molecular 
weight cut off of 100 kDa. Centricon Plus units were spun in a Sorvall RC-5B Plus 
superspeed centrifuge (Du Pont) with a swinging-bucket rotor at a maximum centrifugal force 
of 3 000 rpm. For small volumes (up to 3.5 ml), Microsep TM microconcentrators were spun in 
a Sorval RC-5B Plus fixed-angle rotor at 2 000 rpm. Before use, antibodies were dialysed 
against PBS to remove azide. To determine the concentration (mg / ml) of the antibody, the 
optical density at 280 nm was measured in a Cary IE UV visible spectrophotometer using aI 
cm path length quartz cell. The optical density was divided into the extinction coefficient for 
the antibody (1.3 M-' cm-1 for IgE and 1.4 M-1 cnf 1 for IgG) and multiplied by the path length 
of the cell (I cm). 
SDS-PAGE: Antibody purity was assessed on the basis of size by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE), according to the discontinuous buffer 
system described by Laemn-di (Laemmli, 1970); Atto system gel apparatus was used. 
Twelve-well 4-20 % Tris-glycine gradient gels were purchased from Invitrogen. A5-8% 
gradient gel electrophoresis was performed by Dr. R. Beavil (and is shown in Figure IIA); 
this gel was prepared according to a standard recipe. After placement in the gel tank, the tank 
was filled with running buffer, the comb removed and 20 gl of each sample in combination 
with 5 gl of 5x sample buffer, was loaded after boiling for 2 minutes, alongside 10 gl 
SeeBlueTm Plus2 pre-stained standard marker (Invitrogen). Samples were run at 150 V until 
the dye had reached the bottom of the gel plate. The gel plates were then separated, the 
stacking gel removed and the gel transferred to Coomassie blue for 2 hours for visualisation 
of proteins. Gels were then washed with water and incubated overnight with destain. 
ELISA Procedure: ELISA was used for detection of human IgE in mouse ear 
homogenisation extracts and for estimation of the amount of antibody present in cell culture 
supernatants to determine expected yields before purification by affinity chromatography. A 
standard procedure was followed as described below. Plates were sealed under polythene for 
all incubations. Incubations at 37 T took place in a humidified atmosphere. Plate washing 
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was performed using an Anthos fluido ELISA plate washer (Jencons PLS) programmed to 
wash 4 times in PBS-T. For detection of human IgE, Nunc flat-bottomed ELISA plates were 
coated with either NIP(5)BSA at I gg / ml or 4.15 anti-IgE (antibody with reference number 
16 in Table 2.2) at 10 gg / ml, diluted in carbonate coating buffer (50 gl / well, 4T 
overnight). Without washing, non-specific antigen binding was blocked by addition of 2% 
Marvel in PBS-T (200 jil / well, 2 hours at 37 'Q. Unadsorbed coating antibody and blocking 
solution were removed by standard washing. Test samples were then added to relevant wells 
(50 pl / well, 4T ovemight). Bound material was detected by the addition of the HRP- 
conjugated secondary anti-human IgE antibody P 0295 (antibody with reference number 17 in 
Table 2.2), diluted 1: 2000 in PBS (50 pl / well, I hour at 37 'Q. Following washing, 
chromogenic substrate solution (OPD buffer) was added (50 gl / well) and left for colour to 
develop at room temperature in the dark. The colour reaction was stopped by addition of 3M 
FIG (50 gl / well). The absorbance of each well at 492 nm was measured using an automatic 
ELISA plate reader (Titertek multiskan, Flow), linked to a computer employing Ascent 
software. For quantification of MOvI8 IgE or anti-NP IgE in cell culture supernatants, a 
standard curve was generated using a World Health Organisation IgE standard provided by 
Dr. L. Smurthwaite. For detection of wild type and R334S anti-NP IgE in mouse ear 
homogenates, dilutions of both wild type and R334S anti-NP IgE of known concentration 
were used to confirm equal detection of both wild type and R334S anti-NP IgE and to enable 
adjustment for differences in signal between plates. 
Surface plasmon resonance using Biacore: A Biacore 3000 instrument was used to obtain 
kinetic information about the interaction between both wild type and R334S anti-NP IgE with 
FcF-Rl(x. In a Biacore, the ligand, in this case FcF-RIoc in the form of the (X-y fusion protein 
IgG4-Fc-(sFcERI()C)2 (described in section 2.1), is immobilised on a sensor chip. The sensor 
chip consists of a glass slide, coated on one side with a thin gold film, itself covered with a 
covalently bound matrix to which the ligand is attached. This chip forms one wall of a 
'micro-flow cell', positioned such that the ligand face is parallel to the flow of a solution 
containing the analyte, in this case anti-NP IgE (Figure 2.1). Changes in the concentration of 
analyte in contact with the sensor chip surface can then be measured in real-time using the 
optical phenomenon, surface plasmon resonance (SPR). 
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Figure 2.1. Diagrammatic representation of a vertical section through the flow cell, showing 
how the sensor chip ligand-binding face forms one wall of the flow cell such that analyte is 
able to bind as part of a continuous flow of fluid through the cell. Inset shows direct 
immobilisation of ligand on the sensor surface, which is able to interact with the analyte free 
in solution. 
The term SPR describes the effect that occurs when light energy interacts with a thin 
metal film at the interface between two transparent media of high and low relative refractive 
index respectively, through which the light passes. SPR is dependent upon the light being 
monochromatic, polarised such that the electric vector component is parallel to the plane of 
incidence and above a critical angle of incidence, so that total internal reflection occurs. 
Under these conditions, when the light meets the interface between the two different media 
and is reflected, an evanescent wave is generated. This is an electromagnetic field component 
which penetrates a short distance into the lower refractive index medium (Figure 2.2A). 
Energy from the evanescent wave excites surface plasmons in the metal film, causing them to 
resonate. The effect of SPR is the absorption of the reflected light at a critical angle. This 
angle is dependent on the refractive index of the second media through which the light passes 
on the non-illuminated side of the metal film. 
In a Biacore the glass slide of the chip represents the first transparent medium and the 
second transparent medium is represented by the aqueous layer of analyte immediately 
adjacent to the gold ligand-coated surface of the sensor chip. The refractive index is therefore 
dependent on the state of ligand-analyte interaction. 
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Figure 2.2: A: Diagrammatic representation of the evanescent wave propagated into the 
medium of lower refractive index on the non-illun-finated side of the metal film. This occurs 
under conditions of total internal reflection. B: Diagrammatic representation of surface 
plasmon resonance occurring when light penetrates the gold film of the sensor chip after first 
passing through the glass slide. The change in resonance angle can be plotted as resonance 
units as a function of time to obtain a sensorgram, displaying the progress of the interaction. 
Therefore, when sample and buffer are flowed in alternation for defined time-periods 
over the sensor chip as part of a confinuous flow of fluid, such that analyte binds ligand 
during sample injection, and dissociates when sample injection is stopped and replaced with 
buffer, kinetic analysis of the interaction can be performed. The flow of analyte must not be 
slower than the rate of diffusion of analyte from the laminar flow to the ligand on the chip 
(mass transport) or it will limit the analyte-ligand interaction and incorrect binding kinetics 
will be observed. A trace termed a sensorgram is produced, plotting the change in resonance 
angle as a function of time such that the rise and fall in resonance angle reflects the 
association and dissociation phases of analyte (Figure 2.3). Kinetic information can then be 
extracted from the rate of change of the association and dissociation signals. 
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Figure 2.3: Example of a simple sensorgrarn illustrating binding of analyte to sensor chip 
surface. A sensorgram, displaying association and dissociation kinetics is produced by 
alternating buffer and analyte exposure to the sensor chip for defined time periods as part of a 
continuous flow of fluid. Analyte binds to the surface during the sample injection and 
dissociates when sample is replaced with buffer. 
Protocol usedfor measurement of binding kinetics: All Biacore experiments documented in 
this Thesis were performed by Dr. James Hunt. Assays were performed on a Biacore 3000 
instrument (Pharmacia Biosensor), at 24 T. The IgG4-Fc-(sFccRI(X)2 fusion protein was 
immobilised on a CM5 sensor chip using the amine coupling kit (Biacore) according to the 
manufacturer's instructions. Coupling density was restricted to less than 500 RU. Non- 
specific binding was assessed by preparation of a control surface of IgG4-Fc, in an identical 
manner. Samples of wild type and R334S anti-NP IgE were diluted in HBS, pH 7.4 (supplied 
by Pharmacia Biosensor) and injected over the sensor chip at a flow rate of 20 ýtl / min. A 
420 s association phase was followed by a 420 s dissociation phase. Data were collected for 
both wild type and R334S anti-NP IgE in a concentration range of 12.5 to 100 nM. The 
sensor surface was regenerated by three 60 s pulses of 0.2 M glycine-HCI, pH 2.5. The data 
were analysed using the BlAevaluation analysis package (version 3.2, Pharmacia Biosensor). 
Non-specific binding was subtracted from the specific binding prior to kinetic analysis. 
Previous Biacore analysis and structural studies of the interaction between IgE and 
FcF_Rl have shown it to be biphasic. The biphasicity of the binding kinetics between IgE and 
FcF_RI can be explained by the occurrence of an interaction with 1: 1 stoichiometry, involving 
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two distinct interaction sites (as discussed in section 1.3.3). The BIAevaluation software 
includes a model which describes this biphasic interaction: 
A +B <-+AB 
plus: 
C+B <-+ CB 
Where A and C represent the two different modes of IgE binding and B represents FcCRI. 








= L2 *Cc, (R.. - Ri - 
R2)-kd2 
-R2 dt 
The total response is derived from the sum of the two individual components: 
R =R, +R2 
These equations are solved by the computer. 
2.3.2 Cellular biology methods 
Cytotoxicity/phagocytosis assay: A flow cytornetric assay was set up for quantification of 
tumour cell death induced by MOv 18 IgE or IgG, encompassing a method for detection of the 
proportion of cells that are phagocytosed by effector cells and those killed by cell-mediated 
cytotoxicity. The design and optiniisation of this assay are described in detail in Chapter 4. 
Tumour cell targets and cytotoxic effector cells are distinguished by CFSE and PE-labelling 
respectively, and dead cells are labelled with propidiurn iodide (PI). After incubation of 
effector and target cells with MOvl8 or control antibody, tumour cell targets that have been 
phagocytosed by effector cells can be recognised as a CFSE/PE double positive population 
and tumour cell targets killed externally can be recognised as a CFSE/Pl double positive 
population. This assay is explained schematically in Figure 4.1. 
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Experimental method: Tumour cell targets were stained with USE approximately 24 hours 
prior to performing the killing assay; cells were trypsinised and washed once in standard 
culture media, followed by one wash in serum-free culture media before resuspension to 50 x 
106 cells/mlinPBS. Cells were warmed to 37'C before addition of 20 gl of 0.5 mM CFSE 
per I ml of cell suspension, and incubated at 37 T for 10 minutes, mixing every two minutes 
to improve the uniformity of staining. Staining was stopped with one wash in ice-cold 
standard culture media. Normal culture conditions were resumed until use in killing assay, 
whereupon CFSE-stained tumour cell targets were trypsinised and washed in standard culture 
and re-suspended to 130 000 cells / 200 gl culture media. Effector cells were washed and 
resuspended to the same concentration. 200 gI aliquots of each effector and target cells were 
mixed together in FACS tubes. Where relevant, blocking antibodies were added for 30 
minutes prior to normal incubation for 2.5 hours at 37 OC in the presence of either PBS or 
defined amounts of test antibody (anti-NP IgE, MOvl8 IgE, MOPC or MOvl8 IgG). After 
incubation, cells were washed once in 2 ml ice-cold FACS buffer and effector cells were 
identified by staining with 4 pl of anti-CD89-PE (primary and U937 monocytes) or anti- 
CD49d-PE (primary eosinophils) per tube, for 30 minutes, 4 OC. PE-staining was followed by 
one wash in 2 ml ice-cold FACS buffer and staining of dead cells with 5 gl of 10 gg / ml PI 
for 15 minutes, 4 T. Cells were washed once in 2 ml ice-cold FACS buffer and resuspended 
to 200 gl in FACS buffer for immediate analysis with a Becton Dickinson FACScan flow 
cytometer. Quantification of tumour cell death by MOO 8 in the absence of effector cells was 
performed as above but excluding steps for effector cell addition and effector cell labelling. 
Analysis method: Calculations for quantification of turnour cell death as contributed by 
cytotoxicity or phagocytosis were made using CellQuestTm software on a FACScan flow 
cytometer (131) Biosciences). Two dot plots, were created following the acquisition of 20 000 
events from each tube; representative dot plots are shown in Figure 2.4 (and reproduced in 
Chapter 4 as Figure 4.513). A detailed description of the logic behind this calculation is given 
in section 4.2.5. Each cytotoxicity assay was performed in triplicate. The mean number of 
events in region 'RI' (indicated in Figure 2.4, left-hand plot, large green gate) was calculated 
for three control tubes containing effector and target cells, but no antibody, and the resulting 
value termed the 'RI ratio control'. From this number, the number of events in region RI for 
each 'test' tube was subtracted. The resulting value was added to the number of events in 
region 'RY, divided into the RI ratio control value and multiplied by 100. This number 
represents the percentage of target cells of those originally added to the tube, which have been 
killed by cytotoxic mechanisms. The number of target cells killed by phagocytosis is 
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Figure 2A Dot plots showing the gates used to calculate antibody dependent cytotoxicity 
(ADCC) and phagocytosis (ADCP) in the killing assay described in Chapter 4 of this Thesis, 
and used for experiments described in Chapter 5 of this Thesis. Region I (RI, large green 
gate) contains all CFSE' IGROV I cells acquired. Region 2 (R2, yellow gate) contains those 
IGROVI cells which are also positive for PE and represent phagocytosed IGROVI cells. 
Region 3 (R3, red gate) contains those CFSE' IGROVI cells that are also Pl', and thus 
represent IGROVI cells killed by cytotoxicity. This figure is reproduced in Chapter 4, as 
Figure 4.5B, where the calculation made using the values defined by these gates is described 
in more detail. 
Immunofluorescence imaging of killing: In order to confirm that the populations assumed 
to represent killing of IGROV I tumour cells by cytotoxic and phagocytic mechanisms in the 
novel ADCCP assay described above, Dr. Sophia Karagiannis performed 
immunofluorescence imaging of killing, according to the protocol described below. In brief, 
130 000 CFSE' IGROV I tumour cells (CFSE stained according to the protocol described 
above) were incubated with 130 000 U937 cells, either untreated or cultured for 4 days prior 
to the assay in standard U937 culture rnedia supplemented with 320 U/ ml recombinant 
human IL-4, in glass chamber slides (Lab-Tek 11, SLS, Nottingham, UK) for 2.5 hours at 37 
T, 5 17C C02. Following this incubation, cells were washed twice by gently pipetting ice-cold 
FACS buffer onto the slide, which was immediately tipped off. U937 effector cells were then 
stained with anti-CD89-PE by addition of 14 ýtl of anti-CD89-PE to each chamber, and 
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incubation for 25 minutes at 4 T. Cells were then washed twice with ice-cold FACS buffer 
(as before), fixed in I% paraformaldehyde and mounted in fluorescence preserver (DAKO) 
under a cover-slip for analysis using a Carl Zeiss microscope at a magnification of 200 x. 
2.3.3 Animal model methods 
Nude mouse model of ovarian cancer: Experiments using this model were performed by 
Richard Thompson and Nick East of Frances Balkwill's group, at CRUK, Charterhouse 
Square, London. Xenografts were established in 8-12 week old specific pathogen-free female 
nu/nu mice of a BL/6 background. The human ovarian cancer xenograft used was, HUA 
(Ward et al, 1987). The HUA ovarian cancer xenograft was originally established in the 
peritoneal cavity of nude mice directly from the primary turnour of a 23-year-old patient with 
a moderately differentiated serous cystadenocarcinorna (ascities stage III). HUA is passaged 
in mice whilst retaining its human phenotype. The passage cycle time of the HUA tumour is 
20-22 days when transferred from one nude mouse to another by intraperitoneal injection of 
200 ýtl ascities (Ward et al, 1987). Immunohistochen-tical staining of tumour sections with 
MOvl8 IgE revealed that HUA tumour cells express the folic acid receptor (Karagiannis et 
al., 2003). To implant the HUA tumour mice were injected intraperitoneally with 0.2 ml 
HUA tumour ascities on day 1. 
In the first experiment, the ability of an effector cell population of human PBMC plus 
MOO 8 IgE was compared to human PBMC plus Movi 8 IgG 1, to mediate improved survival 
of HUA-bearing nude mice. To this end, the HUA tumour was transplanted into a total of 16 
mice; these 16 mice were divided into 4 groups of 4 (termed groups A, B, C and D). Mice in 
all groups were treated on days 1,7,14 and 21 with the following treatments: Each mouse in 
Group A was treated identically with 200 gl of PBS, each mouse in Group B was treated 
identically with 200 ýd of PBS containing 4 million human PBMC, each mouse in Group C 
was treated identically with 200 gl of PBS containing 4 million human PBMC in addition to 
100 gg of MOvl8 IgE and each mouse in Group D was treated identically with 200 41 of PBS 
containing 4 million PBMC in addition to 100 gg of MOvl8 IgG. In all experiments, the 
first treatment dose was given on the same day of tumour transplant, a minimum of five hours 
later. PBMC for this experiment were obtained from the same donor, on all treatment doses. 
This experiment was repeated, using an additional 5 mice per group, and a different, single, 
PBMC donor. The results shown in Figure 6.1, represent the compiled results of both 
experiments. 
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The second experiment performed using this model, involved transplant of the HUA 
tumour into a total of 20 mice; these 20 mice were divided into 5 groups of 4 (Groups A- E). 
On days I and 15, each mouse in group A was treated with 200 gI of PBS; each mouse in 
group B with 200 91 of PBS containing 4 million PBMC; each mouse in group C with 200 gl 
of PBS containing 4 million monocytes; each mouse in group D with 200 gl of PBS 
containing 4 million PBMC plus 100 gg of MOvl8 IgE; and each mouse in group E with 200 
[il of PBS containing 4 million monocytes plus 100 ýtg of MOvI8 IgE. A single blood donor 
was used for this experiment, from which both PBMC and monocyes were purified, on both 
treatment dates. 
The third experiment performed using this model, involved transplant of the HUA 
turnour into a total of 15 mice; these 15 mice were divided into three groups of 5 (Groups A- 
Q. On days I and 15, each mouse in group A was treated with 200 gl of PBS; each mouse in 
group B was treated with 200 ýfl of PBS containing 4 million U937 monocytes; and each 
mouse in group C was treated with 200 gl of PBS containing 4 million U937 monocytes plus 
100 gg of MOvl8 IgE. This experiment was repeated by Dr. S. Karagiannis, therefore, the 
results of this experiment, shown in Figure 6.3, represent the compiled results from both 
experiments, therefore n=9. 
The fourth experiment performed using this model, involved transplant of the HUA 
tumour into a total of 30 mice; these 30 mice were divided into three groups of 10 (Groups A 
- Q. On day 1, each mouse in group A was treated with either 200 gi of PBS; each mouse in 
group B was treated with 200 gl of PBS containing 3.6 million human eosinophils; each 
mouse in group C was treated with 200 gl of PBS containing 3.6 million eosinophils with 100 
gg of MOvl8 IgE (Group Q. On day 15, these treatments were repeated, but where 
eosinophils were included, the number was reduced to 2.6 million per mouse, due to a lower 
yield from the same volume of blood, from the same donor. 
In all experiments, mice were killed by cervical dislocation when the abdomen 
became distended to an extent to which the original body weight was increased by no more 
than 10 %, and ascities was removed under sterile conditions into liquid nitrogen or folmol 
saline for 24 hours for inirnunohistochemical processing at a later date. 
'Humanised' mouse model of lung metastases: Experiments in this model involved the 
growth of C26tFR tumour cells as superficial metastases on the lungs of syngenic mouse 
strains. In vitro culture of C26tFR cells was performed in the absence of G418 for 5 days 
prior to injection. Before injection, cells were washed twice in PBS in which they were also 
re-suspended. In all cases, tumour cells were injected intravenously into the tail vein, using a 
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26 Gauge needle, in a total volume of 400 gl. For tumour cell injection, mice were placed 
under ether anaesthefic and restrained in a small ventilated box from which the tail protruded. 
Sacrifice was by cervical dislocation either when mice showed dyspnea or on a specific date 
prior to this. In all cases, lungs were analysed for metastases using the following procedure: 
A midline incision from below the diaphragm to above the throat followed by an incision 
through the salivary glands was used to expose the trachea before opening of the chest cavity. 
Great care was taken to avoid even minor damage to the lungs. Approximately I ml of a 
solution of 15 % India ink in water was infused into the lungs by inserting a syringe (to which 
a p200 Gilson pipette tip was attached) into the trachea via the mouth to fill the alveolar 
spaces and stain all lobes deep black. The lungs were then dissected en bloc, from the 
thoracic cage and placed in a beaker of distilled water for at least 5 minutes to remove excess 
ink. The organ was then placed in Fekete solution (a bleach preservative, see section 2.1.3) 
for 48 hours, after which tumours were visible as white nodules on a black normal lung fissue 
surface (Wexler et al, 1966). 
C26tFR tumour cells were first tested for their ability to grow in hFcF_RI Tg mice. 
This was performed by intravenous injection of 104 C26tFR tumour cells into each of four 
hFccRI Tg mice as described above. This number of tumour cells was chosen for injection 
based on work documented in Rodolfo et al., 1998, where injection of 104 C26tFR tumour 
cells resulted in dyspnea from lung metastases between days 20 and 40. Differences in the 
growth rate of C26tFR cells between Balb/c mice and different strains of hFcF_RI Tg mice 
(FcF_RI Tg h'/' in--, h-1- in"' and h-/' in-/) was tested for by intravenous injection of 104 
C26tFR cells in a volume of 400 gl into a minimum of 4 mice of each strain. Mice were 
sacrificed by cervical dislocation when they showed dyspnea, and the number of survival days 
between tumour injection and sacrifice noted. For set-up of 'metastases counting' 
experiments, the optimal number of tumour cells required for injection and optimal date of 
sacrifice for a high number of superficial lung metastases to have developed was determined. 
Forty-five, eight-week-old Balb/c mice received intravenous injection of either; 5x 10', 104 
or 10' C26tFR tumour cells, resuspended to 400 gl in PBS. Three mice from each group were 
sacrificed on days 15,17,19,21 and 23 by cervical dislocation, and metastases quantified as 
described above. 
WAG rat model of lung metastases: To determine the optimal number of CC53ltFR cells 
for injection in survival experiments, 10-week-old WAG rats, under isofluorane anaesthesia, 
were injected intravenously in the lateral tail vein with CC53ltFR tumour cells (clone 16) 
grown for 5 days prior to injection in G418-deficient media and resuspended to I ml in PBS. 
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Rats received a single dose of 2.5 x 106,5 x 106,10 X 106 , 25 x 
106 or two or three doses of 5 
X 106 CC53ltFR cells. Rats were sacrificed by overdose of carbon dioxide gas when they 
showed dyspnea. Lungs were removed and metastases detected using the same method 
described above for mice. 
Passive cutaneous anaphylaxis model: A mouse model of passive cutaneous anaphylaxis 
was used based on work described in Dombrowicz et al., 1993 and 1996, which itself is based 
on original work by Wershil et al., 1987. This model was used to compare the ability of wild 
type to R334S anti-NP IgE to sensitise FcFRI-expressing cells for IgE-specific antigen- 
activation. A local anaphylactic reaction (local fluid extravasation, fibrin deposition and 
tissue swelling) is induced by intradermal injection of IgE into the dorsal surface of the mouse 
ear, followed by an intravenous antigenic challenge. Specifically, hFcF-RlTg mice (see 
section 2.1.4) were injected under ether anaesthesia with 20 gg, in a 20 gl volume, of wild 
type anti-NP IgE in one ear, and mutant (R334S) anti-NP IgE or PBS in the other ear of the 
same mouse. At defined time-points following sensitisation (48 or 96 hours), animals were 
injected in the tail vein with 200 gl of PBS containing 100 ýtg of NIP-BSA and 2% Evans 
blue dye. Evans blue dye binds serum proteins and so remains largely in the circulation until 
the change in vascular permeability associated with anaphylaxis allows its extravasation. 
Thus, quantification of extravasated Evans blue dye into the IgE-sensitised area following 
intravenous antigen challenge is representative of the intensity of the local anaphylactic 
reaction. As such, animals were sacrificed 1.5 h after intravenous antigen challenge, ears 
were amputated, cut to identical sizes and Evans blue dye extracted into I ml formamide by 
mincing followed by incubation at 80 T until all dye was extracted. The Evans blue dye in 
300 gl of formamide was measured by absorbance at 620 nm after filtration to remove ear 
debris. 
Quantification of human IgE in the ear tissue: For experiments measuring the rate of IgE 
diffusion out of ears, 14 ýtg of anti-NP IgE in a 20 ýd volume was injected into the dorsal 
surface of the mouse ear. Mice were sacrificed either 24,48 or 96 hours later without antigen 
challenge or Evans blue dye injection, and ears removed and cut to identical sizes as above. 
IgE was extracted from ear tissue by homogenisation of each individual ear in Lysis buffer B. 
Four sequential extractions from each ear were made by homogenisation of the chopped ear in 
400 gI of Lysis buffer B using an Anachern cordless motor (Part number K-749540-0000) 
with disposable hornogenisation attachment. This was followed by four sequential sets of 
each a 30-n-ýinute incubation at 4T with gentle shaking, centrifugation at 14 000 rpm (using 
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an ALC Airspeed refrigerated centrifuge (model PK121R) fitted with a fixed angle ALC 
T527 rotor), at 4T for 30 minutes, removal of 300 gI of supernatant followed by replacement 
of 300 ýd fresh Lysis buffer B. Supernatants containing IgE-extracts were stored at -70 T 
until quantification of IgE by ELISA. 
2.3.4 Statistical tests 
Students t-test: Significance of differences between effector cell populations acting either 
alone or in combination with MOvI8 IgE or anti-NP IgE in killing tumour cells or mediating 
improved survival of nude mice, was calculated using 2-tailed, un-paired t-tests unless 
otherwise indicated. P values greater than 0.05 were deemed to be insignificant, and those 
equal to or less than 0.05 deemed to be significant. Calculations were performed using 
Microsoft Excel software. 
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CHAPTER 3: 
Characterisation of cells and antibodies central to work discussed later in this Thesis: 
Cytotoxic effector cells, tumour cell targets, MOv18 IgE and MOv18 IgG1 
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3.1 Introduction 
In this project, I have assessed the ability of MOvl8 IgE and MOvl8 IgGl to trigger 
different FcF, - and Fcy-receptor-expressing effector cell populations to kill (Folate Binding 
Protein (FBP)-expressing) turnour targets, both in vitro and in vivo. The in vitro assay I have 
used is a novel flow cytometric assay designed to distinguish and quantify turnour cell death 
as it occurs by both cytotoxicity and phagocytosis. The set-up and optimisation of this assay 
is described in Chapter 4, and results from experiments using this assay are documented in 
Chapter 5. Work described in Chapter 6, a nude mouse model of human ovarian cancer, 
assessed the efficacy of those same effector cell populations, in triggering MOvl8 IgE- 
mediated turnour cell death in vivo. Additionally described in Chapter 6, is the set-up of two 
new, more clinically relevant in vivo models in which the safety and efficacy of MOvl8 IgE 
can be tested in the future. The purpose of this chapter is to provide an introduction to those 
effector cells, tumour target cell lines and MOvl8 IgE and MOvl8 IgGI antibodies used for 
experiments described in Chapters 4 to 6 of this Thesis. 
3.2 MOvI8 IgE and MOv18 IgG1 antibodies 
Both the MOvl8 IgE and MOvl8 IgGI used in this project are chimaeric human 
antibodies. Chimaeric-human MOvI8 consists of human constant regions and murine 
antigen-binding variable regions (as described in sections 1.4.2 and 2.2.2 and shown 
shematically in Figure 1.10). MOvl8 IgE and MOvl8 IgGl were purified from cell culture 
supernatants by affinity chromatography using an ory-fusion protein and Protein G column 
respectively (see section 2.3.1). SDS-polyacrylaniide gel electrophoresis of the affinity 
purified MOvl8 IgE and MOvl8 IgGI under non-reducing conditions, is shown in Figure 
MA (this 5-8% SDS-PAGE gradient gel, was kindly performed by Dr. Rebecca Beavil). 
This revealed that the products are of the expected molecular mass of approximately 190 000 
Da and 150 000 Da, respectively, and of high purity. That MOvl8 IgE and MOvl8 IgGI 
could bind FBP was confirmed by positive binding to IGROVI tumour cells, which do not 
express IgE or IgG Fc receptors and thus cannot bind anti-NP IgE or control human IgG. The 
ability of MOv18 IgE and MOv18 IgGI to bind FcF-- and Fcy-receptors respectively was 
determined by positive binding to the U937 monocyte cell line, which does not express FBP 
(Figure 3.111). In both cases, MOvl8 IgE and MOvl8 IgGI binding was detected using a 
FITC-conjugated anti-IgE or anti-IgG secondary antibody. The isotype control antibodies for 
MOO 8 IgE was anti-NP IgE, raised against the hapten NP, but also binding NIP. MOPC was 
used as the control antibody for MOv 18 IgG I in cytotoxicity assays. Anti-NP IgE and MOPC 
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Figure 3.1: (A) 5-8% SDS-PAGE gradient gel of MOvl8 IgE and MOvI8 IgGl showing 
products of approximately 190 kDa and 150 kDa, respectively, performed by Dr. Rebecca 
Beavil. (B) FACS histograms showing binding of MOvI8 IgE and MOvI8 IgGl to both 
U937 monocytes and IGROVI tumour targets implying functional F(ab')2 and Fc regions. 
Anti-NP IgE and control hIgG bound to U937 but not IGROVI cells, as expected. The grey 
shaded area represents the negative control (anti-IgE-FITC or anti-IgG-FITC alone), and open 
curves represent the test antibody and secondary antibody. The mean fluorescence intensity 
(MFI) given is representative of the difference between the negative control and test antibody. 
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3.3 Tumour-tar2et cell lines 
3.3.1 Folate binding protein expression 
Three different in vitro maintained tumour-target cell lines have been used in this 
Thesis. These include the human ovarian cancer cell line, IGROVI, the wild type Balb/c 
mouse colon carcinoma cell line, C26, and the WAG rat colon carcinoma cell line, CC531. 
Both C26 and CC531 cell lines were kindly provided by Dr. Silvana Canevari (Isfituto 
Nazionale Tumori, Italy). These tumour cell lines are described in detail in section 2.2.1. 
IGROV I cells constitutively overexpress FBP. Dr. Silvana Canevari also provided a C26 cell 
line transfected to express human FBP, previously used in Rodolfo et al., 1998, and an FBP- 
transfected CC531 cell line. Three FBP-transfected clones of the CC531 cell line were 
received, expressing high (clone 2), medium (clone 11), and low (clone 16) levels of FBP. 
Expression of FBP on each of these cell lines is shown in Figure 3.2, as detected with MOv 18 
IgE and anti-IgE FITC. Neither anti-NP IgE nor MOPC bound to any tumour cell line, nor 
did MOv 18 IgE bind to wild type C26 or CC531 turnour cell lines. This suggests that MOvI8 
IgE and MOvI8 IgGI bind to turnour cell lines through a specific interaction between 
antibody F(ab')2 regions and FBP. 
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Figure 3.2: FBP expression on the three different in vitro maintained tumour cell target lines 
used for experiments described in this Thesis. The grey shaded area represents the negative 
control, which in each case is anti-IgE FITC alone binding to the indicated cell line. FBP 
expression is detected using MOvl8 IgE followed by anti-IgE FITC. The MFI given is 
representative of the difference between the negative control and test antibody. Anti-NP IgE 
binding to each cell line was negative in each case, as was MOvI8 IgE binding to wild type 
C26 and CC531 cell lines. 
Chapter 3 83 
3.3.2 Effects of MOvl8 bindinato FBP 
It was first determined whether the binding of MOv 18 IgE or MOv 18 IgG I to FBP on 
tumour target cells was cytotoxic, either alone or when FBP was indirectly aggregated by 
cross-linking of MOvI8 IgE or MOvl8 IgG1 Fc regions using anti-IgE or anti-IgG 
antibodies, respectively. The purpose of this was to confirm that any death of tumour cell 
targets that was seen in the presence of effector cells and MOvl8 in later Chapters, was a 
result of effector cell activity, and not cytotoxic effects of the MOvI 8 antibody. As described 
in section 2.3.2 tumour cells were incubated in FACS tubes at 37 'C (130 000 cells / tube) for 
2.5 hours with either MOvl8 IgE or MOvl8 IgG1 (2 gg), alone or in combination with an 
excess of whole, bivalent anti-IgE or anti-IgG respectively (antibodies used have reference 
numbers 18 and 21 in Table 2.2). Testing MOvl8 IgE and MOvl8 IgGI in this way 
replicates the conditions of the in vitro killing assay, used in Chapters 4 and 5, but with the 
exclusion of effector cells. Results using IGROVI cells, show both MOvl8 IgE and MOvl8 
IgG I to have no significant effect on the viability of IGROV I cells above background levels 
when incubated together for 2.5 hours (Figure 3.3). In addition, it appears that aggregation of 
FBP on IGROVI cells by cross-linking either FBP-bound MOvl8 IgE or MOvI8 IgGI, does 
not cause cell death. Dead cells were quantified by staining with propidiurn iodide (PI) and 
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Figure 3.3: Effect of MOvI8 IgE and MOvI8 IgGI alone on IGROVI viability. IGROVI 
turnour cell targets (130 000 cells / FACS tube) were treated with either PBS, 2 gg MOvl8 
IgE or 2 ýjg MOv 18 IgG I, and incubated for 2.5 hours at 37 OC. Where indicated, cells were 
additionally incubated with bivalent anti-IgE or and-IgG antibody for the 2.5 hour incubation 
at 37 T. Dead cells were detected by flow cytornetry as Pr events on a FLl/FL3 dot plot. 
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Results with IGROV I cells contrast from those obtained with C26tFR cells, shown in 
Figure 3.4 below. MOv 18 IgE alone has a substantial cytotoxic effect on C26tFR cells, with 
greater than 50 % of the population being killed in a 2.5 hour period. MOvl8 IgE had no 
effect on wild type C26 cells, and anti-NP IgE no effect on C26tFR cells. However, not only 
was an equivalent effect not seen with MOvl8 IgGl, but pre-treatment of C26tFR cells with 
MOvl8 IgGI before MOvl8 IgE incubation, was able to substantially inhibit MOvl8 IgE- 
mediated cytotoxicity (Figure 3.4A). Incubation of C26tFR cells with MOvl8 IgGI in the 
presence of anti-IgG, did not induce cytotoxicity, and anti-IgE also did not increase MOv 18 
IgE-mediated cytotoxicity any further (Figure 3.4B). 
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Figure 3A Effect of MOV18 IgE, anti-NP 19E, and MOvI8 IgGI alone on wild type and 
FBP-transfected C26 cell viability; (A) also shows the effect of MOvI8 IgE following pre- 
treatment of cells with anti-NP IgE or MOvl8 IgG; (B) shows the effect on cell viability 
when whole, bivalent anti-IgE or anti-IgG was additionally included for the duration of the 
2.5 hour incubation at 37 OC. Dead cells were detected by flow cytometry as Pl' events in the 
FL3 channel of a FLI/FL3 dot plot. 
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A cytotoxic effect of MOvI8 IgE alone was also tested for on FBP-transfected 
CC531 cells (Figure 3.5). Results of MOvI8 IgE cytotoxicity on each clone of FBP- 
transfected CC531 cells, suggest that killing through FBP by MOvI8 IgE is proportional to 
the level of FBP expression (see Figure 3.2 for FBP expression levels). However, IGROV I 
cells express levels of FBP substantially higher than that of CC53ltFR clone 2 and C26tFR 
(see Figure 3.2), but do not show the same susceptibility to MOvI8 IgE mediated 
cytotoxicity. Therefore, it appears the effect is either specific for cells expressing high FBP 
levels gained through transfection, or, for rodent cell types expressing human FBP. 
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Figure 3.5: Cells of each clone of CC531 were incubated with either PBS or 2 gg MOvl8 
IgE for 2.5 hours at 37 OC. Dead cells were stained with PI and detected by flow cytornetry 
on a FLI/FL3 dot Plot. 
3.4 Effector cell Populations 
Of the cell populations implicated in IgE-mediated immune responses (and discussed 
in section 1.3.5), those demonstrated to possess IgE-mediated. cytotoxic effector functions 
include mast cells, basophils, monocytes and eosinophils. In addition, they are primary 
tumour-infiltrating leukocyte populations (as discussed in section 1.1.2). If monocytes and 
eosinophils could perform MOv 18 IgE-mediated tumour cell death in vitro and or in vivo, this 
would suggest that it might be possible to manipulate those monocytes or eosinophils, either 
resident within turnours or actively recruited to tumour sites, to perform anti-tumour effector 
functions in human patients following treatment with MOvI8 IgE. Monocytes have already 
been shown to have the ability to kill FBP-expressing human tumour cells in a MOvl8 IgE- 
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dependent manner, both alone and as part of a population of PBMC (Karagiannis et al., 
2003). In this project, purified monocytes have been studied further; the ability of purified 
human eosinophils to act as effector cell populations in MOvl8 IgE-mediated killing of 
turnour cells both in vitro and in vivo, has also been studied. 
3.4.1 Monocytes 
Monocytes are the blood-circulating developmental stage of the mononuclear 
phagocyte lineage. This lineage originates from a granulocyte-macrophage colony-forming 
unit in the bone marrow under the influence of the lineage-determining cytokines M-CSF and 
GM-CSF, in addition to IL-3, KIT and TNF-family members, to form pro-monocytes. Once 
mature, pro-monocytes leave the bone marrow to circulate in the blood with a half-life of 
approximately 3 days. These blood circulating mature monocytes are also known as 
'immature macrophages' as they either constitutively, or upon receipt of specific signals (as 
discussed in section 1.3.5), are induced to migrate out of the blood to become fissue-dwelling 
macrophages. In tissues, macrophages may live for months, with characteristics specific to 
the particular tissue in which they reside (Johnston, 1988). Tissue-dwelling macrophages 
may mature further, into terminally differentiated muld-nucleated giant cells. The cells of the 
mononuclear lineage perform roles critical in host defence, including cytotoxicity, 
phagocytosis and secretion of soluble factors to co-ordinate the activities of other cells. They 
also play roles in tissue turnover and wound repair. Furthermore, as discussed in section 
1.1.2, monocytes and macrophages may have the ability to recognise and kill tumour cells in 
vivo; but this function appears to be suppressed as part of the successful evolution of a 
developing tumour (Pollard, 2004). The ability of monocytes and macrophages to defend the 
host by rapid phagocytosis is conferred by their expression of complement receptors and Fc 
receptors for IgG and IgE. 
As mentioned in section 1.3.2, the first description of FcERI expression on monocytes 
purified from human peripheral blood came from Maurer and co-workers in 1994. However, 
the methods used in this study, acid stripping of endogenous pre-bound IgE followed by 
detection of receptors using the anti-FcERI antibody, 15-1, meant that FcERI was only 
detected on monocytes from atopic donors. Experiments performed since this time have 
shown FcERI to be detectable also on monocytes from healthy human donors (Reischl et al., 
1996), although this required removal of carbohydrate from the cell membrane by 
neuraminidase digestion. In 2003, Karagiannis et al., reported the level of FcERI expression 
to be in the region of 2550 molecules per CD14-positive cell. They also showed that MOvl8 
IgE-mediated tumour-cell killing by monocytes is proportional to their level of free FcFRI 
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expression; monocytes from non-atopic individuals, which express a greater number of free 
FccRI than atopic individuals (where FcFRl is occupied by endogenous allergen-specific IgE), 
are more effective in MOvl8 IgE-mediated turnour cell killing. Therefore, donors used in in 
vitro assays in this Project, were chosen on the basis of having no history of allergic 
symptoms. Monocytes used in in vivo experiments were taken only from individuals 
characterised as non-atopic by skin prick testing. 
FccRI and CD23 expression levels were analysed by indirect immunofluorescence 
and flow cytometry on monocytes from all donors whose monocytes were used in killing 
assays described in this Thesis. FcFRI expression from a representative donor is shown in 
Figure 3.6. Monocytes were identified using an anti-CD14-PE antibody. Total IgE receptor 
expression on monocytes was determined by saturation of free IgE receptors with human IgE 
(MOvl8 IgE or NP IgE) and detection of total IgE (endogenous and added IgE) by secondary 
staining with anti-IgE FITC (antibody reference 18 in Table 2.2). A mean of 31.2 % (n = 3) 
of CD14-positive cells gave a positive anti-IgE-FITC signal (range was 27.6 - 36.2 %). The 
percentage of cells expressing free IgE receptors was determined by subtracting the 
percentage of cells with pre-bound endogenous IgE from the number of cells staining positive 
for IgE following saturation with IgE. This gave a mean of 14.8 % of cells with free FccRI 
(range was 14.6 - 15 %). The mean number of CD14-positive cells expressing free IgE 
receptors, when detected with 15.1 and anfi-IgGI-FITC, was roughly consistent at 24.25 % 
(range 11.5 - 37 %). These results are in accordance with those reported in Karagiannis et 
al., 2003. 
CD23 is not constitutively expressed by primary monocytes freshly purified from the 
peripheral blood of normal human donors. However, they may be induced to express CD23b 
in response to specific signals, most importantly, IL-4 (Vercelli et al., 1988 and Yokota et al., 
1988). Stimulation of monocytes with IL-4 may be associated with their activation and 
maturation into fissue-dwelling macrophages. Accordingly, no CD23 expression was 
detected on monocytes from any of the three blood donors tested. CD14-positive cells from 
each donor were demonstrated to be CD23-negative using the anti-CD23 antibody, BU38, in 
conjunction with anti-IgGI-FITC. 
Chapter 3 88 
I Lk, býcý. d 009 1 UIbI-kd 001 1 Ubl-ý. d 000 
5% 0.5% 
uJ 













-- ' -- ' "-- - 162 '0S 
,, 64 
100 101 "2 '03 "4 10 10' 110 1ý2 10 10 FL 144 FL I-H FLI-H 
Dual Negative No stain Anti-CD23-FITC 
Ur6bxked 002 Unblocked 003 Unblocktd 004 









< 0.5% < 0% < 0.5 
10 000 11 1&2 103 
;11 ;2 03 4V 104 0'101 10 0 101 1P I 
FL 144 FL 144 FL 144 
Anti-IgG-FITC IgG Iso. control + anti-IgG-FITC 15.1 + anti-IgG-FITC 
UnbI. Ckd 005 Unblock*d 0,06 U. N-ý. d 007 
60% 14.6% 385% 36.2% Lu 48% 27.6%, 6 
CL 
CL 
Ld 0% Lu Q_ 
C) 0 L J_ 
< 
4.5ý 17% 1 2.2% 
1 00 10,1; 
2 ý03 1 10 1 ý)' 16,1 4 _110 i, II. 1 -03 --1 ;4 
FL144 FL 141 FLIý 
Anti-IgE-FITC M008 IgE+ anti-IgE-FITC Anti-NP IgE+ anti-IgE-FITC 
Figure 3.6: Monocyte expression of IgE receptors. These data, from one blood donor, are rn 
representative of those obtained for the three non-allergic monocyte donors used in this 
project. Monocytes are defined as CD14' cells. CD23 expression was negative by BU38 and 
anti-IgG-FITC staining. Unoccupied FcF_Rl were detected using the anti-FcF-Rl antibody, 15- 
1, In conjunction with anti-IgGI-FITC. Occupied and free FceRI were detected by anti-IgE- 
FITC detection of endogenous IgE, compared to anti-IgE FITC staining of monocytes pre- 
treated with an excess of human IgE (MOv 18 IgE or anti-NP IgE). 
The IgE receptor expression status of U937 rnonocytes was also determined. A 
uniformly high expression of both FccRI and CD23 was found (Figure 3.7A). FcFRI was 
detected using 15-1 and anti-IgGl-FITC, giving a mean fluorescence intensity of 39.05. 
CD23 was detected using BU38 and anti-IgGI-FITC, to give a mean fluorescence intensity of 
3.98. As has often been reported since the original evidence was provided by Kawabe et al., 
1988, treatment of U937 cells with IL-4 upregulates CD23 expression (Figure MA; far right 
histogram) with an increase in mean fluorescence intensity from 3.98 for untreated U937 cells 
to 31-91 for IL-4-treated U937 cells. Surprisingly, it was observed that both MOv 18 IgE and 






Chapter 3 89 
U937 cells with a blocking antibody against CD23; anti-CD23 antibodies IDEC-152, BU38 
and TO gave the same result. No blocking was seen with the anti-Fcp-Rl antibody, 15-1 
(Figure 3.713). 
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Figure IT IgE receptor expression by U937 monocytes. (A) Left histogram; FcF_RI 
expression detected by 15-1 and anti-IgGI-FITC. Middle histogram; CD23 expression 
detected by BU38 and anti-IgGl-FITC. Right histogram; CD23 expression (again detected 
using BU38 and anti-IgGi-FITC) on untreated cells (black line) and the increase in CD23 
expression after 4 days culture in IL-4- supplemented medium (red line). The grey shaded 
area in each histogram represents the negative control. (B) Binding of MOvI8 IgE and anti- 
NP IgE to U937 monocytes as detected by anti-IgE FITC, and effect on IgE binding of pre- 
treatment of cells with anti-CD23 (IDEC- 152) or anti-FcF_RI (15- 1) blocking antibodies. 
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There are three different classes of Fcy-receptor, FcyRI (CD64), FcyRII (CD32) and 
FcyRlll (CD16). Details of these Fc receptors for IgG are given in Table LL Their 
expression by primary monocytes was extensively characterised in Karagiannis et al., 2003, 
and high expression levels for all three IgG-Fc receptors were found. The Fcy receptor 
expression status of U937 monocytes is shown in Figure 3.8, as detennined in this project. 
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Figure 3.8: Expression of IgG-Fc receptors on U937 monocytes. FcyRI (CD64), FcyRII 
(CD32) and FcyRIll (CD16) were all tested for by indirect immunofluorescence using mouse 
anti-human IgGI antibodies in combination with goat anti-mouse immunoglobulins 
conjugated to FITC. The grey shaded are represents the isotype control. 
Primary human monocytes and the U937 cell line were also confirmed to express 
CD89, the IgA Fc receptor (Figure 3.9) as reported in Patry et al., 1996. CD89 is used in the 
in vitro killing assay described in Chapters 4 and 5 of this Thesis, as a marker to distinguish 
monocyte effector cells from IGROV I tumour cell targets, which are CD89-negative. 
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Figure 3.9: FACS histograms of primary and U937 monocytes cells showing CD89 
expression to be absent on IGROVI tumour cells, and positive on both U937 and primary 
monocytes, using a PE-conjugated anti-CD89 antibody. Thee grey shaded area represents the 
isotype control. 
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3.4.2 Eosinophils 
Eosinophils develop from CD34' progenitors in the bone marrow under the influence 
of IL-5, which promotes their maturation and movement into the circulation. Their precise 
function in the human immune system is not clearly understood. They are the most abundant 
infiltrating cell population in many parasitic and allergic diseases and, although they are 
associated with some host protection in the former, they cause significant host pathology in 
both. The IgE-FcF-Rl-mediated effector functions of eosinophils are discussed in detail in 
section 1.3.5. Eosinophils purified from the peripheral blood of healthy human donors, 
express FccRl (Kayaba et al., 2001). Culture of eosinophils in IL-5 and IgE has been shown 
to upregulate FcF-RI expression (Kayaba et al., 2001). IL-5 serves to prolong eosinophil 
viability and enhance their effector functions (Lopez et al., 1988; Rothenberg et al., 1989). 
Although evidence for eosinophil FcF-Rl expression in Kayaba et al., 2001 is 
convincing, expression is very low, and in other studies, FcF-Rl expression has been deemed 
to be absent (Sihra et al., 1997; Serninario et al., 1999). Therefore, FcERI expression was 
analysed on freshly purified human eosinophils from one of the donors used as a source of 
eosinophils for cytotoxicity assays documented in Chapter 5. Using indirect 
immunofluorescence and flow cytometry, a positive signal for FcF-RI expression was obtained 
with the anti-hFcF-Rl(x antibody, 15-1, in conjunction with an anti-IgGI-PE secondary 
antibody. Although the positive signal for FcF_Rl is very low in Figures 3.10A and B, its 
specificity is demonstrated in two ways. Firstly, 15-1 binding could be blocked by pre- 
treatment of the cells with IgE and, similarly, IgE binding could be blocked by pre-treatment 
of the cells with 15-1. When MOvI8 IgE was replaced with anti-NP IgE, the same result was 
achieved (data not shown). For no donor tested was FcFRI expression detectable using a 
FITC-conjugated secondary antibody against 15-1 or hIgE (data not shown). This low level 
of FcERI expression on the eosinophil surface is despite a large intracellular pool of 'IgE 
receptor' as demonstrated by anti-IgE detection of MOvI8 IgE in permeabilised eosinophils 
(Figure 3.10Q. This is likely to be FcF-Rl oc-chain, as this receptor has been detected at high 
levels in the cytoplasm of eosinophils in previous work (Kayaba et al., 2001). 
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Figure 3.10: Surface and intracellular IgER expression by human peripheral blood 
eosinophils from a normal donor. (A) FcF_R1 expression. The grey shaded area represents 
Strep-PE staining alone. Endogenous IgE binding is detected using anti-IgE biotin + Strep- 
PE. The total number of FccR1 expressed (both unoccupied and bound with endogenous IgE) 
was detected by treatment of cells with MOv 18 IgE followed by anti-IgE biotin and strep-PE 
staining. MOvl8 IgE binding could be blocked with 15-1. (B) FcERI expression detected 
with 15-1 and anti-IgG I -PE. 15-1 binding was blocked by pre-treatment of cells with MOv 18 
IgE. (C) Intracellular IgER-expression as detected with M008 IgE in conjunction with anti- 
IgE biotin and strep-PE in permeabilised eosinophils. 
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To the best of my knowledge, there has been no convincing evidence for the 
expression of CD23 on eosinophils purified from the human peripheral blood of normal 
donors to date. In the few cases where the donors tested were normal (not atopic or 
hypereosinophilic), CD23 expression was shown to be extremely low to negative (Lantero et 
al., 2000), or negative (Seminario et al., 1999). It may be that expression of CD23 on 
eosinophils is inducible, and occurs upon migration of eosinophils from the circulation to the 
tissues, as occurs upon monocyte to macrophage maturation (Janeway et al., 4 th Edition). 
CD23 expression on eosinophils from the same population used to detect FcERI expression in 
Figure 3.10 above, is shown in Figure 3.11, below. Results were determined by indirect 
immunofluorescence using the anfi-CD23 antibody BU38, and an anti-IgGI-PE secondary 
antibody. The absence of CD23 expression on this particular donor is consistent with the data 
showing that human IgE binding was completely blocked by pre-treatment of cells with the 
anti-Fcp-Rl(x antibody, 15-1. Therefore, if CD23 is expressed on the surface of eosinophils 
from this donor, its levels are below the limits of detection of this method. 
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Figure 3.11: Expression of CD23 on the surface of human peripheral blood eosinophils from 
a normal donor. CD23 was detected using the anti-CD23 antibody, BU38, and anti-IgG I -PE. 
Eosinophils also express on their surface FcR y-chain (Serninario et al., 1999), a 
component of FcyRIII, in addition to FcFRI. Surface expression of FcyRIII has been reported 
to occur on approximately 6% of eosinophils purified from the human peripheral blood of 
normal donors (Zhu et al., 1998). Like FcERI, a sizeable pool of FcyRllI can be detected in 
the cytoplasm of all eosinophils. Furthermore, eosinophils express high levels of the IgG Fc 
receptor, FcyRII, but are negative for FcyRl (Grazanio et al., 1989; Koenderman et al., 1993; 
Kita et al., 1999). Also relevant to work described in later Chapters of this Thesis is the 
expression of CD49d (an integrin) by eosinophils. CD49d was chosen as a marker to 
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distinguish eosinophils from IGROV I tumour target cells due to its high expression level on 
the fonner, and absence of the latter (Figure 3.12). 
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Figure 3.12: CD49d was found to be negative on IGROV I tumour cells and positive on 
primary eosinophils, as detected with a PE-conjugated anti-CD49d antibody. The grey 
shaded area represents the isotype control. 
3.5 Discussion 
in this chapter, I have described the phenotypic characteristics of cells relevant to this 
Thesis. The tumour cell lines introduced include the human ovarian cancer cell line, 
IGROV 1, the Balb/c mouse colon carcinoma cell line, transfected with human FBP, C26tFR 
and the WAG rat colon carcinoma cell line, transfected with human FBP, CC53ltFR. 
Effector cell populations introduced include the U937 monocyte cell line, primary monocytes 
and primary eosinophils, purified from human peripheral blood. 
In section 3.3.2,1 describe experiments performed to determine whether MOv 18 IgE 
or MOvl8 IgGI alone cause cytotoxicity to each tumour cell line through binding to and 
cross-linking FBP. For IGROV I cells this has been tested previously and no cytotoxicity has 
been seen (Gould et al., 1999; Karagiannis et al., 2003). No reports of this kind for C26tFR 
cells have been made, and these are the first studies to be performed with CC531 tFR cells. In 
summary, what has been found in this chapter is that, as expected, neither MOvl8 IgE nor 
Mov 18 IgG I binding to FBP on IGROV I cells is cytotoxic, either alone or when cross-linked 
by anti-IgE or anti-IgG antibodies, respectively. This makes the IGROV I tumour cell line a 
suitable target for exclusive measurement of (antibody-dependent) cell-mediated killing. 
Furthermore, the high level of FBP expression on this cell line has previously been shown to 
enhance susceptibility to ADCC in vitro (Coney et al., 1994), a significant finding when taken 
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with the association of high FBP expression with poor prognosis in human ovarian cancer 
patients (Campbell et al., 1991 and Toffoli et al., 1994). As such, IGROV I cells are used as 
the turnour target cell line in the in vitro killing assays described in Chapters 4 and 5. 
Regarding the effect of MOvl8 IgE and MOvl8 IgGI on the viability of C26 cells 
transfected to express FBP, quite different findings were made: MOvl8 IgE was highly 
cytotoxic to C26tFR, but not wild type C26 cells. In contrast, anti-NP IgE had no cytotoxic 
effect on either wild type C26 or C26tFR cells. This suggested that MOvl8 IgE was 
mediating its cytotoxic effects on C26tFR cells through an interaction between MOvl8 IgE 
F(ab')2 regions and FBP. However, an equivalent cytotoxic effect on C26tFR cells was not 
seen from MOvl8 IgGl. Not only does MOvl8 19GI not display this cytotoxic effect, but 
pre-incubation of cells with excess MOvl8 IgGl, before MOvl8 IgE addition, was able to 
significantly reduce the cytotoxic effects of MOvl8 IgE. Anti-NP IgE, with its structurally 
identical Fc region to MOv 18 IgE but no FBP-binding F(ab')2 region, was unable to confer a 
similar blocking effect, supporting the apparent mediation of MOv 18 IgE cytotoxicity through 
FBP. This phenomenon will be investigated further as part of the continuing MOvl8 IgE 
project. Indeed, differential effects of some, but not other IgEs on the survival and activation 
of different cell lines are not unprecedented (Asai et al., 2001; Kalesnikoff et al., 2001; 
Kitaura et al., 2003). Work described in this Thesis has been performed under conditions 
where this effect does not apply, by using the IGROVI tumour cell line for in vitro studies, 
and clone 16 of the CC53ltFR cell line for an in vivo model (Chapter 6). Experiments using 
the C26tFR cell line (or clones 2 and II of CC5 31 tFR) in the future, will require additional 
controls to account for the contribution of killing coming from MOvl8 IgE-alone binding; 
suitable controls are suggested in the relevant parts of later Chapters. 
Expression of Fc-receptors, to which MOvl8 IgE or MOvI8 IgGI could bind on 
effector cells, were also characterised. U937 monocytes have been shown to be able to bind 
both anti-NP IgE and MOv 18 IgE via CD23, and not FccRI, despite expression of the latter at 
a higher level. This phenomenon has not previously been reported for FcF-RI on U937 
monocytes, although it has for primary monocytes (as discussed in section 2.2.3 and Reischl 
et al., 1996), where it was found that treatment of primary monocytes with neuraminidase was 
able to restore IgE-binding capacity through the removal of sialic acid residues that were 
blocking IgE binding. However, treatment of U937 monocytes with neuraminidase by Dr. 
Sophia Karagiannis, was found to have no effect on IgE binding to FcF-RI. It may be that 
FceRI expressed by U937 monocytes is blocked by a different carbohydrate, requiring a 
different enzyme for its removal. To see if it was in fact carbohydrate groups in IgE that were 
preventing binding, Dr. Rebecca Beavil deglycosylated some anti-NP IgE and MOvl8 IgE 
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(using PGNase), which Dr. Sophia Karagiannis found were still unable to bind FcF-Rl (Dr. 
Rebecca Beavil and Dr. Sophia Karagiannis, personal communication). The consequence of 
the inability of this U937 clone to bind human IgE, for work described in this Thesis, is that 
they can be used to assess contribution of CD23 alone to MOvI8 IgE-mediated killing of 
tumour cells by U937 monocytes. 
In confirmation of previous reports, approximately one third of primary human 
monocytes, purified from the peripheral blood of non-atopic donors, were shown to express 
FccRI, of which typically half were occupied with endogenous IgE (Reischl et al., 1996). 
Furthermore, as generally accepted (and discussed in Reischl et al., 1996) CD23 appeared not 
to be expressed by freshly purified human peripheral blood monocytes from the three normal 
donors tested in this Project. Primary human eosinophils, from a single donor, were also 
shown to express very low levels of FcF-RI, but no detectable CD23. Finally, it was shown 
that CD89 expression on monocytes (primary and U937) and CD49d expression on 
eosinophils occurred at sufficiently high levels on these cell types that they could be used to 
clearly distinguish them from IGROVI tumour cells, on which these antigens are absent. 
Such a marker was required for the killing assay described in Chapter 4 of this Thesis. 
Expression of Fc receptors for IgG on primary human monocytes and eosinophils has 
previously been well characterised, with primary monocytes expressing high levels of FcyRI, 
FcyRII and FcyRIII (Karagiannis et al., 2003) and eosinophils expressing only FcyRII at high 
levels (Seminario et al., 1999). Eosinophils are known to additionally express FcyRIlI at low 
levels on approximately 6% of cells, but the procedure used for eosinophil purification in this 
Thesis (section 2.2.3) involves their negative selection from a population of neutrophils, by 
use of anti-CD16 (FcyRUI) magnetic beads, and therefore any FcyRIII-expressing eosinophils 
are removed. It is important to note that FcyRII exists in a number of functionally 
heterogeneous subsets (see Table 1.1), including activatory ITAM-coupled isoforms 
(FcyRIla) and inhibitory ITIM-coupled isoforms (FcyRIIb). FcyRII on primary monocytes 
has been shown to include both inhibitory and activatory isoforms. To the best of my 
knowledge, it is not known which isoform(s) of FcyRII is expressed by eosinophils, although 
FcYRIIa expression is typically associated with granulocytes (Table 1.1). As expected, the 
U937 clone used for studies reported in this Thesis showed expression of both FcyRI and 
FcyRII (U937 expression of FcyRI was originally demonstrated by Allen and Seed in 1989 
and of FcyRII, by Stuart et al., 1987). It has previously been demonstrated (Cameron et al., 
2002) that the isoform of FcyRII expressed on U937 monocytes is FcyRIIa. Cameron et al. 
also detected transcripts for FcyRIIb, but expression of the protein was shown to be dependent 
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on differentiation of the U937 monocytes into a more macrophage-like phenotype upon 
stimulation with dibutyryl cyclicAMP. 
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CHAPTER 4: 
Development of a novel flow cytometric antibody-dependent cell-mediated cytotoxicity 
phagocytosis assay (ADCCP) 
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4.1 Introduction 
In this Chapter, I describe the development of a novel method for quantifying tumour 
cell death, triggered by Fc-receptor-expressing effector cells armed with a tumour-specific 
antibody. When an effector cell is conferred with antigen-specificity in this way, it is able to 
kill cells either by phagocytosis (internally) and or by cytotoxicity (externally): the mode(s) 
of killing used depends on the properties of both effector and target cells, the isotype of the 
antibody and the immune context of the interaction. The parameter used to quantify cell 
death in the most commonly used cytotoxicity assays, such as chromium (Brunner et al., 
1968) or LDH (Korzeniewski et al., 1983) release assays, is based on the loss of membrane 
integrity which occurs as a cell dies. In the 5 'Cr-release assay, this requires the target cells to 
be loaded with 5 'Cr prior to incubation with effector cells and antibody. Thi S5 'Cr is released 
from the targets as they die, into the extracellular medium, where it is measured. In the LDH 
assay, release of the cytosolic enzyme lactate dehydrogenase from dying cells catalyses the 
conversion of lactate and NAD' into pyruvate and NADH, following which a sample of the 
extracellular medium is mixed with diaphorase for conversion of NADH and the tetrazolium 
salt INT (2-p-iodophenyl-3-p-nitrophenyl-5-phenyI tetrazolium chloride) into a red formazan 
product (and NAD'), which is measured in a colorimeter. Clearly, measuring cell death on 
the basis of a change in a component of the extracellular media resulting from release of a 
substance from the cell cytosol, will not take into account any tumour cells which have been 
phagocytosed, as the markers of cell death will instead be released from the damaged target 
cell into the phagocyte (as shown previously to be the case by Munn and Cheung, 1989). 
Previous in vitro assessment of MOvl8 IgE-mediated tumour cell death has been 
made using both chromium (Gould et al., 1999) and LDH-release methods, in addition to a 
flow cytometric (FCM) method based on the same principle (uptake of the DNA-binding dye, 
EthDI through damaged cell membrane) (Karagiannis et al., 2003). However, 
immunofluorescence imaging of MOvI8 IgE-mediated tumour cell killing by monocytes 
(Karagiannis et al., 2003) suggests phagocytosis may also play a prominant role as a 
mechanism of tumour cell killing. Indeed, CD23 has a recognised role in mediating 
phagocytosis (as discussed in section 1.3.6). Therefore, it may be that a proportion of cell 
death is unaccounted for in this system. Although the FCM assay mentioned above (and 
described in Karagiannis et al., 2003) is based on the same principle as chromium and LDH 
release, like other FCM assays of ADCC, it has the advantage that dead cells are directly 
quantified on a single cell basis. Direct visualisation of all cells in this way and the ability to 
measure additional fluorescent markers in the flow cytometer allows for potential 
measurement of further parameters of cell death in the same assay population. 
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In this chapter, I explain the set-up of a new flow cytometric approach for quantifying 
antibody-mediated turnour cell death occurring by both cytotoxicity and phagocytosis. This 
assay is based on the same principle as those FCM assays used in Karagiannis et al., 2003, 
Radosevic et al., 1990 and Lee-MacAry et al., 2001, as just a few examples. What makes the 
assay described in this chapter different from those previously used is the inclusion of a third 
fluorophore that allows quantification of phagocytosis in addition to cytotoxicity. 
4.2 Principle of assav 
A schematic representation of the principle of this assay is shown in Figure 4.1, 
below, for reference throughout the remainder of this chapter. Each individual step involved 
in this assay is described in detail below. In summary, this flow cytometric assay involves the 
use of three different fluorophores. Before the assay is begun, tumour target cells are stained 
with the green fluorescent dye, USE (for more details, see section 4.2.1); this is step one. 
Tumour cells are then incubated with unstained effector cells (step two) and antibody 
(MOvl8 IgE or the control antibody, anti-NP IgE). After effector and target cell incubation, 
effector cells are labelled with the fluorescent dye, Phycoerythrin (PE), against an antigen 
expressed only on effector but not target cells; following this, all dead cells are labelled with 
Propidium Iodide (PI) (step 3). The change in the viability of the cells is then assessed by 
flow cytometry (step 4). Five different (useful) cell populations can be distinguished in total. 
These include (1) five tumour targets (CFSE+, PE-, PF), (2) live effector cells (CFSE-, PE+, 
PF), (3) dead turnour targets (CFSE', PE-, Pl+), (4) dead effector cells (CFSE-, PE+, Pl'), and 
(5) tumour cells which have been phagocytosed (CFSE+, PE+, Pl- or +). The set-up of this 
assay was begun by first separately optimising the single staining of individual cell types. 
Staining intensity was later adjusted such that the three fluorophores could be used in 
combination. 
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Figure 4.1: Schematic representation of the different cell populations distinguishable at the 
beginning and end of the ADCCP assay described in this chapter. The coloured boxes are for 
cross-reference with Figure 4.5B (at a later stage of reading this chapter); the green box 
corresponds to Region 1, the yellow box to Region 2, and, the red box to Region 3. 
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4.2.1 Target cell preparation 
The tumour cell target line chosen was IGROV I (the reasons for which are described 
in Chapter 3), and the target-cell fluorescent label chosen was CFSE. CFSE is cell permeant 
and non-fluorescent until inside the cell, whereupon its acetate groups are cleaved by 
intracellular esterases and it can bind free amino groups of intracellular proteins to become 
both fluorescent and cell impermeant. The optimal method for labelling tumour cell targets 
with CFSE was finally determined to be by incubation of 50 x 106 tumour cell targets in I ml 
of PBS with 20 pl of 5 mM CFSE for 10 minutes in a 37 T water bath (as described in 
section 2.3.2). The staining reaction was stopped by washing the cells twice in the (ice-cold) 
standard complete media in which they are normally grown. Normal culture conditions of the 
tumour cells were then resumed for 24 hours, after which time they were removed from 
culture for use in the killing assay. Initially, a titration of CFSE was performed to find the 
concentration at which staining of tumour targets is maximal. To this end, IGROV I tumour 
cell targets were stained with 0.03,0.06,0.125,0.255 or 0.5 mM CFSE using the same 
protocol as above, but with immediate flow cytometric analysis (i. e., cells were not returned 
to culture between staining and analysis). It can be seen from Figure 4.2, that CFSE staining 
does not plateau within this concentration range. However, staining was deemed to be 
sufficiently high for a preliminary cytotoxicity assay, following optinlisation of PE and PI 
staining of effector and dead target cells respectively, as described below in sections 4.2.2 and 
4.2.3. 
AB 
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Figure 4.2: (A) Titration of IGROV I CFSE staining. The grey shaded are represents 
unstained IGROV I cells Ctreated as stained, where USE was replaced with PBS), followed 
in order of increasing USE staining intensity with 0.03 (pink line), 0.06 (green line), 0.125 
(brown line), 0.25 (blue line) or 0.5 mM (red line) USE staining. (B) The FL I' population 
on this plot represents IGROV I cells stained with 5 mM USE 24 hours before analysis (and 
returned to culture between staining and analysis). L- 
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Preliminary killing assays showed that there was leakage of USE fluorescence into 
the FL2 channel that was too high to be compensated for, and therefore the staining intensity 
needed to be reduced. It was decided that instead of using a lower USE concentration, it 
would be better to follow staining with a 24 hour culture period, before using the cells in a 
killing assay. This would allow the excess USE to be quenched, but the tenacious retention 
of fluorescent USE dye means that cells should remain sufficiently bright (even in those that 
have divided). It can be seen from comparison of the red line on each of the histograms in 
Figure 4.2A and B that an overnight incubation of IGROV I tumour cells stained with 0.5 mM 
USE lead to a reduction in USE mean fluorescence intensity from 1540 to 84; the uniform 
nature of this reduction suggests it is due to catabolism and not cell division. The advantage 
of this culture period (in addition to reducing USE staining intensity) is that the tumour cells 
have time to recover from the staining procedure, potentially reducing background cell death 
in the ADCCP assay. 
4.2.2 Effector cell preparation 
The effector cell population used in the set-up of this killing assay was the U937 
monocyte cell line. This choice was based on its IgE receptor expression, uniform nature and 
virtually limitless availability, removing the need for time-consuming cell purification 
procedures, and the variability associated with using single cell populations from different 
donors. CD89 (the IgA Fc receptor), expressed on the surface of U937 cells, was chosen as a 
marker to distinguish effector from target cells. This antigen was determined to be suitable, 
due to its absence on IGROVI cells and high expression level on U937 cells (see section 
3.4.1, Figure 3.9). Effector cells were stained after the killing phase of the assay, so that 
labelling would not interfere with their ability to kill turnour targets. Anti-CD89-PE staining 
of U937 cells was titrated and analysed on an individual population basis before being used in 
a preliminary killing assay (Figure 4.3). Staining with 4 ý11 of undiluted anti-CD89-PE 
(antibody with reference number II in Table 2.2) was deemed to be a suitable compromise 
between staining brightness (MFI = 50) and cost-effective use of antibody. 
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Figure 4.3: Titration of CD89-PE staining of U937 monocytes. The grey shaded area 
represents unstained U937 monocytes, followed by order of increasing FL2 MFI by staining 
with I g] (red line), 2 pI (blue line), 4 gl (pink line), 8 pl (brown line) and 10 pl (green line) 
of anti-CD89-PE, per 130 000 cells. 
4.2.3 Cytotoxicity / 12hagocytosis assay 
Labelled IGROV I tumour target cells (CFSE') were incubated in triplicate in 12 x 75 
mm FACS tubes (Falcon, Becton Dickinson) with unstained effector cells and antibody 
(MOv 18 IgE, MOv 18 IgG, anti-NP IgE, MOPC or 'no-antibody control' tubes) at 37 T, 5% 
C02. The total number of cells in each tube was 260 000 in a 400 PI volume (these figures 
were based on those used for the flow cytometric killing assay used in Karagiannis el (d., 
2003). These three components were always added in immediate succession in the order of 
targets, effectors then antibody, although a change in this order had no effect on killing 
(results not shown). Following the incubation at 37 T (for 2.5 hours unless otherwise 
indicated) during which killing is expected to occur, the contents of each FACS tube was 
washed once in 2 n-d of ice cold FACS buffer, and then U937 effector cells were labelled with 
anti-CD89-PE. Subsequent to this staining step, cells were again washed in 2 rril ice cold 
FACS buffer, following which any dead cells were labelled with Pl. Cells were washed 
again, and then resuspended to 250 pl in ice-cold FACS buffer for immediate analysis, during 
which they were kept on ice. 
PI was chosen as a suitable dead-cell marker due to the ability to view its emitted 
fluorescence in the FL3 channel. PI cannot cross an intact plasma membrane, and therefore 
dead cells are labelled when membrane integrity is lost to the extent to which PI entry is 
allowed. PI intercalates between bases in the double stranded DNA and emits red 
fluorescence when excited by blue light. Cells were killed and membranes permeabilised 
Chapter 4 105 
using the DAKO fixation / permeabilisation kit (as described in section 2.2) for titration of PI 
in dead (CFSE') IGROV I tumour cells with 5 pl of either 0.3,0.6,1.25,2.5,5 or 10 Pzg, / ml 
of PI (Figure 4-4). Staining with 10 pg / ml PI was deemed to be sufficiently high (MFI 
1186), although it had not reached a plateau. 









Figure 4.4: Optimisation of PI staining of killed CFSE' IGROV I cells. The grey shaded area 
represents dead CFSE' IGROV I cells not stained with Pl. Populations with FL3' 
fluorescence, represent (beginning with the lowest MFI) cells stained with 0.3 (brown line), 
0.6 (pink line), 1.25 (dark green line), 2.5 (light green line), 5 (blue line) and 10 (red line) ltg / Z-1 
MI of Pl. 
4.2.4 Flow cytometry 
Cells were analysed on a dual laser FACSCaliburTm (Becton Dickinson). A threshold 
was set on a forward and side scatter plot to exclude the minimum amount of cell debris. 
Cells were excited by an Argon ion laser emitting at 488 nm. CFSE-labelled cells were 
detected in the FLI channel (530/30 nm band pass filter). PE-labelled cells were detected in 
the FL2 channel (585/42 nm band pass filter). PI used to identify dead cells was detected in 
the FL3 channel (670 nrn LP band pass filter). Photomultiplier voltages were set to place the 
CFSE-labelled cells predominantly in the third log decade of the FL I channel and the first log 
decade of the FL2 channel. Following this, voltage and compensation adjustments were made 
using a series of control tubes, such that PE' cells were placed predominantly in the second 
log decade of the FL2 channel and the first log decade of both FL I and FL3 channels, and 
that PI+ cells were placed in the fourth log decade of the FL3 channel and first log decade of 
both FLI and FL2 channels. Control tubes used to achieve this included live unstained 
effectors, live PE' effectors, live CFSE+ effectors and killed (using Dako fixation / 
permeabilisation kit, see Table 2.1) CFSE' targets either subject. or not, to PI staining (PI- / 
CFSE' and Pl+ / CFSE+ respectively). 
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4.2.5 Calculation of cytotoxicity and phagocytosis 
Acquisition was stopped after 20 000 events had been acquired and two dot plots 
were created from which to calculate the proportion of killing coming from both cytotoxicity 
and phagocytosis (Figure 4.513). The gates shown in Figure 4.5B were set using the same 
series of control tubes used to optimise instrument settings as described above in section 4.2.4 
(and shown individually below in Figure 4.5A). 
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Figure 4-5: (A) Control tube populations used for instrument settings and determination of 
where quadrants should be set. (B) Dot plots from which calculations were made: Region I 
(RI) includes events representing CFSE+ turnour cell targets alone. The CFSE+ tumour cell 
targets may be present within PE-stained effector cells (where they have been phagocytosed)-, 
these events are found in Region 2 (R2). Region 3 (R3) contains those tuniour targets which 
have been killed externally of effector cells (cytotoxicity) and are thus CFSE+/Pl+. Schematic 
representations of those cells found within these gates can be found in Figure 4.1. 
'Z II- 
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Region I (RI) was set to include all CFSE-positive events acquired, regardless of 
their PI and PE status. When effectors and targets were mixed at an original ratio of 1: 1, RI 
was expected to contain approximately 10 000 events, representing half of the 20 000 events 
acquired in total. Due to both background death and additional andbody-mediated death 
(where relevant), the number of events in RI was consistently lower than 10 000, reflecting 
the increase in ratio of live effectors to targets, in the tube. The amount by which the number 
of events in RI is reduced, represents the proportion of tumour cells which had been killed 
and fragmented, to the extent to which they cannot be acquired (as a cell / 'event') and go 
unrepresented on these FACS plots. To quantify this population, the number of events in RI 
of each of the three 'no-antibody control' tubes (containing only effector and target cells) was 
averaged, and referred to as 'RI ratio control'. For each test tube, the difference between its 
RI value and the R1 ratio control was determined. For the purposes of MOvl8 IgE / U937- 
mediated tumour cell death, the assumption has been made that the death of this population of 
killed IGROV I results does not involve phagocytosis. The justification for this is based on 
the fact that the time frame of the assay (optimised at 2.5 hours, see section 4.3 below) was 
insufficient for tumour cell phagocytosis followed by the death and complete disintegration of 
the effector cell to have occurred. 
Region 2 (R2) was set to include all USE / PE double positive events, regardless of 
their PI status. This region reflects the number of tumour cells that have been phagocytosed 
by effector cells, with each event representing a USE positive tumour target (or proportion 
of) inside a PE-positive effector cell. That this is indeed the case, has been confirmed by Dr. 
Sophia Karagiannis by immunofluorescence imaging of killing, as described in section 4.4 
below. It has been assumed that where the mean fluorescence intensity of the USE / PE 
double positive population in the FLI channel remains equal to that of the corresponding 
single positive populations, that this represents phagocytosis of one target cell by one effector 
cell. A shift in FLI to the left would indicate that one target cell is being phagocytosed by 
more than one effector cell. 
Region 3 (R3) was set to include USE / PI double positive events. This reflects the 
population of IGROVI tumour target cells (CFSE') which have been killed by cytotoxicity 
such that their membranes have lost integrity sufficient to allow PI to enter and fluoresce, but 
have not fragmented such that they have become undetectable as single events (and formed 
part of the population responsible for deviations in the RI value from the 'RI ratio control'). 
The final calculation for determination of cells killed by cytotoxicity and or phagocytosed, 
was therefore as follows: 
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Percentage of original IGROV I cells in the assay which were killed by cytotoxicity: 
RI ratio control - R1 = X. 
(X + R3) /RI ratio control x 100 
Percentage of original IGROV I cells in the assay which are phagocytosed: 
R2 /RI ratio control x 100 
4.3 Optimisation of U937/MOvl8 12E mediated Wing of IGROV1 turnour cells 
To determine the IgE concentration, effector to target ratio and time point at which 
MOvl8 IgE-mediated killing of IGROVI cells by U937 effectors was optimal, titrations were 
performed. The effector to target ratio was performed first, using a time-point of 2.5 hours 
and 2 ýtg antibody. It can be seen from Figure 4.6A, that a 1: 1 effector to target ratio was 
optimal. A timecourse demonstrated 2.5 hours to be optimal (Figure 4.6B). Using the 
optimal time-point of 2.5 hours, and effector to target ratio of 1: 1 at which cytotoxicity is 
maximal, MOvl8 IgE (and anti-NP IgE) were titrated (Figure 4.6Q, and 2 Rg of MOvl8 IgE 
was shown to give optimal killing. These results are discussed in more detail in chapter 5, 
where primary monocytes and eosinophils are compared to U937 monocytes for their ability 
to act as effectors of MOv 18 IgE-mediated tumour cell killing. 
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Figure 4.6: Titrations to deterrifine optimal (A) effector to target ratio (B) timepoint and (C) 
amount of MOvI8 IgE (per 260 000 cells / 400 gI / tube). Blue bars represents effector and 
target cells incubated together in the presence of no MOvI8 IgE or anti-NP IgE, red bars 
represent effector and target cells incubated together in the presence of anti-NP IgE and black 
bars represent effector and target cells incubated together in the presence of MOv 19 IgE. 
Filled bars represent killing by cytotoxicity and hollow bars, phagocytosis. 
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4.4 Immunofluorecence hnazina of killine 
Dr. Sophia Karagiannis found that when U937 monocytes were cultured for four days 
in the presence of (360 U/ in]) recombinant human IL-4, prior to their use as effector cells in 
the ADCCP assay, MOv 18 IgE-mediated tumour cell killing was increased over that mediated 
by untreated U937 monocytes; this involved a notable increase in phagocytosis (compare 
Figure 4.7A to Figure 4.8A). The USE / PE double positive population, assumed to 
represent phagocytosis on the dot plot from which the number of cells which have been 
phagocytosed are calculated (as shown in Figure 4.511 and described in section 4.2.5 above), 
was indeed very prominent, as shown in Figure 4.8B. This 'phagocytic' killing of IGROVI 
tumour cells by IL-4-treated monocytes was used to confirm that the USE / PE double 
positive population assumed to represent phagocytosis, was reliable, and not in fact a measure 
of contact between effector and target cells. To this end, killing of IGROV I tumour cells by 
untreated U937 monocytes was directly visualised by immunofluorescence imaging in 
chamber slides and compared to IL-4-treated U937 monocytes. This work, the results of 
which are described below, was carried out by Dr. Sophia Karagiannis according to the 
protocol outlined in section 2.3.2. 
Figures 4.7 and 4.8 show killing of IGROVI tumour cells by untreated and IL-4- 
treated U937 monocytes, respectively, with focus on the phagocytic aspect of killing in both 
cases. Figure 4.7A shows the total killing of IGROVI tumour cells by untreated U937 
monocytes either in the presence of no antibody, anti-NP IgE or MOv 18 IgE. It is clear from 
the black portion of each bar that the dominant mechanism of tumour cell killing is cytotoxic 
as phagocytosis, which is represented by the white portion of the bar, does not reach above 
background levels. This small amount of phagocytosis can be seen as a minor, FLl/FL2 
double positive population, on an FLI/FL2 dot plot (shown in Figure 4.713). Accordingly, 
when killing was visualised, by Dr. Sophia Karagiannis, in a chamber slide, the presence of 
any green IGROV1 tumour cells within U937 effector cells (after incubation of effector and 
target cells together with MOvI8 IgE), was rarely seen (Figure 4.7Q. In contrast, as shown 
in Figure 4.8, when U937 cells were treated with IL-4 for four days prior to their use as 
effector cells in this assay, the don-dnant mechanism of IGROVI tumour cell killing was by 
phagocytosis, as indicated by the white portion of the bars in Figure 4.8A. The phagocytosis 
could be clearly seen as a prominent FLl/FL2 double-positive population, on the FLI versus 
FL2 dot plot shown in Figure 4.813. In accordance, when killing was visualised after 
incubation of effector plus target cells and MOvl8 IgE in a chamber slide, green CFSE' 
IGROVI tumour cells could regularly seen to be present within U937 effector cells 
(appearing orange); this was not seen when control antibody, anti-NP IgE, was used instead of 
MOv 18 IgE (Figure 4.8Q. 
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Figure 4.7: This figure shows killing of IGROV I turnour target cells by untreated U07 
effector cells. (A) Graph to show quantified killing of IGROV I turnour cells as it occurs h\ 
both cytotoxicity (black portion of bars) and phagocytosis (white portion of bar). The while 
portion of the bar, representing the low, background level of MOvl8 IgE-mediatcd 
phagocytosis of IGROV I cells is shown in (B) on a FL I versus FI-2 dot plot. In accordance. 
when killing was visualised by Dr. Sophia Karagiannis, as shown in (C), phapocytosis was 
rarely seen in the presence of either MOv 18 IgE, or control antibody, anti-NP IgE. 
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Figure 4.8: This figure shows killing of IGROV I tumour target cells by IL-4-treated U937 
effector cells. Results shown in this figure (ADCCP assay and immunofluorescence imaging) 
are from experiments performed by Dr. S. Karagiannis. (A) Graph to show quantified killing 
of IGROVI tumour cells as it occurs by both cytotoxicity (black portion of bars) and 
phagocytosis (white portion of bar). The white portion of the bar representing the high level 
of MOv 18 IgE-mediated phagocytosis of IGROV I cells is shown in (B) on a FL I versus FL2 
dot plot. In accordance, when killing was visualised by Dr. Sophia Karagiannis and shown in 
(C), CFSE' IGROVI tumour cells could frequently be seen inside U937 effector cells. 
CFSE' tumour cells phagocytosed by PE-stained effector cells, appeared orange. 
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4.5 Discussion 
Work described in this chapter documents the procedures leading to the development 
of a novel flow cytometric assay with which to quantify antibody-dependent cell-mediated 
cytotoxicity and phagocytosis. In this chapter, the effector cells, target cells and antibody 
used in the set-up and optimisation of the assay were the IgE-receptor-expressing U937 
monocyte cell line, the FBP-expressing tumour cell line, IGROVI and the FBP-specific 
antibody, MOvI8 IgE respectively. That this assay is indeed able to measure death of tumour 
cells occurring by cytotoxicity (based on their loss of membrane integrity) and by 
phagocytosis, was confirmed by Dr. Sophia Karagiannis, using immunofluorescence imaging 
techniques. 
The main advantage of this killing assay over those commonly used killing assays 
such as "Cr- and LDH-release, is the ability to include in the tumour cell death count, those 
tumour cells which have been killed by phagocytosis, which would otherwise have gone 
unaccounted for. Furthermore, as for all FCM cytotoxicity assays, this ADCCP assay has the 
advantage of allowing analysis to be conducted on a single cell basis. This provides an 
increased level of sensitivity compared to 5'Cr- and LDH-release assays, where it is not 
possible to determine whether the marker of cell death has been released in its entirety from a 
few cells of the target population, or partially released from all. Other advantages include the 
ease and uniformity of (IGROVI) target cell labelling with CFSE (which excludes the need 
for volatile, expensive and difficult to dispose of, radiochemicals). In addition, this assay is 
cost-effective, requires minimal manual labour and is quick to perform and analyse. 
A disadvantage of this assay is the inability to deterrnine whether cells were 
phagocytosed alive or dead, i. e., whether phagocytosis is being used as a mechanism of cell 
killing or for clearance of dead cells. It may be possible to re-optin-ýise the assay to include PI 
within the culture during effector and target cell incubation with antibody, such that target 
cells may take up PI immediately after death but before phagocytosis, and be represented as a 
population of cells triple-positive for CFSE, PI and PE. An additional disadvantage of this 
ADCCP assay is that compensation of the overlap of USE emission into the FL2 channel can 
be challenging; although this has been optimised for the experiments described in this Thesis, 
it would have to be re-optimised if cell types or cell-staining procedures were changed. 
As discussed in Lee-McAry et al., 2001, FCM assays of this kind offer the potential 
for measurement of up to four different fluorochromes. In the assay described in this chapter, 
three fluorochromes are used (CFSE, PE and PI) and killing by cytotoxicity and phagocytosis 
are measured. A similar assay, described in Derby et al., 2001, uses the three fluorochromes 
PKH 67 (for target cell labelling), 7-AAD (for dead cell labelling) and Annexin V-PE (for 
labelling of phosphatidyl serine). In this way, they are able to determine whether or not the 
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mode of cytotoxic death was an apoptotic one or not. In this study, they also pre-treat target 
cells with Concanamycin A prior to their incubation with effector cells and antibody. 
Concanamycin A is a perforin inhibitor, and therefore can be used to determine whether 
tumour target cell death has been mediated by the release of toxic granule proteins from the 
effector cell. Application of these methods to future work advancing that described in 
Chapter 5 of this thesis, may help to elucidate the mechanisms of MOvl8 IgE-mediated 
tumour cell death shown to be mediated by eosinophils and monocytes. 
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CHAPTER5: 
In vitro activity of monocytes and eosinophils as effector cells in MOv18-mediated 
IGROV1 tumour cell killing 
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5.1 Introduction 
The purpose of this chapter is to assess the ability of monocytes (both primary and the 
U937 cell line) and eosinophils to act as effector cells in antibody-dependent killing of 
IGROVI tumour cells in vitro. This is achieved using the ADCCP assay described in the 
previous chapter and represented schematically in Figure 4.1. Results presented below are 
divided into three sections. The first, section 5.2, describes MOvl8 IgE-mediated killing of 
IGROV I cells by the different effector cell populations. Also documented in this section are 
the attempts made to inhibit MOvl8 IgE-mediated turnour cell killing by blocking IgE 
binding to either FcF_RI or CD23, in order to determine which IgE receptor mediates killing. 
The second, section 5.3, looks at MOvl8 IgGl-mediated killing of IGROVI cells by the 
different effectors. Thirdly, in section 5.4, the effect of culturing eosinophils in IL-5 either 
alone or in combination with anti-NP IgE or MOvI8 IgE, on their turnouricidal activity, has 
been assessed. For this chapter, knowledge of IgE and IgG Fc receptor expression by 
different cell types is useful; this information has been provided in Table 1.1 of Chapter 1. 
5.2 M008 IgE-mediated tumour cell death 
ADCCP assays were performed as described in section 2.3.2. Effector cells used 
were U937 monocytes, primary monocytes or primary eosinophils (purified as described in 
section 2.2.3), and target cells were IGROVI tumour cells, which were introduced in section 
3.3. For each effector cell type, three triplicate experiments were performed unless otherwise 
indicated, each with a different blood donor (where effectors are primary cells). Specificity of 
MOvI8 IgE-mediated tumour cell killing was determined by comparison with anti-NP lgE- 
mediated killing, and incubation of effector and target cells together in the absence of 
antibody. AS described in section 4.3, the optimal conditions for MOvI8 IgE-mediated 
killing of IGROVI turnour cells by U937 monocytes were determined to be an effector to 
target ratio of 1: 1, a 2.5 hour incubation period for targets and effectors with antibody, and 2 
gg of MOvl8 IgE (per 260 000 cells / tube). The results of MOvl8 IgE-mediated killing of 
IGROVI tumour cells by U937 monocytes under optimal conditions are reproduced from 
section 4.3 as Figure 5. IA below, to facilitate comparison with equivalent assays using 
different effector cells, described in this Chapter. Those parameters optimal for MOv 18 IgE- 
mediated killing of IGROV I tumour cells by U937 monocytes, were also used when effector 
cells were primary monocytes or eosinophils, for which results are shown below in Figures 
5.1 B and 5.2, respectively. 
As shown in Figure 5.1 A, U937 monocytes killed a mean of 40±1 1% of the IGROV I 
cells (ADCC + ADCP) with which they were incubated in the presence of MOvl8 IgE. This 
is statistically significantly greater (P =<0.05, n= 3) than turnour cell killing by U937 
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monocytes, either in the absence of antibody (I 8±5 %) or the presence of anti-NP IgE (I 5±4 
%). It is clear from Figure 5AA, that cytotoxic killing mechanisms (represented by the black 
portion of each bar) account for the majority of this turnour cell death. Tumour cell death 
occurring by phagocytosis, in the presence of either no antibody, anti-NP IgE or MOv 18 IgE, 
are all within error of each other (represented by the white portion of each bar). 
When effector cells are primary monocytes, total MOv 18 IgE-mediated killing leads 
to death of a mean of 24±5 % of IGROVI turnour cells, and anti-NP IgE to the death of a 
mean of 17±4 % of turnour cells. Again, specific killing is mediated by cytotoxic 
mechanisms as judged by the size of the black portion of the bar. Although tumour killing by 
primary monocytes in the presence of MOvI8 IgE, compared to anti-NP IgE, is low, these 
results represent the compiled data from three triplicate experiments and therefore, as a trend 
towards increased killing in the presence of MOvl8 IgE is observed, it may be that if more 
experiments were performed the difference between MOvl8 IgE- and anti-NP IgE mediated 
killing may be greater. Furthermore, it is important to note that not only are the monocytes 
used in these experiments only 70 to 80 % pure (giving an actual effector to target ratio 
potentially as low as 0.7 to 1) but the conditions under which these experiments were 
performed were optimised for U937, not primary, monocytes. Therefore, it may be that that 
monocytes are able to mediate greater MOvl8 IgE-dependent tumour cell killing than these 
three triplicate experiments suggest. 
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Figure 5.1: Killing of IGROVI tumour cells by (A) U937 rnonocytes or (B) Primary 
monocytes, in the presence of either no antibody, 2 pg anti-NP IgE or 2 ýtg MOv 18 IgE. For 
each effector cell type, results represent the mean of three separate experiments, each 
performed in triplicate. The black portion of each bar represents cytotoxic killing, and the 
white portion, phavocytic killing. The effector to target ratio was 1: 1. and the time period of 
effector, target and antibody incubation was 2.5 hours. 
As discussed in section 3.4.2, CD49d, an integrin expressed on eosinophils but not 
IGROV I cells, has been used as a marker to distinguish these two cell types in the ADCCP 
assay. For work described in this Chapter, CD49d staining of eosinophils was first titrated on 
a single population basis, and then the instrument settings of the flow cytometer were adjusted 
for use of CD49d-stained eosinophils in combination with CFSE-positive IGROV I tumour 
cells and PI-stained dead cells (results not shown). Tumour cell killing by primary human 
eosinophils in the presence of different concentrations of MOvI8 IgE (per 260 000 cells in 
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total / tube) is shown alongside controls in Figure 5.2 below. Killing was optimal in the 
presence of 2 pg of MOvI8 IgE at an effector to target cell ratio of 1: 1, in a 2.5 hour 
incubation with MOvI8 IgE, conditions optimised for U937 monocytes. The mean total 
(ADCC + ADCP) of MOvI8 IgE-mediated killing of IGROVI tumour cells by primary 
human eosinophils, was 34±2 % compared to 19±3 % for anti-NP IgE, and 21±6 % in the 
absence of antibody. MOvI8 IgE-mediated killing is therefore statistically significantly 
greater than either anti-NP IgE or no antibody controls (P = 0.001 and 0.003 respectively, n= 
5). The amount of specific MOv 18 IgE-mediated killing was calculated to be approximately 
15 %, when anti-NP IgE-mediated killing is subtracted from MOv 18 IgE-mediated killing. It 
is clear from Figure 5.2, from the proportion of each bar that is black, representing killing by 
ADCC, that killing is mediated by cytotoxic mechanisms. 
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Figure 5.2: Killing of IGROV I tumour cells by primary cosmophils, in the presence of either 
no antibody, anti-NP IgE or MOv 18 IgE (at indicated pg per 260 000 cells / tube). Results 
represent the mean of five separate experiments, each performed in triplicate. The black 
portion of the bar represents cytotoxic killing. and the white portion, phagocytic killing. The 
effector to target ratio was 1: 1, and the time period of effector, target and antibody incubation 
was 2.5 hours. 
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Experiments were then performed to determine through which of the IgE receptors, 
FcF, Rl or CD23, MOvI8 IgE acts to mediate tumour cell killing, for each effector cell type. 
To this end, as described in section 2.3.2, effector cells were incubated with an excess of anti- 
FcF, Rl or anti-CD23 blocking antibody (introduced in section 2.1.2) for 30 minutes prior to 
their incubation with target cells either alone or in the presence of 2 gg of anti-NP IgE or 
MOO 8 IgE, as in the standard killing assay (section 2.3.2). 
Results of attempts to block MOvl8 IgE-mediated killing of turnour cells by U937 
monocytes are shown in Figure 5.3 below. Figure 53A gives the results of MOvl8 IgE- 
mediated killing of IGROVI cells by U937 monocytes, which were subject to the same 
protocol used to block IgE receptors, but with replacement of blocking antibody with PBS 
('treated as blocked' positive control, performed in every ADCCP assay). These results 
represent the mean of 7 separate experiments, each performed in triplicate. U937 monocytes 
treated in this way killed a total of 28±9 % of IGROVI tumour cells in the presence of 
MOvl8 IgE; this is within error of MOvl8 IgE-mediated IGROVI cell killing by U937 
monocytes not treated in this way, as shown above in Figure 5AA, which killed a total of 
40±11 % of turnour cells. However, this MOvl8 IgE mediated killing of IGROVI tumour 
cells by 'treated as blocked' (positive control) U937 monocytes, is no longer statistically 
significantly greater than anti-NP IgE-mediated tumour cell killing by the same 'treated as 
blocked' U937 monocytes. Therefore the results shown below in Figure 5.3 are discussed in 
ten-ns of 'trends'. 
Blocking of IgE binding to FccRI expressed by U937 monocytes, was with the anti- 
FaRla-chain antibody, 15-1, which, like other anti-FccRI and anti-CD23 antibodies used in 
this project, is described in section 2.1.2. The effect of 15-1 can be seen from Figure 53B to 
be an increase of non-specific IGROV I turnour cell killing to approximately 40 %, regardless 
of the presence of anti-NP IgE or MOvI8 IgE. From the size of the black portion or each bar, 
it is clear that this 15-1 -mediated killing occurs through cytotoxic mechanisms. Two different 
antibodies, each able to block binding of IgE to CD23, BU38 and IDEC-152, were also tested. 
Pre-treatment of U937 monocytes with 10 gg of BU38 also upregulated non-specific tumour- 
cell killing (Figure 5.3Q, triggering U937 monocytes to kill a mean total of 78±6 % of 
IGROVI tumour cells in the absence of either anti-NP IgE or MOvl8 IgE; the presence of 
either anti-NP IgE or MOvl8 IgE had no further effect on killing. All tumour cell killing by 
BU38-treated U937 cells, above that occurring non-specifically by untreated U937 
monocytes, was mediated by phagocytic mechanisms. This is in contrast to the MOvI8 IgE- 
independent killing triggered by 15-1. When U937 monocytes were pre-treated with 25 gg of 
IDEC-152, MOvl8 IgE-mediated killing of IGROVI tumour cells remained, within 
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experimental error, the same as MOvI8 IgE-mediated killing by the positive control 'treated 
as blocked' U937 cells, with a mean killing total of 24±5 % (Figure 5.313). F(ab')2 fragments 
of IDEC-152 mediated a similar effect to whole IDEC-152 (Figure 5.3E), which again was 
within error of MOvI8 IgE-mediated killing by control U937 monocytes. When U937 
monocytes were pre-treated with anti-NP IgE, a slight trend towards reduced killing is 
observable (Figure 5.3F). 
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Figure 5.3: U937 monocytes were treated for 30 minutes at 37 T with either A: PBS, B: 25 
ýtg 15.1, C: 10 ýig BU38, D: 25 pg of whole IDFC-152 antibody, E: 25 ýtg IDE'C-152 F(ab')2 
fragments, or F: 25 gg NP IgE. before their use as effector cells in a standard killing assay. 
The black portion of the bar represents the proportion of IGROVI tuniour cells in the 
population which were killed by antibody-dependent cytotoxic mechanisms (ADCQ and the 
white portion, phagocytic (ADCP) mechanisms. Experiments were perfon-ned in triplicate. 
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Similar experiments involving pre-treatment of eosinophils with PBS, anti-FcERI or 
anti-CD23 antibodies before performance of the ADCCP assay, were carried out, and results 
are shown in Figure 5.4 below. As for U937 monocytes, the eosinophils which were 'treated 
as blocked' (Figure 5.4A) killed to a level lower than, but within error of (30±5 %), the 
untreated fresh eosinophils shown in Figure 5.2, which killed a mean of 34±2 % of IGROVI 
tumour target cells. However, MOvI8 IgE-mediated killing of IGROVI tumour cells by 
'treated as blocked' eosinophils, remains statistically significantly greater than anti-NP IgE- 
mediated killing of IGROVI tumour cells, by the same eosinophils (P =<0.05, n= 5). In 
contrast to U937 monocytes, no blocking antibody had any observable effect on eosinophil 
killing of IGROVI tumour cells, positive or negative. Blocking antibodies tested, included 
the anti-FcF-Rl(x antibodies 15-1 (Figure 5.413) and 15A5 (Figure 5.4Q, and the anti-CD23 
antibody, IDEC-152 (Figure 5.413). 
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Figure 5A Eosinophils were treated for 30 minutes at 37 T with either A: PBS, B: 25 ltg 
15.1, C: 25 pg 15A5 or D: 25 ýLg IDEC-152, before their use as effector cells in a standard 
killing assay. The black portion of the bar represents killing of IGROVI tuniour cells by 
cytotoxic mechanisms (ADCC) and the white portion, killing by phagocytic mechanisms 
(ADCP). Experiments were performed in triplicate. 
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5.3 MOvl8 IgGl-mediated tumour cell death 
The ability of monocytes and eosinophils to perform MOvI8 IgGl-mediated tumour 
cell killing was tested. As can be seen from Figure 5.5, neither U937 monocytes, primary 
monocytes nor primary eosinophils were able to kill IGROV I tumour cells by MOv 18 IgG I- 
mediated mechanisms above background levels. The results shown in Figure 5.5 are 
representative of those performed using an effector to target ratio of 1: 1, incubation time of 
effector and target cells together with antibody of 2.5 hours, and 2 gg of MOvI8 IgGI or 
MOPC antibody per tube; these are the conditions determined to be optimal for MOv 18 IgE- 
mediated IGROV1-killing by U937 monocytes. However, for each effector cell type, 
negative results were also found over a range of MOvl8 IgGI concentrations (1,2,5 and 10 
gg per 260 000 cells / tube) and time points (45 minutes, 4,6 and 8 hours), the results of 
which are not shown. Different ratios of effector to target cells were not tried due to 
insufficient time. 
Before it can be concluded that none of the effector cell populations tested (U937 
monocytes, primary monocytes and primary eosinophils) are able to act as effectors of 
MOvI8 IgGI-dependent tumour-cell killing in vitro, a suitable positive control must be 
performed. As human PBMC have previously been shown to act as effectors of MOvl8 
IgGl-dependent IGROVI turnour cell killing in vitro, as described in Gould et al., 1999, 
reproduction of this MOvl8 IgGI-dependent tumour-cell killing with PBMC, using this 
ADCCP assay, needs to be performed. As PBMC are a mixed effector cell population they 
could not easily be uniformly labelled, as required in the ADCCP assay for detection of 
phagocytosis in addition to cytotoxicity. However, MOvl8 IgGI-dependent killing of 
IGROV I cells by PBMC was detected in Gould et al., 1999, using a "Cr-release assay, and in 
Karagiannis et al., 2003, using an LDH-release assay. Therefore analysis of cytotoxicity 
alone should be sufficient to detect killing where it occurs. In the event of a successful 
positive control of MOvI8 IgGI-dependent tumour cell killing, it will be necessary to 
perform an effector to target ratio titration for MOvI8 IgGI-mediated tumour cell killing by 
each effector cell type tested above (U937 monocytes, primary monocytes and primary 
eosinophils), in addition to testing longer time periods of effector and target cell incubation 
together with antibody. 
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Figure 5.5: MOv 18 loG I mediated killing of tumour cell targets compared to MOPC isotype Cý 
control and no antibody controls with A; U937 monocyte effectors, B; primary monocyte 
effectors and C; primary eosinophil effectors. For each cell type, three triplicate experiments 
were performed. 
Chapter 5 125 
5.4 Effect of IL-5 and IgE culture on eosinouhil tumouricidal activity 
Culture of human eosinophils in media supplemented with human IgE has been 
reported to upregulate FcERI expression, as discussed in section 2.2.3. In Kayaba et al., 2001, 
the increase in FcF-RI expression was shown to plateau after 4-days of culture in 10 gg / ml 
IgE and 2.5 ng / n-d IIL-5. The reason for inclusion of IL-5 in the culture media is that without 
it, eosinophils are unable to survive in vitro. As well as upregulating FcFRI expression, the 
effect of eosinophil culture in the presence of IgE, is the loading of FcFRI with the IgE in 
which they are incubated. In this work, primary human eosinophils were cultured in standard 
culture media supplemented with either IL-5 alone, IL-5 + 10 gg / ml of anti-NP IgE or IL-5 
+ 10 gg / ml of MOvI8 IgE (as described in section 2.2.3). Cultured eosinophils were then 
used as effector cells in ADCCP assays against IGROV I tumour cells, as described below. 
After the 4-day, IL-5 -supplemented culture, eosinophil viability was in some cases 
reduced to as little as 60 %; this is in accordance with work described in Rothenberg et al., 
1989. Therefore, although the killing assays with cultured eosinophils were performed at an 
effector to target ratio of 1: 1, a large proportion of these effector cells were dead. These dead 
eosinophils had a greatly increased autofluorescence, which can be seen in conjunction with 
CFSE' IGROVI cells in Figure 5.6A, on an FL-1 (CFSE) / FL-2 (CD49d-PE) dot plot, as a 
distinct population with a fluorescence between that of viable eosinophils (FL- I -negati ve) and 
CFSE-stained IGROVI cells (FLI-positive). These FLI-positive eosinophils are also visible 
as PI-positive (and thus dead) cells on the FL-I (CFSE) / FL-3 (PI) dot plot (the population 
indicated in Figure 5.6B, by the red arrow). This FLI-positive population of eosinophils fell 
within the RI gate (shown in Figures 5.6C and 4.5B), supposed only to include CFSE- 
positive IGROVI tumour cells (as discussed in section 4.2.5), and so were isolated in a 
separate gate (shown in Figure 5.6A), and excluded from the plots used to calculate killing by 
cytotoxicity and phagocytosis (Figures 5-6C and D; Figure 4.5B). The calculation used to 
determine the percentage of IGROVI cell death, which had occurred by cytotoxicity and 
phagocytosiS, was then performed as normal (as described in sections 2.3.2 and 4.2.5), using a 
theoretical effector to target ratio of 1: 1. However, as approximately 40 % of the eosinophils 
effectors were dead, this equates to a functional effector to target ratio of only - 0.6: 1. 
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Figure 5.6: Dot plots showing how a population of dead, cultured eosinophils, were removed 
from the 'Rl' gate. shown on plot (C) which is used to determine the number of IGROV I 
cells remaining in the sample after incubation with effector cells and antibody has occurred. 
(A) FLUFL2 dot plot showing the (gated) highly autofluorescent population of dead 
eosinophils between CD49d-PE' (FL2) viable eosinophils on the left, and CFSE' IGROVI 
cells on the right. The same population is confirmed to be dead by its uptake of PI, shown in 
(B) on an FLI/FL3 dot plot, as the population indicated with the red arrow. Events falling 
within the gate made on the FLl/FL2 dot plot shown in (A), were excluded from the two dot 
plots (shown in this figure as C and D) which are used to normally calculate killing by 
cytotoxicity (events within R3 on plot D) and phagoeytosis (events within R2 of plot C). 
As discussed above, eosinophils were cultured for four days in culture media 
supplemented with either (A) IL-5, (B) IL-5 plus anti-NP IgE. or, (C) IL-5 plus MOv 18 IgE, 
and then used as effector cells in ADCCP assays. For the ADCCP assay, eosinophils from 
each culture condition were mixed with IGROV I target cells (at an effector to target ratio of 
'1: 1', for 2.5 hours), either in the presence of no additional antibody, 2 Pg of anti-NP IgE or 2 
pg of MOvI8 IgE. Therefore, eosinophils cultured in IL-5 for four days, were then mixed 
with IGROV I tumour cells at a 1: 1 ratio, and either no antibody (Figure 5.7; left bar), or, 2 [ig 
of anti-NP IgE (Figure 5.7-. middle bar), or, 2 pg of MOv 18 IgE (Figure 5.7-, right bar), for the 
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2.5 hour duration of the culture period with effector cells. The same method was applied to 
those eosinophils cultured with IL-5 plus anti-NP IgE (Figure 5.8), and to those eosinophils 
cultured in IL-5 plus MOv 18 IgE (Figure 5.9). The purpose of the addition of fresh antibody, 
for the duration of the 2.5 hour incubation period of effector cells with targets, was to load 
any FcERI which had been upregulated during culture, but which remained unoccupied by 
IgE. 
Figure 5.7 (below) shows that eosinophils cultured in IL-5 alone and mixed with 
IGROV I tumour cells for 2.5 hours in the presence of no additional antibody (Figure 5.7; left 
bar), kill a mean of 45±10 % of tumour targets in total (by cytotoxic mechanisms). From the 
middle bar of Figure 5.7, it is clear that killing is increased no further when anti-NP IgE is 
present for the 2.5 hour period of incubation with targets (mean = 45±6 %). Incubation of IL- 
5-cultured eosinophils, for 2.5 hours with tumour targets and MOv18 IgE (right bar-, Figure 
5.7), results in a mean of 58±7 % tumour cells being killed. Comparison of the middle and 
right-hand bars of Figure 5.7A, indicates that only a very low level of this killing is 
specifically MOvl8 IgE-mediated (approximately 13 %). This is less than the specific level 
of MOvl8 IgE-mediated killing of IGROVI tumour cells by fresh, uncultured, eosinophils, 
shown in Figure 5.2. 
F, osinophils cultured in IL-5 alone. 
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Figure 5.7: Killing of IGROV I tumour cells when the effector cell population of eosinophils 
was cultured for 4 days prior to the killing assay in IL-5 -supplemented media. IL-5 cultured 
eosinophils were mixed with IGROV I target cells at a 1: 1 ratio, for 2.5 hours, with either no 
antibody, 2 ltg of anti-NP IgE or 2 ltg of MOv 18 IgE. This graph represents a mean of three 
experiments, each performed in triplicate. The black portion of each bar represents killing 
which occurred by cytotoxic mechanisms. and the white portion of the bar, phagocytosis. 
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Figure 5.8 below shows that eosinophils cultured in IL-5 + anti-NP IgE and mixed 
with IGROV I tumour cells for 2.5 hours in the presence of no additional antibody kill a mean 
of 61±24 % of tumour cells (Figure 5.8; left bar). Killing remains within error of this, when 
additional anti-NP IoE (Figure 5.8; middle bar) or MOv 18 IgE (Figure 5.8; right bar) is added 
for the 2.5 hour incubation period of the assay (61±27 and 70±20 % respectively). This non- 
specific killing by IL-5 + anti-NP IgE cultured eosinophils of IGROV I tumour targets (Figure 
5.8; left bar) is greater than specific killing mediated by either fresh eosinophils and MOv 18 
IgE (Figure 5.2) or IL-5-cultured eosinophils and MOv 18 IgE (Figure 5.7). 
Losinopluls Cultured in IL-5 - anti-NP 
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Figure 5.8: Killing of IGROV I tumour cells when the effector cell population of eosinophils 
was cultured for 4 days prior to the killing assay in IL-5 and anti-NP IgE-supplemented 
media. IL-5/anti-NP IgE-cultured eosinophils were mixed with IGROV I target cells at a 1: 1 
ratio, for 2.5 hours, with either no antibody, 2 gg of anti-NP IgE or 2 pg of MOv 18 IgF. This 
graph represents a mean of three experiments, each perforined in triplicate. The black portion 
of each bar represents killing which occurred by cytotoxic mechanisms, and the white portion 
of the bar, phagocytosis. 
It can be seen from Figure 5.9 below, that when eosinophils are cultured with IL-5 
MOvl8 IgE, killing is increased even further over those incubated with IL-5 + anti-NP IgE Z- 
(Figure 5.8), in the absence of additional antibody, killing by IL-5 + MOv 18 IgE-cultured 
eosinophils is 74±38 % (Figure 5.9. left bar). This is within error of the IGROV I tumour- 
killing mediated by eosmophils cultured in IL-5 + MOvI8 IgE and then incubated for the 
duration of the assay with 2 pg of anti-NP IgE (Figure 5.9; middle bar) or MOv 18 IgE (Figure 
5,9; right bar), which kill 74±39 and 78±31 % respectively. 
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Figure 5.9: Killing of IGROV I tumour cells when the effector cell population of eosinophils 
was cultured for 4 days prior to the killing assay in IL-5 and MOvI8 IgE-supplemented 
media. IL-5/MOV18 IgE-culturedeosinophils were mixed with IGROVI target cells at a 1: 1 
ratio, for 2.5 hours, with either no antibody, 2 pg of anti-NP IgE or 2 Pg of MOv 18 IgE. This 
graph represents a mean of three experiments, each performed in triplicate. The black portion 
of each bar represents killing which occurred by cytotoxic mechanisms, and the white portion 
of the bar, phagocytosis. 
5.5 Discussion 
Results in this Chapter demonstrate that U937 monocytes, primary monocytes and 
primary eosinophils are effective at killing IGROVI-tumour cells by ADCC when the 
ic antibody is of the IgE isotype (MOv 18 I-E). These results show that IgE can tumour-specifi 
effectively mediate tumour cell death in vitro when (lie effector cells are IgE receptor- 
expressing effector cells (demonstrated in Chapter 3). In contrast, at an effector to target ratio 
of i: l, neither U937 monocytes. primary monocytes nor primary eosinophils were able to 
perform MOvl8 IgGl-rnediated killing of tumour cells, at the antibody concentrations and 
time periods of effector and target cell incubation with MOvl8 IgGI, which were tested. 
Also shown in this Chapter is the effect of culturing eosinophils in IL-5 and IgE; the result 
was a high level of non-specific IGROVI tuniour cell killing that occurred Independently of 
MOv 18 IgE. 
In section 5.2. the attempts that were rnade to block MOvl8 IgE-inediated tumour 
cell killing by U937 monocytes and primary eosinophils are described. Pre-treatment of 
effector cells (U937 monocytes or eosinophils) with a selection of different antibodies to 
block IgE binding to either FccRI or CD23 failed to prevent subsequent MOv 18 IgE-mediated 
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tumour cell killing. It is possible that MOvI8 IgE-dependent killing can be mediated through 
either FcF-RI and / or CD23, but that blocking of IgE binding to these receptors using anti- 
FcF-RI or anti-CD23 blocking antibodies is inefficient. If this is the case, it is likely that 
MOvl8 IgE-mediated killing by U937 effector cells occurs through CD23, and not FCERI, as 
the U937 clone used in this Thesis appears not to bind IgE via FcF-RI; IgE binding can be 
completely blocked with anti-CD23 antibodies. For primary human monocytes, it is likely 
that MOvl8 IgE-mediated killing occurs through FcFRI, and not CD23, as this cell type 
appears not to express CD23 (reported in section 3.4.1). Explanations for the potentially 
inefficient blocking of FcF-Rl and CD23 are discussed below. 
The only anti-FcF-Rl blocking antibody used when U937 monocytes were effector 
cells, was 15-1. Regardless of whether or not 15-1 efficiently prevented IgE binding, the fact 
that it non-specifically activated effector cells (with the effect of mediating high levels of 
cytotoxicity towards tumour cells) means that a role for this receptor in MOvl8 IgE- 
dependent tumour cell killing (with monocyte or eosinophil effectors), cannot be excluded. In 
fact, no conclusions can be drawn about the role of this receptor in U937/MOvl8 IgE- 
mediated killing of IGROV I tumour cells, except that 15-1 is able to induce the U937 cells to 
kill turnour cells. This MOvI8 IgE-independent killing by 15-1 might be mediated by 
'bystander killing', resulting from the cross-linking of FcF_Rl by the bivalent antibody, 
activating the U937s to release mediators cytotoxic to IGROVI cells. Indeed the 15-1 
antibody has been shown previously to activate primary human basophils to release histamine 
(Riske et al., 1991), and activate human monocytes to mediate sustained cytosolic calcium 
increases (Maurer et al., 1994). Use of monovalent Fab fragments of 15-1 in the future may 
therefore provide effective blocking in the absence of non-specific cellular activation. 15-1 
did not, however, activate eosinophils to kill tumour cells non-specifically; it is possible that 
the very low number of FcFRl expressed on the eosinophil cell surface prevented a similar 
cross-linking of FcERL by bivalent 15-1. 
The other FcF-RI-blocking antibody tested, 15A5, also failed to block MOvl8 IgE- 
mediated killing of tumour cells, when eosinophils were the effectors. The 15A5 antibody 
also did not activate the eosinophils to kill tumour cells in a MOv I 8-IgE-independent fashion. 
It is possible that MOvl8 IgE-mediated killing by eosinophil effectors is very sensitive, and 
that only a few IgE receptors are required to be occupied by MOv 18 IgE for killing to occur. 
Therefore, if a small number of IgE receptors are able to escape blocking, and MOv 18 19E is 
able to bind, the cross-linking of these few receptors by a FBP-expressing tumour target may 
be sufficient to mediate tumour cell killing. This high level of sensitivity may also explain 
the inability of anfi-NP IgE to effectively out-compete MOvl8 IgE, and completely block 
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IGROV I tumour cell killing by U937 monocytes. As an alternative to blocking FcF-RI with 
Fab fragments of anti-FcCRI blocking antibodies, blocking of FcF-Rl-mediated effector cell 
activation may be a better approach. This might be performed with the anti -FcERIec-chain 
antibody, 51-15F8, which does not block IgE binding to FcF-Rl(x, but instead prevents 
downstream signalling (Nechansky et al., 2001). 
Similar explanations may be applied to the failure of anti-CD23 antibodies to block 
any MOvl8 IgE-mediated killing, which might be triggered through this receptor. Like 15-1, 
regardless of whether or not BU38 effectively blocked IgE binding to CD23' no conclusions 
can be drawn as to the role of CD23 in killing from these experiments as BU38 treatment of 
U937 monocytes activated them to kill IGROVI cells in a MOvl8 IgE-independent manner. 
As with 15-1, this is likely to be a result of CD23 cross-linking by bivalent BU38 antibody. 
Similarly, use of BU38 monovalent Fab fragments may be effective in blocking IgE binding 
and thus any CD23-mediated killing. The inability of IDEC-152 to block killing may be 
explained by this antibody having a lower affinity for CD23 than IgE; the affinity of IDEC- 
152 for CD23 is not known. It might therefore be displaced by MOvl8 IgE during the 
ADCCP assay, allowing killing to occur as normal. The relatively low affinity of IgE for 
CD23 (compared to FcF_RI) may also allow for displacement of anti-NP IgE with MOv 18 IgE, 
preventing killing being effectively blocked in this way. 
Finally, it may be that MOvl8 IgE-mediated killing is mediated through neither 
FcERI nor CD23. This would explain the inability of either anti-NP IgE, anti-FccRI or anti- 
CD23 antibodies, used separately or together, to block subsequent MOvl8 IgE-mediated 
killing; the attempted blocking of U937-mediated tumour cell killing using anti-FcF-Rl and 
anti-CD23 blocking antibodies simultaneously, has been performed by Dr. S. Karagiannis 
(results not shown). It is unlikely that MOvl8 IgE-dependent killing is acting non- 
specifically, firstly, as cell-mediated killing of (FBP-expressing) IGROVI tumour cells 
cannot be mediated in either the presence of anti-NP IgE nor MOvl8 IgGl, suggesting that 
both FBP and IgE-receptor specificities are required. That MOvl8 IgE is indeed binding FBP 
on IGROV I cells, and not non-specifically to another antigen, is unlikely due to two reasons. 
Firstly, anti-NP IgE does not bind to IGROVI cells (shown in Figure 3.113). Secondly, 
MOvl8 IgE binds to FBP-transfected C26 or CC531 tumour cells, but not to their wild type 
counterparts (Figure 3.2). That MOvl8 IgE is indeed binding to IgE receptors on effector 
cells, is demonstrated by the ability to block its binding with anti-IgE receptor antibodies; 
anti-CD23 blocks MOvl8 IgE and anti-NP IgE binding to U937 cells and anti-FcERI blocks 
MOvl8 IgE and anti-NP IgE binding to primary eosinophils. The interesting possibility 
therefore remains, that a third IgE receptor may be involved in mediating MOvl8 IgE- 
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dependent turnour cell killing; the most likely candidate for this role is epsilon binding protein 
(introduced in section 1.3.8). 
Results described in this chapter show MOvl8 IgE-mediated tumour cell killing by 
both primary and U937 monocytes to be mediated by cytotoxic and not phagocytic 
mechanisms. This is in contrast to previous immunofluorescent imaging of IGROV I tumour 
cell killing reported in Karagiannis et al., 2003, which showed monocytes to be 
phagocytosing turnour cells in a MOvl8 IgE-dependent manner. However, experiments 
described in both these studies (Karagiannis et al., 2003; this Thesis), were performed under 
quite different conditions. Experiments described in Karagiannis et al., 2003, were performed 
in chamber slides, to which the monocytes adhere; experiments described in this Thesis, were 
performed in FACS tubes, to which the cells do not adhere; adherance of monocytes to a 
plastic substrate has been shown to impact positively on their activation state (Maurer et al., 
1994). In addition, a different effector to target ratio was used in each study, 50: 1 
(Karagiannis et al., 2003) compared to 1: 1 (this study), as was a different time period for 
which effector and target cells were incubated together with antibody (90 minutes compared 
to 2.5 hours, respectively). Furthermore, the monocytes seen to phagocytose turnour cells in 
the study by Karagiannis et al., 2003, were doing so as part of a mixed effector cell 
population (PBMQ, whereas monocytes used for experiments described in this Thesis, were 
70 to 80 % pure. 
The earlier time point at which monocytes were detected phagocytosing turnour cells 
as described in Karagiannis et al., 2003, might be explained by the fact that in these studies, 
monocytes composed a smaller proportion of the total cell population, which were whole 
PBMC. Therefore, it may be that a different cell type which is present in PBMC, but less 
prevalent in the 70 - 80 % pure population of monocytes used in experiments described in 
this Thesis, is in fact mediating tumour cell death, with monocytes merely acting to clear the 
tumour cell debris by phagocytosis. One potential candidate for this role are basophils, which 
were frequently observed in contact with turnour cells in the presence of MOv 18 IgE, but not 
control antibody, anti-NP IgE, in the immunofluorescent imaging described in Karagiannis et 
al., 2003. 
In this Thesis, the 'cytotoxic' mechanism by which monocytes mediate MOvl8 IgE- 
dependent tumour cell death, may be through the secretion of the pro-inflammatory cytokine 
TNF-(X, which is secreted upon FcF_RI cross-linking (Kraft et al., 2002). As suggested by its 
name 'tumour necrosis factor', this cytokine has well characterised anti-tumour activity. Also 
secreted upon cross-linking of FcF_RI on monocytes, are MCP-1, MIP-IP and IL-6 (Kraft et 
al., 2002; von Bubnoff et al., 2002) in addition to the immunomodulatory cytokine, IL-10 
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(Novak et al., 2001). Cross-linking of CD23 expressed by U937 monocytes may lead to 
tumour cell killing through the secretion of IL-6, TNF-cc and or IL- IP (Ouaaz et al., 1993), as 
occurs following cross-linking of CD23 on primary monocytes (Paul-Eugene et al., 1992; 
Borish et al., 1991). The IgE-dependent cytotoxic mechanisms by which eosinophils might 
be activated to kill tumour cells include the release of granule proteins and eosinophil 
peroxidase (Gounni et al., 1994). It would be interesting to assay for the presence of any of 
these soluble mediators of turnour cell killing in the culture media in which the killing assay 
was performed. 
Human eosinophils cultured for 4 days in IL-5 -supplemented media, were shown to 
mediate high levels of MOvl8 IgE-independent tumour cell killing. The original purpose of 
including IL-5 in the eosinophil culture media was to allow these cells to survive in vitro, so 
that the effect of their culture in anti-NP IgE or MOvI8 IgE on their ability to perform 
MOvl8 IgE-dependent ADCC of tumour cells could be assessed. The reason for including 
IgE in the culture media was in response to the reported demonstration of the ability of IgE 
culture of eosinophils to increase their level of (IgE-loaded) FcFERI at the cell surface (Kayaba 
et al., 2001). However, what were 'control' eosinophils cultured in IL-5 alone were 
significantly more cytotoxic to tumour cells than fresh, uncultured eosinophils, regardless of 
the presence of IgE in the culture media. 
The enhancement of human eosinophil viability during in vitro culture, using IL-5, is 
well recognised; in the absence of IL-5 less than 10 % of eosinophils typically survive 3 days, 
and none survive 4 days of culture in enriched medium (Lopez et al., 1988; Rothenberg et al., 
1989). IL-5 culture of eosinophils is also associated with a change in eosinophil density. 
Eosinophils freshly purified from 'normal' (not hypereosinophilic or allergic) donors have a 
4normodense' phenotype, but after 3 days of culture in IL-5-supplemented media they become 
'hypodense', similar to eosinophils freshly purified from hypereosinophilic donors. 
Eosinophils with the hypodense phenotype in patients with hypereosinophilia associated with 
chronic helminthic infection, have been shown to be 'functionally enhanced', with enhanced 
effector function in ADCC (Rothenberg et al., 1989; Rivoltini et al., 1993). This reduction in 
eosinophil density (normodense to hypodense) may also be associated with an increase in 
concentration of cytotoxic eosinophil-derived products in the cell culture media (Rothenberg 
et al., 1989); it is possible that such increased toxicity of the culture media accounts for the 
high levels of antibody-independent tumour cell killing seen in experiments described in this 
chapter. 
The ability of eosinophils to act as effector cells in IgG-mediated ADCC of either 
parasite (Khalife et al., 1989) or turnour cell (Rivoltini et al., 1993) targets in vitro, is 
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dependent on their activation status; eosinophils purified from normal donors (normodense), 
are ineffective, and those purified from hypereosinophilic donors (hypodense), are effective. 
Therefore, the lack of MOvl8 IgGl-mediated killing of IGROVI turnour cell targets by 
freshly purified human eosinophils from normal donors reported in this chapter, is in 
accordance with these previous studies. In view of the fact that eosinophils primarily express 
only FcyRII of the three FcyR (Seminario et al., 1999) and that this receptor could be of either 
the inhibitory or stimulatory isotype, these results may not be surprising. Interestingly, 
eosinophils from cancer patients receiving IL-2 therapy acquire the hypodense phenotype and 
accordingly, are able to act as effectors of IgG-mediated cytotoxicity against tumour cells in 
vitro, in contrast to the normodense eosinophils purified from the same patients before 
treatment (Rivoltini et al., 1993). This acquired, IgG-mediated, cytotoxicity was comparable 
to that mediated in vitro with IL-5 cultured eosinophils (Rivoltini et al., 1993). 
In Chapter 3, Fcy-receptors expressed by U937 monocytes were shown to include 
FcyRI, and of FcyRII, the non-inhibitory FcyRIIa isoform (Cameron et al., 2002). Primary 
monocytes express FcyRI, FcyRH (both inhibitory and stimulatory isoforms) and FcyRIII 
(Ravetch and Kinet, 1991; Woof et al., 2004). Cross-linking of stimulatory IgG Fc receptors, 
including FcYRI, FcXIa and FcyRIIIa, is associated with the phagocytosis, cytotoxicity and 
release of inflammatory mediators by expressing cell types (see Table 1.1). In contrast, cross- 
linking of FcyRIlb is associated with inhibitory signals (Ravetch and Kinet, 1991). Co- 
aggregation of the inhibitory FcyRIIb with a stimulatory Fc receptor (including FcyR, Fc(XR, 
FcF, R and also the TCR and BCR) is also associated with the suppression of signalling 
initiated by these receptors (Ravetch and Kinet, 1991). 
Primary (and U937) monocytes were unable to act as effectors of MOvl8 IgGl- 
dependent tumour cell killing under the conditions tested. Previously, primary monocytes 
freshly purified from normal donors have proved to be effective in IgGI-dependent turnour 
cell killing (Steplewski et al., 1988). However, this cytotoxicity required long time periods of 
effector and target cell incubation together with turnour specific IgG and high effector to 
target ratios. Experiments described in Steplewski et al., 1988, using an ["Inlindium oxine- 
release assay, show a ratio of 10 monocyte effectors to I turnour cell target incubated with 
tumour-specific chimaeric IgGI to mediate - 13 % turnour cell lysis after 18 h, and - 30 % 
lysis after 18 h when the E: T ratio was increased to 50: 1. It may be that MOvl8 IgGl- 
dependent cytotoxicity by primary monocytes in this work could be mediated if these longer 
timepoints were used alongside a higher ratio of effector to target cells. The longest timepoint 
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tested in work described in this chapter was 8 hours, and the only effector to target ratio tried 
was 1: 1; there was insufficient time to perform additional experiments. 
It must also be noted that there have been studies performed in which IgG-dependent 
killing of turnour cells by primary monocytes was poor, even using high effector to target 
ratios and long timepoints. It has been found that treatment of primary monocytes with 
cytokines including M-CSF, GM-CSF or IFN-y, known to stimulate the maturation of 
monocytes into a more macrophage-like phenotype, increases their capacity to act as effectors 
of IgG-dependent tumour-cell killing (Munn and Cheung, 1989; Keler et al., 2000). M-CSF- 
cultured monocytes have been shown to mediate FcyRII and FcyRIII-dependent phagocytosis 
of turnour cells, and IFN-y-cultured monocytes to be efficient mediators of FcyRI-dependent 
ADCC (Van Schie et al., 1992; Munn and Armstrong, 1993). Indeed, the (significant, but 
low levels of) turnour-cell killing by unstimulated monocytes shown in Steplewski et al., 
1988 was increased significantly by pre-treatment of the monocytes for 2 days prior to the 
assay in IFN-y-supplemented-media. Dr. S. Karagiannis is currently performing experiments 
to assess the ability of IL-4-stimulated monocytes to act as MOvI8 IgE-dependent effectors 
of tumour cell killing, as IL-4 is known to upregulate the expression of CD23 by primary 
monocytes. 
it is also interesting to note that MOO 8 IgG I -dependent killing of IGROV I cells by 
a mixed effector population, PBMC, determined using a chromium-release assay in 
experiments described in Gould et al., 1999, required an effector to target ratio of 50: 1, and an 
incubation period of effector and target cells together with MOv 18 IgG I, of at least 5 hours. 
Experiments using an LDH-release assay to assess MOvl8 IgGl-dependent killing of 
IGROV1 cells by PBMC, described in Karagiannis et al., 2003, required an effector to target 
ratio of 50 - 100: 1, and an incubation period of effector and target cells together with MOv 18 
IgGi of 20 hours. Although it is not known which cell type(s) amongst this mixed effector 
cell population were mediating MOvl8 IgGl-dependent killing of IGROVI cells, these 
results support the idea that IgGl-dependent tumour cell killing requires a higher effector to 
target ratio, and incubation period of cells with MOO 8 IgG 1, than those tested in experiments 
described in this chapter. 
In summary, whether or not conditions can be optimised such that U937 monocytes, 
primary monocytes or primary eosinophils could act as MOv 18 IgG I -dependent effectors of 
IGROV I tumour cell killing, the relative simplicity with which monocytes and eosinophils 
can be triggered to act as MOv 18 IgE-dependent effectors of tumour cell killing gives support 
to the hypothesis that tumour-specific antibodies of the IgE isotype may be more effective 
than IgG I in triggering an anti-tumour immune response. 
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CHAPTER 6: 
In vivo models of MOv18 activity 
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6.1 Introduction 
In this chapter I describe how the in vivo modelling of MOvl8 activity is being 
pursued in the most physiologically relevant ways possible. This requires the dual modelling 
of both human cancer and a functional IgE-mediated immune response in one system. As 
discussed in section 1.3.2, mouse FcERI(x chain is unable to associate with y2-dimers in the 
absence of P-chain. This means that mice can only express tetrameric FcF-RI, consequently 
limiting the expression of this receptor to mast cells and basophils. This is in contrast to the 
human FcFRl expression profile, which additionally includes expression of an FcERI-(XY2 
trimer on Langerhans cells, dendritic cells, monocytes, eosinophils and platelets. For tumour- 
bearing animals to be treated with chimaeric MOv 18 IgE, turnours used in animal models are 
required to express human folate binding protein (FPB). 
The two models previously described for this project have overcome these problems 
by creating 'human' mouse models of cancer (Gould et al., 1999; Karagiannis et al., 2003). 
Both models involve engraftment of immunocompromised mice with human turnour and 
treatment of these tumour-bearing mice with human immune cells and chimaeric-human 
MOvl8 (see section 1.4.2). The first model (Gould et al., 1999) involved growth of the 
human (FBP-expressing) ovarian cancer cell line, IGROVI (introduced in sections 2.2.1 and 
3.3.1), as a solid, subcutaneous tumour in SCID mice. Treatment was by intravenous 
injection of human PBMC effector cells and MOvl8, and efficacy was determined by 
comparing the size of subcutaneous turnours in treated to untreated control mice at time- 
points after engraftment. The second model (Karagiannis et al., 2003), involves transplant 
and growth of the human (FBP-expressing) ovarian tumour, HUA, in the peritoneal cavity of 
nude mice in the form of ascities. Therefore, the anatomical location of the HUA tumour in 
the nude mouse model mimics human ovarian cancer more closely than the SCID mouse 
model. 
6.2 Nude mouse model 
The nude mouse model mentioned above has been used in a series of experiments 
described below. In summary, four different human immune (effector) cell populations have 
been tested for their ability to mediate improved survival of HUA-tumour-bearing nude mice 
when given alone or in combination with MOvl8 IgE. In addition, MOvl8 IgE has been 
compared to MOvI8 IgGI where the effector cell population is human PBMC. MOvl8 IgE 
has previously been compared to MOvl8 IgGI in the SCID mouse model, also mentioned 
above (Gould et al., 1999). The result was a superior efficacy of MOv 18 IgE, compared to 
MOvI8 IgGI, in inhibiting tumour growth. This contrasted with in vitro results in Gould et 
al., 1999, which showed MOvI8 IgGI to be more effective than MOvI8 IgE in triggering 
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PBMC to kill IGROVI turnour cell targets in a chromium-release assay. These results 
support the hypothesis that in vitro activity of tumour-specific IgE does not reflect its 
potential in vivo. The purpose of comparing MOv 18 IgE to MOv 18 IgG I in the nude mouse 
model, was to see if this enhanced effect of MOvl8 IgE over MOvl8 IgGI could be 
replicated in a disparate, and more physiological, in vivo system. 
A standard protocol was used for survival experiments in nude mice, described in this 
chapter, whereby mice were transplanted with the human ovarian cancer, HUA, on day I and 
received treatments of human effector cells and antibodies on specific dates thereafter, as 
described in detail in section 2.3.3. In all experiments survival was measured in terms of the 
number of days between the transplant of the tumour and sacrifice of the mouse. Sacrifice 
was performed when the swelling of the peritoneal cavity, due to growth of the tumour, was 
such that the weight of the mouse was increased by approximately 10 % (Home Office 
limits). 
In the first nude mouse experiment discussed below, each mouse was treated, on days 
1,7,14 and 21, with either (A) PBS, (B) PBS containing 4 million human PBMC, (C) PBS 
containing 4 million human PBMC plus 100 49 MOvl8 IgE or (D) PBS containing 4 million 
human PBMC plus 100 gg MOvl8 IgGI. The first three of these treatment groups (A-C) 
have been compared before, in Karagiannis et al., 2003, but those mice received only two 
treatment doses, on days I and 15, and this was sufficient to confer upon mice in the third 
treatment group (C), a significant survival advantage over the first two groups (A and B). In 
addition, results of experiments comparing MOvl8 IgE to MOvl8 IgG1 in the SCID mouse 
model described in Gould et al., 1999, showed that only one dose of MOv 18 IgE was needed 
for it to be more effective than MOO 8 IgGl. This was proposed to be a reflection of the long 
IgE-FcF-RI binding half-life. The purpose of the increased dosing in the first nude mouse 
experiment described in this chapter, was to ensure MOv 18 IgG I had the maximum chance of 
producing an effect equivalent to, or better than, MOv 18 IgE. 
As expected, control mice receiving tumour alone died within approximately 20 days. 
Mice receiving PBMC in conjunction with MOvI8 IgE survived significantly longer than 
control mice receiving PBS alone (P = 0.002; n= 9), and closely approached statistical 
significance compared to mice receiving PBMC alone (P = 0.056; n= 9). Mice receiving 
PBMC alone (Figure 6.1) did not survive significantly longer than mice receiving PBS (P = 
0.067; n= 9). Survival of mice receiving PBMC in conjunction with MOvl8 IgGI also did 
not survive significantly longer than either group of control mice (P = 0.3; n=8 in both 
cases). These P-values are obtained using a two-tailed student's T-test. However, it is 
justifiable to use a one-tailed T-test based on the fact that treated mice are not expected to 
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survive a shorter period of time than control mice. In this case, the survival of mice receiving 
PBMC plus MOvl8 IgE do survive statistically significantly longer than mice receiving 
PBMC alone, P=0.028. In the similar experiment, shown as Figure IA in Karagiannis et al., 
2003, and mentioned above, the mean survival of group A was 22±0A group B was 30±1.1 
and group C, 40±3.4 days (these results represent the mean ± the standard error). In Figure 
6.1, these equivalent three treatment groups showed no further improvement in survival as a 
result of the increased treatment doses, with mean survival times of 19±2,26±11 and 40±17 
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Figure 6.1: Survival of nude mice bearing HUA ovarian cancer xenografts and receiving on 
days 1,7,14 and 21 the following intra-peritoneal treatments: Group A= PBS alone, Group 
B= PBS containing 4 million PBMC, Group C= PBS containing 4 million PBMC plus 100 
Vg MOvI8 IgE and Group D= PBS containing 4 million PBMC plus 100 Pg MOvl 8 IgG 1. 
In Karagiannis et al., 2003. it is described how immunohistochemistry was performed 
on the HUA tumour sections taken from mice that received treatments of PBS, PBMC or 
PBMC in combination with MOvI8 IgE. The results showed large numbers of human CD68' 
monocytes / macrophages to be infiltrating the tumour islands in sections taken from mice 
that received MOvl8 IgE with PBMC, in contrast to those that received PBMC alone. In 
addition to this, immunofluorescence visualisation of tumour cell killing by PBMC (also 
described in Karagiannis et al., 2003) and in vitro cytotoxicity assay data, described in this 
Thesis (Figure 5.113), suggested human CD14' monocytes could act as effector cells in this 
system. In response to this information, a population of monocyte-enriched human PBMC 
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(70 to 80 % pure) were tested for their ability to improve the survival of HUA-xenograft- 
hearing nude mice in conjunction with MOvl8 IgE. Due to the fact that no survival 
advantage was conferred by increasing the number of treatment doses from two to four in 
Figure 6.1, mice in this experiment received only two treatment doses. Treatments included 
either (A) PBS alone, (B) PBS containing 4 million monocytes, or (C) PBS containing 4 
million monocytes plus 100 ýtg MOvl8 IgE, per mouse. As a positive control, one group of 
mice each received treatment of PBS containing 4 million PBMC in combination with 
MOvl8 IgE, and one group each received PBS containing 4 million PBMC alone. 
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Figure 6.2: Survival of groups of nude mice bearing HUA ovarian cancer xenografts and n 
receiving the following treatments on days I and 15: (A) PBS alone, (B) PBS containing 4 
million PBMC. (C) PBS containing 4 million monocytes. (D) PBS containing 4 million 
PBMC plus 100 pg MOvl8 1, --E or (E) PBS containing 4 million i-nonocytes plus 100 pg 
MOvI8 IgE. 
it can be seen from Figure 6.2, that mice receiving monocytes alone, or in 
combination with MOvl8 IgE, failed to show a trend of increased survival over control 
groups. The positive control group of PBMC plus MOvI8 IgE did show a trend towards 
increased survival, as observed in the previous experiment (see Figure 6.1). However, asonly 
four mice per condition have been used in this experiment, survival differences are not 
statistically significant. To see if the U937 monocyte cell line could improve survival of these 
tumour-bearing mice, a similar experiment was set up. Turnour-bearing nude mice each 
received treatments on days I and 15 of either (A) PBS alone, (B) PBS containing 4 million 
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U937 monocytes or (C) PBS containIng 4 million U937 monocytes in combination with 100 
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Figure 6.3: Survival of nude mice bearing HUA ovarian cancer xenografts and treated on the 
day of HUA transplant and again 14 days later with either PBS, PBS containing 4 million 
U937 monocytes or PBS containing 4 million U937 monocytes and 100 lig MOv 18 IgF. 
The results shown in Figure 6.3, above, represent the combined results from two 
identical experiments, one of which was performed by Dr. Sophia Karagiannis. It can be seen 
from Figure 6.3 that mice treated with U937 monocytes, In combination with MOvl8 IgE, 
survive for 27±8 days, this is statistically significantly longer than the survival of mice 
receiving treatments of either U937 monocytes alone (19±6 days; P=0.042, n= 8) or PBS 
alone (16±3 days; P=0.002, n= 9). As expected, mice receiving treatment with U937 cells 
alone did not survive significantly longer than mice receiving PBS treatment (P = 0.19, n= 9). 
Due to the efficacy of eosinophils in killing tumour cells in vitro (shown in the 
previous Chapter), and their documented anti-tumour activity in vivo (Tepper et al., 1992), the 
capacity of a purified population of eosinophils to enhance the survival of HUA-turnour- 
bearing nude mice in combination with MOvI8 IgE was tested. Turnour-bearing nude mice 
were treated on day I each with (A) PBS, (B) PBS containing 3.6 million eosinophils or (C) 
PBS containing 3.6 million cosinophils plus 100 lig MOv 18 IgE. On day 15 these treatments 
were repeated, but when eosinophils were included, they were reduced to 2.36 million per 
mouse (due to a lower eosinophil yield per ml of blood from the same donor). It can be seen 
from Figure 6.4 that eosinophils either alone or in combination with MOv 18 IgE, conferred 
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no survival advantage upon HUA-tumour-bearing nude mice, with negligible differences 
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Figure 6A Survival of nude inice bearing HUA ovarian cancer xenografts and treated on the 
day of HUA transplant with either (A) PBS, (B) PBS containing 3.6 million eosinphils or (C) 
PBS containing 3.6 million eosinophils and 100 pg MOvl8 IgE. On day 15, each mouse 
received a second treatment dose. but where eosinophils were included, they were reduced to 
2.36 million per mouse. 
The disadvantage of the nude and SCID mouse xenograft models is that treatment 
relies on the persistence of human effector cells in mice, while in humans the supply of 
effector cells would be constant. and so treatment with MOvI8 IgE is likely to be more 
effective. Furthermore. these models rely on the activity of a restricted population of IgE 
receptor-expressing cells that are responsible for only a minor component of the allergic 
immune response, which in effect, is the immune response we are trying to target to the 
tumour cells. The absence of the additional IgE receptor-expressing effector cells in these 
immunodeficient models is likely to result in an underestimation of the beneficial effects 
conferred by treatment with MOvl8 IgE. However, use of an animal model which 
underestimates the efficacy of MOv 18 IgE treatment for cancer, may also not give a reliable 
indication of whether or not treatment with MOvI8 IgE will trigger systemic anaphylaxis. 
This highlights the need for an immunocompetent host, including functional mast cells and 
basophils, to model anti -tumour activity of MOv 18 IgE. Anaphylaxis resulting from MOvl8 
IgE treatment would require the secretion of large amounts of multivalent IgE-specific tumour 
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antigen into the circulation, and a serum IgE concentration above -10 7 M-', the threshold 
required to induce FcFRl expression on circulating IgE effector cells (Gould et al., 1999). 
Therefore as a treatment for patients, in the unlikely event of anaphylaxis occurring, 
preventative measures based on these criteria could be taken. Furthermore, FBP is not 
multivalent. 
6.3 'Humanised' FcFRl Tit model of lung metastases 
in response to this, I have therefore set up a more physiological model using the 
'humanised' FcCRI transgenic mouse (described in section 2.1.4) as the host. This work was 
carried out at the Pasteur Insititute, Lille, under the supervision of Dr. David Dombrowicz. 
These mice express FccRI as a composite of human a-chain and murine P- and or y-chains. 
The ability of human a-chain to associate with a (murine) y-chain dimer, in the absence of P- 
chain means FcERI can be expressed in both trimeric and tetrameric forms, in these hFcERI 
Tg mice. This means that hFccRI Tg mice express FcFRI on the same cell types on which it 
is found in humans. The Balb/c colon carcinoma, C26, transfected with human FBP 
(C26tFR), was chosen for the tumour target in this model (Rodolfo et al., 1998) and was 
provided by Dr. Silvana Canevari, of the Isituto Nazionale Tumori, Milan, Italy, as part of a 
collaboration on this model. As hFcERI Tg mice are backcrossed to a Balb/c background, the 
C26tFR cell line was likely to be syngeneic. Intravenous injection of C26 cells leads to their 
growth as artificial lung metastases. The combination of human-IgE-binding FcF-RI, and 
human FBP-expression means these mice can be treated with chimaeric-human MOv 18 IgE. 
The suitability of this model for assessing MOvl8 IgE activity is supported by work 
documented in both Rodolfo et al., 1996 and 1998. Work in these publications demonstrates 
the susceptibility of the C26tFR cell line (growing as artificial lung metastases in Balb/c 
mice) to eradication by induction of a humoral immune response (of the IgG isotype), Most 
importantly, they show that passive treatment, intravenously, with MOv 18 IgG I and MOv 19 
(an IgG2a antibody specific for an epitope of FBP different from that of M008), markedly 
reduces the number of metastases on the lungs of these mice. The difference between this 
BaIb/c-C26tFR model described in Rodolfo et al., 1998, and the model being set-up here is 
that the Balb/c host mouse is replaced with the hFcF_Rl Tg mouse, allowing an IgE-mediated 
immune response, closer to that of humans, to be examined. 
Reported in Chapter 3, is the observation that C26tFR cells are susceptible to death 
induced by MOvl8 IgE alone. Therefore, an additional control group will need to be 
included to allow for adjustment of results from MOvl8 IgE-alone killing. This control group 
would involve injection of C26tFR tumour into two separate groups of Balb/c mice, one of 
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which would subsequently receive treatment with MOvI8 IgE, while the other would remain 
untreated. The inability of human IgE to bind to murine FccRI (Conrad et al., 1983) in Balb/c 
mice means that any increase in survival of these mice over untreated tumour-bearing Balb/c 
mice will be due to non-effector cell mediated effects of human chimaeric MOvI8 IgE. 
Therefore, four groups of tumour-bearing mice would be needed in total: (1) a group of 
C26tFR tumour-bearing hFcFRl Tg mice, to be treated with MOvI8 IgE; (2) a group of 
C26tFR turnour-bearing hFcF_RI Tg mice, to receive no treatments; (3) a group of C26tFR 
tumour-bearing Balb/c mice, to be treated with MOvI8 IgE; and (4) a group of C26tFR 
tumour-bearing Balb/c mice, to remain untreated. 
Following confirmation that C26tFR tumour cells were able to grow in humanised 
FcF-Rla Tg mice, I investigated whether human FaRloc-chain expression in the transgenic 
mice had any effect on the rate of tumour growth. To this end, survival was compared 
between mice of four different genotypes each injected on day I with 104 C26tFR tumour 
cells. The genotypes included Balb/c (n = 5), FcF-RI(x h"'ryf'- (n = 4), FccRI(x h--m4 (n = 3), 
and FcF-RI(x h-/+m-/+ (n = 5), (Dombrowicz et al., 1996). This number of tumour cells (104) 
was chosen for injection based on work documented in Rodolfo et al., 1998. Mice were 
sacrificed when they showed dyspnea. As can be seen in Figure 6.5, survival in the syngeneic 
Balb/c strain was identical to all hFcF-RI Tg strains, demonstrating that FcF-RI is not involved 
in tumour growth or spread. In addition, mice treated with 104 tumour cells survived for the 
expected duration of approximately 20 days, suggesting this to be an appropriate number of 
tumour cells for injection, since survival duration is the parameter used to determine treatment 
efficacy. 
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Figure 6.5: Sur,. i,, al of different strains of mouse syng-eneic with the C20tl-'R tuniour ccll 
line. Balb/c mice and three strains of hFcF-RI Tg mice received intravenous iRiection of If) 
C26tFR turnourcells. Results plotted repre,, cill thc II[IIIII)c] of (LIY' 111111t)[11 )HICk 1W11 
and sacrifice upon development of dyspnea. 
An alternative method for quantifying MOvl8 IgE activity in this model is by 
counting the number of metastases on the lungs of each mouse in every group, on one specific 
day after tumour injection. For this method, injection of a higher number of tuniour cells is 
required for the development of extensive superficial lungs metastases. Determination of' the 
average number of metastases on the lungs of mice frorn each group is possible by follow, 110 
sacrifice with a lung infusion of India ink before their removal en bloc and placement in 
Fekete solution (Fekete, 1939; sections 2.1.3 and 2.3.3). Fekete solution bleaches tunlour 
metastases, but not normal lung tissue, causing metastases to show up as white nodules on I 
black background of healthy lung tissue. For determination of the optimum number of' 
tumour cells to be injected and optimum day for sacrifice in metastases-counting experiments. 
mice were divided into 3 groups of 15. Group A received an intravenous injection (on day I) 
of 5x 10' C26tFR tumour cells in 400 gl PBS-, group B, 104 and group C 10". Three mice 
from each group were then sacrificed on each of days 15,17,19,21 or 23 (see section 2.3.3). 
Balb/c mice were used for this experiment, justified on the basis of there being no strain- 
related differences in tumour growth when compared as described above (shown in Figure 
6.5). The purpose of this was to conserve the more limited numbers of hl`cV. RI Tg mice 
available. A selection of lungs bearing metastases were photographed. and are shown below 
in Figure 6.6-. these results are discussed in detail, below. 
Chapter 6 146 
I 
Figure 6.6: Images of tumour growth in metastaSes counting experiments. All three blocks 
(A-C) represent lungs from n&e injected with 10-5 C26tFR tuniour cells In 400 P1 PBS on day 
1. Front and back views of lungs from each of three different inice sacrificed on day 15. (A). 
day 17, (B), and day19, (C). One lung image (the front view of lungs from mouse 3. 
sacrificed on day 17) has been enlarged, and a few of the many nielastases have been 
indicated with red arrows. The black areas represent normal lung tissue. 
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There was no evidence of metastases on the lungs of mice receiving 5x 10' tumour 
cells on any of the sacrifice dates (results not shown). Mice receiving 104 tumour cells and 
sacrificed on days 15,17 and 19 were also completely free of metastases (results not shown). 
Of the three mice receiving 104 tumour cells that were sacrificed on day 21, one of them had 
one small tumour nodule (results not shown). Of the three mice from the same group 
sacrificed on day 23, again there was one mouse with one small tumour nodule, and another 
with two small nodules (results not shown). This correlates with the mean survival time of 
mice shown in Figure 6.5, which were also injected with 104 tumour cells. Most tumour 
growth was seen in the group receiving 105 tumour cells; photographs of the lungs of each of 
the mice sacrificed in groups of three on days 15,17 and 19 are shown in Figure 6.6. Mice 
sacrificed at the two later time points (days 21 and 23) were very ill and accordingly showed 
large turnour nodules (results not shown). However, it can be seen from Figure 6.6 that there 
is a lot of variability within groups, and, although the turnour nodules were extensive in mice 
sacrificed on days 21 and 23, it would be unethical to choose this time point for sacrifice as 
these mice were very ill, and indeed some may die prior to this date. Therefore, it was 
determined that day 17 or 19 would be optimal for sacrifice of mice receiving 10" tumour 
cells. This is in accordance with data in Rodolfo et al., 1998. Personal communication with 
Dr. Silvana Canevari revealed that wide variations in the growth of this tumour are normal, 
and the use of large groups should enable observation of differences in metastases between 
groups. Variation was minimised for these experiments by using a large intravenous injection 
volume of 400 gl, which reduces tumour cell clumping. 
6.4 Wistar Albino Glaxo (WAG) rat model of lung metastases 
As discussed in Chapter 1, there is now evidence to suggest that FcF-Rl expression in 
rats mirrors that of humans in terms of cellular distribution. Therefore, an immunocompetent 
rat bearing a syngeneic rat tumour expressing human FBP would provide a good model in 
which to look at MOvl8 IgE activity. Additionally, rat eosinophils are more strongly 
cytotoxic than mouse eosinophils, making the rat a better model of human IgE effector 
mechanisms (Dr. David Dombrowicz, personal communication). A suitable rat model has 
therefore been optimised, as described below. Again, this work was carried out at the Pasteur 
Insititute, Lille, under the supervision of Dr. David Dombrowicz. Dr. Jianguo Shi cloned and 
expressed murine MOvl8 IgE, with which to treat these tumour-bearing rats. MurineMOvl8 
IgE differs in only a few amino acid positions from rat IgE and interacts with the same 
affinity as rat IgE binding to rat FcFRl (Sterk and Ishizaka, 1982). This model is also likely to 
include CD23 function (as discussed in section 1.3.6). The rat colon carcinoma line CC531, 
was transfected to express human FBP by Dr. Silvana Canevari for the purpose of this work, 
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so that CC531 tumour cells can be cross-linked to IgE receptor-expressing immune cells by 
murine MOvI8 IgE. The CC531 turnour line is syngeneic with the WAG strain rat, and 
grows as lung metastases when injected intravenously. This transfected line had not 
previously been used in the WAG rat, but results below show that expression of human FBP 
did not prevent tumour growth. Clone 16 of the CC53ltFR cell line was chosen over clones 
II and 2 due to results described in section 3.3.2 of Chapter 3, which show that the higher 
level of FR expression on clones II and 2 makes them susceptible to death by treatment with 
MOvl8 IgE alone. 
Firstly, an experiment was performed to determine the number of CC53ltFR tumour 
cells that would cause death of the rats within approximately one month of tumour injection. 
This time scale was intended to provide a short enough experimental time frame for 
production of results at a reasonable rate, whilst allowing time for the treatments to have an 
effect. Previous studies documenting growth of the untransfected CC531 line in WAG rats 
have pre-treated rats first with cyclophosphamide in order to reduce immune activity and give 
more rapid tumour growth from injection of fewer cells. As the rats in this model were to be 
treated with an immunotherapeutic agent, with which we hoped to trigger their own immune 
systems to kill the tumour cells, we wanted to keep the rats as healthy and immunocompetent 
as possible and so avoid the use of cyclophosphamide. One reference to rats intravenously 
injected with CC531 cells without prior cyclophosphamide treatment (Marquet et al., 1984) 
used 5x 10' CC531 cells to produce lung metastases that resulted in death of the rats within 5 
months. Clearly injection of a significantly higher number of tumour cells was necessary to 
produce tumour growth within the shorter time frame required for these experiments. As a 
starting point, 2.5 million CC531 cells were injected. When 2.5 million tumour cells were 
injected in cyclophosphamide pre-treated rats in work of both Kuppen et al., 1994 and 
Hagenaars et al., 2000, macroscopically visible lung metastases developed after 
approximately two weeks. In my experiment however, this number of tumour cells was not 
sufficient to produce lung metastases even by day 100 (Figure 6.7). Doubling the number of 
tumour cells injected, to 5x 106, led to sacrifice (due to dyspnea) of one of the two rats 
injected on day 40 and the other on day 59; extensive lung metastases were seen upon autopsy 
in both rats. 
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Figure 6.7: (A) Time-course of WAG rat development of lung nietastases following 
intravenous injection of CC53 I tFR tumour cells. Rats under isofluorane anaesthesia received 
intravenous injection in I ml PBS of CC53ltFRtumour cells: 25 million, 10 million, 2 
injections of 5 million, 3 injections of 5 million, I injection of 5 million or I injection of 2.5 
million cells. (B) Typical lung metastases seen following sacrifice after development of 
dyspnea; these lungs were taken from a rat that received a single dose of 10 million 
CC531tFR tumour cells. The peritoneal and chest cavities were opened and lungs infused 
with India ink by injection via the mouth and trachea. Lungs were then removed ell bloc and 
placed in Fekete solution for a minimum of 24 hours. 
However, survival durations under these conditions were still long, and so to reduce 
them, higher numbers of tumour cells were used. Two rats were injected with 25 million 
tumour cells intravenously. However, rats receiving this many tumour cells died under 
anaesthesia immediately following tumour injection, possibly due to blockage of the 
vasculature by the large numbers of tumour cells. The dose was then decreased to 10 million 
tumour cells. Four rats received this dose, two of which died under anaesthesia. However, 
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the two surviving rats showed lung metastases at an optimal time point, 30 - 40 days after 
tumour injection. Therefore, rats were given 10 million cells over two doses in one day to 
allow the tumour cells time to disperse. The two rats each receiving two doses of 5 million 
cells (in one day) tolerated the two injections well with no apparent suffering following 
anaesthesia and turnour injection. At the same time, two additional rats were given three 
injections (thus receiving a total of 15 million cells) to see if this had a further effect. From 
Figure 63A, injection of 10 million tumour cells given over two doses in one day can be seen 
to cause death from development of lung metastases in an optimal time frame (- 30 days), 
and indeed at the same time as rats receiving three doses of 5 million cells. Typical lung 
metastases for all rats showing dyspnea following injection of 10 million cells can be seen in 
Figure 6.713. It can be seen that the metastases are small and evenly spread making this 
injection number also suitable for 'metastases counting' experiments. 
6.5 Discussion 
Experiments described above using the nude mouse model originally used for this 
project, as described in Karagiannis et al., 2003, demonstrate that treatment of HUA tumour- 
bearing mice with human PBMC in conjunction with MOvI8 IgE, but not MOvl8 IgGl, 
mediates improved survival of mice. Mice treated with 4 million PBMC in conjunction with 
100 ýtg MOvIg IgE each survived for a mean of 40±17 days compared to 26±11 for mice 
treated with PBMC alone, or 21±7 for mice treated with 4 million PBMC plus 100 gg Mov 18 
IgGl. These results are in accordance with those using the SCID mouse model of human 
ovarian cancer (Gould et al., 1999), which also demonstrate increased in vivo efficacy of 
MOvI8 IgE over MOvl8 IgGl. In the SCID model, mice were injected subcutaneously with 
2.5 x 106 IGROVI tumour cells, which in control mice leads to development of a 
subcutaneous tumour greater than 200 mm2 in size by day 35. Treatment was once, one day 
after tumour challenge, and involved intravenous injection with chimaeric MOvI8 IgE or 
MOvI8 IgGI (100 gg) in combination with human PBMC (3 x 106), per mouse. MOvl8 
IgGI did have some activity, inhibiting tumour growth for 19 days after one treatment dose. 
However, MOvI8 IgE was able to provide the same protection as MOvI8 IgGl, but for 
longer, with tumour growth still being inhibited by 62 % on day 35. Together, these results 
support the proposal that the efficacy of MOvI8 IgE in mediating tumour cell death by human 
PBMC effector cells is underestimated using in vitro cytotoxicity assays. 
In the nude mouse model used above (section 6.2), antibody and effector cell 
treatment doses are given directly into the peritoneal cavity, where the tumour grows as 
ascities; tumour islands amongst tumour cells in suspension. Some solid tumour is observable 
in late stage disease attached to the peritoneal organs. Therefore, unlike the SCID mouse 
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model where treatments are given intravenously and the tumour grows subcutaneously, 
effector cells and antibody are not required to penetrate tissues from the blood. Additionally, 
four once-weekly doses of effector cells and antibody were given to maximise chances of 
MOvI8 IgGI activity compared to MOvI8 IgE. Therefore, it was surprising that MOvl8 
IgGI in conjunction with PBMC mediated no improvement in the survival of HUA-bearing 
mice whatsoever. One explanation may be that the nude mouse model is a less sensitive 
method for assessing anti-tumour activity than the SCID mouse model, which allows for 
continuous measurement of tumour growth over a longer period of time. As HUA tumour- 
growth in the nude mouse model, at the dose used in these experiments, is life threatening 
within approximately 20 days, MOvl8 IgGI may temporarily inhibit tumour cell growth, but 
overall the turnour growth could be overwhelming, such that any effect does not lead to 
enhancement of mouse survival. 
The longer half-life for which IgE binds to FcERI-expressing effector cells compared 
to IgGI binding to any FcyR, is likely to be a significant contributory factor in the enhanced 
ability of MOvl8 IgE over MOvl8 IgGI, to provide protection against tumour growth (see 
section 1.3.4). That survival of mice receiving four doses of PBMC in combination with 
M0vI 8 IgE (Figure 6.1) is no longer than in previous similar experiments (Karagiannis et al., 
2003), where mice survived for the same length of time after only two doses of the treatment, 
supports this proposal. These results correlate with the dramatic effect on turnour growth 
with PBMC and MOvI8 IgE, mediated with only one single dose in the SCID mouse model 
(Gould et al., 1999). The inability of MOv 18 IgG I to improve the survival of tumour-bearing 
nude mice even with weekly treatment doses may therefore be explained by its inability to 
remain bound to FcyR-expressing effector cells for sufficient time to confer them with anti- 
tumour activity. Indeed, the half-life of receptor-bound IgG is in the order of days, compared 
to weeks for IgE bound to FcFRI on mast cells in tissues (see section 1.3.4). The results with 
MOvl8 IgE also imply good survival of the PBMC-effector cells in these mice, as was 
expected from results in Mosier et al., 1988, and immunohistochernistry described in 
Karagiannis et al., 2003. 
The human effector cell populations tested above for their ability to kill tumour cells 
by M0v18 IgE-mediated mechanisms in vivo included PBMC, a monocyte-enriched (70 to 80 
% pure) population of PBMC, a greater than 95 % pure population of peripheral blood 
eosinophils and the U937 monocyte cell line. Of the primary cell populations, only whole 
PBMC were able to mediate an increased duration of survival when given in combination 
with MOvl8 IgE. The U937 monocyte cell line was also able to perform this effect. The 
inability of an enriched population of primary monocytes to enhance the survival of tumour- 
bearing mice when injected in combination with MOvl8 IgE (Figure 6.2) could be due to one 
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or more possible reasons. Firstly, monocytes may simply not be the cell type amongst the 
population of PBMC that mediate tumour cell killing to improve the survival of nude mice. 
Immunohistochernical demonstration of CD68' monocytes / macrophages infiltrating tumour 
cell islands in tumour sections taken from equivalent experiments in Karagiannis et al., 2003, 
does not mean they are also killing, and may in fact represent macrophage clearance of 
tumour cell debris following tumour cell-killing by a different effector cell type, such as 
basophils. Alternatively, it is possible that in the absence of other cell types, the 70 - 80 % 
pure monocytes did not receive specific signals, normally provided, to enable them to (a) 
survive (e. g., CSF / M-CSF), (b) mature into activated macrophages which are in fact the 
tumour-killing cells (e. g., IL-4 or IFN-y), or (c) mediate effector mechanisms for tumour cell 
killing (e. g., IL-4-induced upregulation of CD23). 
Like monocytes, the inability of a purified population of eosinophils to mediate 
improved survival of HUA tumour-bearing nude mice may relate to their inability to survive 
in mice. It is possible that co-injection of eosinophils with recombinant human IL-5 might 
have aided these cells to survive in vivo, as it does in vitro (Lopez et al., 1988; Rothenberg et 
al., 1989). There was insufficient time to analyse tumour sections from these mice by 
immunohistochernistry to study eosinophil survival. Nude mice are deficient only in (Xp T 
cells, and in fact not even entirely deficient in these, as a subpopulation of cco T cells that 
develop extrathymically have been shown to exist (Budzynski and Radzikowski, 1994). This 
leaves nude mice with a completely intact innate immune system, and so normal numbers of 
monocytes, macrophages, NK cells and y8 T cells, in addition to a functional humoral 
immune system. Therefore, nude mice have the capacity to make significant immune 
responses against both the human tumour xenograft and the human treatment cells. This 
immune response against the human eosinophils following their injection into the peritoneal 
cavity of these mice may have led to their immediate degranulation or death, preventing them 
from having any specific anti-tumour effects. 
The experiment looking at the ability of U937 cells in combination with MOv 18 IgE 
to improve the survival of HUA tumour-bearing nude mice was performed before 
experiments in Chapter 4 determined that IgE was unable to bind FcF-RI expressed by this 
particular U937 clone. Therefore, although originally the experiment intended to address 
whether or not monocytes per se, could improve the survival of mice as a pure population, it 
also tests what functionally may represent a population of CD23-expressing cells, assuming 
MOvI8 IgE is unable to bind FcF-RI on U937s in vivo, as in vitro data suggests. Although the 
improved survival of HUA tumour-bearing nude mice by MOv 18 IgE and U937 monocytes is 
statistically significant compared to controls, it may not be physiologically relevant, due to 
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the fact that U937 cells are a transformed cell line and may not have the same functional 
ability as primary monocytes. 
The improved survival of HUA tumour-bearing nude mice receiving treatments of 
PBMC alone is likely to be a result of the fact that the PBMC are allogenic with respect to the 
HUA tumour and indeed murine tissue antigens, such that the lymphocytes (CD8' T cells and 
CD56+ NK cells) in the PBMC population recognise these MHC differences and mediate an 
allo-anti-tumour immune response. However, where enhanced survival is seen in those mice 
receiving MOvl8 IgE in combination with human effector cells, either human PBMC or 
U937 monocytes, this increased survival can be reasonably judged to be a result of human 
FcF_RI or CD23-expressing effector cells, mediating IgE-antibody-dependent HUA tumour 
cell-killing. The fact that human IgE does not bind mouse IgE receptors (Conrad et al., 
1983), provides further support for these survival effects being due to human rather than 
mouse cells. It does remain possible that IgE-mediated killing could be enhanced by the 
effect of activated human effector cells, stimulated by HUA tumour cells releasing 
chemoattractants and/or cytokines to recruit and activate nude mouse cytolytic effector cells 
in a bystander fashion. 
it is not expected that the increased survival of nude mice receiving treatments 
containing MOvl8 IgE in addition to effector cells, is conferred by direct cytotoxic effects of 
MOvl8 IgE alone. A control group of HUA tumour-bearing mice receiving treatments of 
MOvl8 IgE alone has not been performed yet, but is not expected to have any effects for 
three reasons. Firstly, SCID mice bearing a subcutaneous IGROVI tumour showed 
equivalent tumour growth when mice were treated with PBS or MOvl8 IgE alone. Secondly, 
MOvl8 IgE has no effect on IGROVI tumour cells in vitro (see section 3.3.2). Thirdly, 
effector cell treatments, given in combination with MOvl8 IgE, do not always confer a 
survival advantage, as was the case with both monocytes and eosinophils. If indeed MOvl8 
IgE acted to induce turnour cell death on its own, then it would likely produce effects in all 
effector cell treatment groups where it was present. 
Xenograft models of human cancer, such as the nude mouse model used above, do 
not completely replicate the process of turnourigenesis in humans, the human immune system 
or the dynamic relationship between the two. In this way, they allow direct assessment of 
whether or not a tumour-specific antibody has the capacity, in the simplest in vivo system, to 
trigger significant tumour cell death. They also allow exposure of any overt toxicifies of the 
treatment. These issues must be addressed directly before it is worth assessing, beyond 
theoretical speculation, the impact of any more detailed aspects of human cancer and the 
human immune system on the efficacy of the therapy. A positive result in such models allows 
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determination of whether or not the time-consuming pursuit of developing a more clinically 
relevant model is worthwhile. The survival advantage conferred by PBMC in conjunction 
with MOv 18 IgE, but not MOv 18 IgG 1, in the nude mouse model above, taken with previous 
in vivo results achieved in a SCID mouse model (Gould et al., 1999), and in vitro data, 
suggest that for MOvI8 IgE, this pursuit is indeed worthwhile. Using the hFccRl Tg / 
C26tFR model, the effect of MOvI8 IgE treatment can now be assessed by either measuring 
the duration of survival in untreated and MOvI8 IgE treated mice injected with 10' tumour 
cells on day 1, or by counting metastases on the lungs of all mice at approximately day 17-19 
after injection of 105 tumour cells. Experiments using the WAG rat / CC53ltFR tumour 
model may also now begin, following the successful cloning and expression of murine 
MOvl8 IgE. 
The immunocompetent hFcFRI Tg mouse and WAG rat models have a number of 
advantages over the xenograft models. Firstly, the IgE systems in both models are much 
closer to the human immune system, with a similar profile of FcF-Rl expression found in both 
hFccRI Tg mice and rats; the rats additionally have the potential of MOvl8 IgE activity 
through CD23, as discussed in section 1.3.6. Therefore these models are less likely than the 
xenograft models to underestimate both beneficial MOvl8 IgE activity and the potential 
induction of anaphylactic shock. It would be logical for initial experiments performed in each 
of the hFccRI Tg and WAG rat models, to assess whether treatment of turnour-bearing 
animals with MOvI8 IgE is able to mediate any beneficial anti-tumour effects. Then, in the 
event of a positive effect of MOvl8 IgE on the survival of tumour-bearing animals, any 
toxicity associated with MOv 18 IgE treatment should be studied. 
My suggestion is that preliminary experiments in these models should be designed to 
give MOv 18 IgE treatment every advantage to mediate anti-tumour activity, and then to work 
'backwards' to determine the minimal dosing regimen able to mediate anti-tumour effects. 
This might involve intravenous injection of a group of WAG rats and or hFcERI Tg mice with 
an excess of MOvI8 IgE, prior to tumour injection, to saturate all IgE receptor-expressing 
effector cells with MOvI8 IgE, without also saturating FBP expressed by tumours, and 
preventing ADCC due to equivalence. When excess MOvI8 IgE had been cleared, as judged 
by an absence of free MOvI8 IgE in the circulation, turnour-injection could be performed in 
MOvI 8 IgE pre-treated and a control group of untreated animals. If the tumour was unable to 
grow, then this would prove the principle that MOvI 8 IgE could mediate anti-tumour effector 
function. In this case, animals could be treated first with tumour, and then at timepoints after 
tumour injection, treatment with MOvl8 IgE could be given. Where a survival advantage is 
conferred by treatment with MOvI8 IgE, it would be interesting to perform histological 
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analysis of the tumour site to determine which effector cell populations are infiltrating tumour 
areas in MOv 18 IgE-treated compared to untreated control animals. 
If MOv 18 IgE treatment of turnour-bearing WAG rats or hFcFRl Tg mice was indeed 
able to confer a survival advantage, then the next step would be to assess whether or not 
treatment with MOvl8 IgE is associated with symptoms of anaphylaxis, if indeed these signs 
are not already evident. Systemic anaphylaxis manifested by collapse or death of the animals 
would be apparent immediately after administration of MOvl8 IgE. However, a more 
sensitive measurement of signs of systemic anaphylaxis would be rectal temperature as a 
function of time after administration of MOvI8 IgE. As only very few FcF-Rl on the mast cell 
surface are required to be cross-linked for cellular activation, it may be that only very small 
amounts of tumour-specific IgE are required to effectively mediate tumour cell killing 
(Metzger, 1992), thus limiting the potential for triggering anaphylaxis. The advantage of 
treating ovarian cancer with MOvI8 IgE is that treatment can be administered locally, directly 
into the peritoneal cavity. 
The ability of a full immune system to take part in a MOvI8 IgE-mediated immune 
response also offers potential for the development of an active immune response against the 
tumour after MOvI8 IgE treatments; the priming of an immune response in vivo, by tumour- 
specific IgE antibodies, has been demonstrated in principle, in Reali et al., 2001. If treatment 
with MOvl8 IgE was found to confer a survival advantage in CC531-tumour bearing WAG 
rats, which should include both FcF-RI and CD23 function, then turnour-specific CTLs and 
serum antibodies of all isotypes could be assayed to see whether treatment with MOvI8 IgE 
leads to the induction of an acquired immune response compared to control, untreated, 
turnour-bearing animals. 
What the hFcF-Rl Tg mouse model and the WAG rat model do not allow, is 
assessment of the impact of the human tumour microenvironment; the effect on MOv 18 IgE 
treatment of the presence of the immune cells which have developed in synergy with the 
tumour over many years; their activity both influencing and being influenced by the tumour 
itself. However, positive results of MOvI8 IgE activity in these models, alongside a good 
safety record, may provide sufficient evidence that MOvI8 IgE is worth taking into Phase I 
clinical trials. 
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CHAPTER 7: 
Biological effects of reducing IgE affinity for FcERI 
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7.1 Introduction 
In the previous two chapters, the potential for using turnour-specific IgE antibodies to 
trigger immune responses towards tumour cells as a form of cancer immunotherapy was 
considered. As discussed in section 1.3.4, the high affinity of the interaction between IgE and 
FcF, Rl is proposed to confer upon allergen-specific IgE the ability to bind mast cells in the 
tissues of allergic individuals, such that they are essentially permanently primed for activation 
immediately upon exposure to specific (multivalent) allergen. This property of the IgE- 
mediated immune response is also proposed to give tumour-specific IgE antibodies properties 
advantageous for tumour cell killing. Experiments described in this chapter were performed 
to determine whether a reduction in the affinity of the IgE-FcF-Rl interaction was associated 
with any biological consequences in an in vivo model. 
7.2 Construction of an anti-NP IP-E with reduced affinity for FceRI 
IgE with reduced affinity for FcERI was constructed by mutation of the arginine 
residue at position 334 in the N-terminal region of CF-3 of both IgE heavy chains. As 
discussed in section 1.3.3, R334 is well characterised as a critical binding residue in the IgE- 
FcF-Rl interaction, with the R334 residue from both CO domains of IgE forming a direct 
interaction with FcF-Rl(x (Henry et al., 1997 and Garman et al., 2000); the consequence of an 
arginine for serine mutation at position 334 in IgE-Fc, is a reduction in IgE Fc affinity for 
FcF-Rl(x of approximately two orders of magnitude (Henry et al., 1997). This reduction in 
affinity is primarily a consequence of an increased rate of dissociation of IgE from FcERI. 
For the purposes of work described in this chapter, the same R334S mutation was introduced 
into an anti-NP IgE heavy chain for construction of a whole IgE with reduced affinity for 
FcF-Rl. The construction of the mutant R334S anti-NP IgE heavy chain and its permanent 
transfection into the J558L cell line (a mouse myeloma cell line expressing human X light 
chain) was performed by Dr. Jianguo Shi, as described in section 2.2.2. 
7.3 Production of wild type and R334S anti-NP 12E 
The cell line containing the wild type anti-NP IgE construct was a gift from Dr. 
Michael Neuberger (the construction of which is documented in Bruggemann et al., 1987). 
As with R334S anti-NP IgE, this is a permanently transfected J558L cell line. Purification of 
R334S and wild type anti-NP IgE from cell culture supernatants was performed using the 
same two-step procedure; affinity chromatography using an (x-y fusion column (see reference 
20 in Table 2.2) followed by gel filtration on a Gilson HPLC system using a SuperdexTm 200 
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column. The purity of the final antibody preparations was assessed by both analytical gel 
filtration and SDS-PAGE. 
Figures 7.1 A and B show the analytical gel filtration profiles for wild type and 
R334S anti-NP IgE respectively, after affinity chromatography but before the gel filtration 
purification step. From these traces, it was determined that collection of fractions 7-9 in each 
case would give final preparations free of the aggregated material clearly present in each case 
as a smaller peak eluting at approximately 10 minutes. After isolation of these fractions, 
analytical gel filtration was repeated to confirm that the species were indeed entirely 
monomeric; both wild type and R334S anti-NP IgE displayed the expected gel filtration 
profile for pure IgE (as seen for both in Figure 7.1 Q. Figure 7.1 D shows the final isolated 
proteins as single bands, each with an apparent molecular mass of approximately 190 kDa, on 
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Figure 7.1: Gel filtration profiles for wild type (A) and R334S (B) anti-NP IgE upon affinity 
chromatography. Purification of fractions 7-9 of both wild type (A) and R334S (B) anti-NP 
IgE, gave pure and homogeneous preparations: green line = wild type anti-NP IgE and red 
line R334S anti-NP IgE (Q. (D) Non-reducing SDS-PAGE on 4-20 % gradient gel showing 
final preparations of wild type (right) and R334S (left) anti-NP IgE. 
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7.4 Kinetics of wild type and R334S IgE interaction with FcF-Rl(x 
Experiments to determine the kinetics with which both wild type and R334S anti-NP 
IgE bound to FcF-Rl(x, were performed by Dr. James Hunt using surface plasmon resonance, 
according to the protocol described in section 2.3.1. As discussed in section 1.3.3, IgE 
binding to FcF-RI involves a fast and a slow association phase, in addition to a fast and a slow 
dissociation phase. This biphasic interaction is proposed to reflect the complex nature of the 
interaction between IgE and FcERL involving more than one binding site (in IgE) and the 
occurrence of a conformational change in IgE, required for FccRI(x chain to access all 
receptor-binding residues, and generate a high affinity interaction. Therefore the data shown 
below in Figure 7.2 were obtained by fitting to a biphasic model; the random nature of the 
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Figure 7.2: Sensorprams of (A) wild type and (B) R334S anti-NP IgE binding to immobilised 
IgG4-Fc-(sFccRI(X)2. Anti-NP IgE was injected onto the sensor surface at five different 
concentrations in the range 12.5 to 100 nM. A 360 s association phase was followed by a 
360 s dissociation phase with HBS buffer flowing over the sensor surface at 20 pL / min. 
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From visual analysis of the sensorgrams in Figures 7.2 A and B it is clear that there is 
a major difference in the binding properties of wild type and R334S anti-NP IgE for IgG4-Fc- 
(sFcF-R](X)2 (the IgE-binding fusion protein described in section 2.1.2); this difference lies 
primarily in a significantly faster rate of dissociation of R334S anti-NP IgE from FCERI(X, 
compared to wild type anfi-NP IgE. Table 7.1 below shows the kinetics of both wild type and 
R334S anti-NP lc--, E binding to FcF-Rl; the rate constants for the second phase of both 
association and dissociation of IgE from FcF-Rl are highlighted in grey. 
constant IgE wt 19E R334S Deviation of R334 from wild 
r-1 105 105 
type IgE 
ký I (Nf s (0.85 ± 2.7) x (1.27 + 0.24) x Insignificant 
kd I (s-') (2.14 + 
0.48) x 10-2 (1.32 + 0.16) x 10-2 Insignificant 
ka2 (M-1S-1) (1.88 + 0.51) x 105 (8.25 + 2.3) x 104 -2x slower 
kd2 (S-1) (1.23 + 0.31) x 10-4 (1.71 + 0.12) x 10-3 - 10 x faster 
Kýj (M-') 0.40 x 107 0.96 x 107 Insignificant 
Kz, 2 (M-1) 1.53 x 109 4.68 x 10' 
33 x lower 
RilRo 0.03+0.01 0.31 +0.04 
Table 7.1: Kinetic parameters and affinity constants derived from the SPR analysis of wild 
type and R334S anti-NP IoE binding to immobilised FceRI(x. Both wild type and R334S Z-- 
anti-NP IgE were analysed using a biphasic interaction model from which association and 
dissociation constants were derived for each component (shown +/- standard deviation for at 
least five detertninations in the concentration range 12.5-100 nM). RI/R,, describes the 
fractional contribution of the first component to the overall fit. 
From the RilRo values given in Table 7.1, it can be seen that for both wild type and 
R334S IgE, the second phase of the interaction of IgE from FcF-RI is dominant (with the first 
phase describing the interaction of 3% of wild type and 31 % of R334S anti-NP IgE with 
FccRl); thus the K. 2 value for both wild type and R334S anti-NP IgE interacting with FcCRl 
(1.53 x 109 and 4.68 x 107 M-1 respectively), is representative of the overall affinity of the 
majority of IgE molecules interacting with FcF-RI. As expected for wild type IgE, the 
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dominant, second phase of the interaction, is characterised by a slower dissociation rate 
(kd2 - 
1.23 x 10-4 compared to 
kdl 
- 2.14 x 
10-2S-1). 
importantly, the effect of the R334S mutation in IgE is a reduction in its affinity for 
FcF-RI, compared to wild type IgE, of approximately 33-fold (determined by comparing the 
K,, 2 of wild type and R334S anti-NP IgE; 
1.53 x IW / 4.68 x 107 = 32.6). From comparison of 
the kd2 values for wild type and R334S anti-NP IgE, which are -1.23 x 10-4 and -1.71 X 10-3 
s-1 respectively, it is clear that this difference comes primarily from a 10-fold increase in the 
rate of dissociation of IgE from FcF-RI. This is in accordance with the significant difference 
between the affinity of an R334S IgE-Fc compared to wild type lgE-Fc (Henry et al., 1997). 
As discussed in section 1.3.4, the half-life of wild type IgE binding to mast cells is of 
the order of weeks in tissue, and days in serum. From data in Table 7.1, it is possible to 
calculate the effect of a 33-fold reduction in IgE-FcrrRI interaction affinity (exemplified by 
R334S IgE), relative to wild type IgE, on the half-life for which IgE remains FcF-Rl-bound. 
By taking the reciprocal of the dissociation rate constant for the second (dominant) 
component of the interaction, kd2, the half-life for IgE binding to FcF-Rlcc can be calculated to 
be 2.26 hours for wild type IgE, and only 9.7 minutes for R334S IgE. These values are not 
absolute, but reflect a relative difference in the FcFRl-binding half-lives of wild type 
compared to R334S IgE, of 13.9 fold. Thus, if the half-life of wild type IgE bound to mast 
cells in tissues is taken to be 14 days, this equates to approximately I day for R334S IgE, 
making the R334S-FcF-Rl interaction equivalent to that of IgG I -FcyRIII (see Table 1.1 and 
section 1.3.4). The effect of a reduction of this magnitude in IgE-FcCRI interaction affinity on 
allergic reactions could be profound, as it may prevent the normal long-term sensitisation of 
mast cells and basophils with allergen-specific IgE, and consequently, abolish immediate 
hypersensitivity. The aim of the experiments described in the following sections was to 
detennine if this affinity change could indeed mediate any biological effects in vivo. 
7.5 Optimisation of passive cutaneous anaiDhylaxis model with wild tvue anti-NP IgE 
The in vivo model used to compare the biological effects of wild type and R334S 
anti-NP IgE was a mouse model of passive cutaneous anaphylaxis (PCA). This work was 
performed in the laboratory of Dr. David Dombrowicz, at the Pasteur Institute, Lille. The 
mouse host used in this model was the 'humanised' FcF-RI transgenic mouse (hFcERI Tg) 
described in section 2.1.4, which expresses human (x-chain in combination with murine P- 
chain and y2-dimer (or y2-dimer alone) to make a functional FcCRI capable of binding human 
but not murine IgE (Dombrowicz et al., 1996). The minimal amount of wild type anti-NP IgE 
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required to give maximal passive cutaneous anaphylaxis in these mice was first determined, 
as PCA experiments had not previously been performed in hFccRI Tg mice'. 
In summary, as described in section 2.3.3, eighteen mice were divided into 6 groups 
of 3. Cutaneous mast cells in one ear of each group of three mice were sensitised with a 
specific (indicated) concentration of wild type anti-NP IgE in PBS by intradermal injection in 
a total volume of 20 gl (see Figure 73A). Equivalent injections containing PBS alone were 
performed in the other ear such that each mouse acted as its own control. Antigen challenge 
was performed 48 hours later by intravenous injection via the tail vein, of 100 ýtg of 
NIP(5)BSA in 200 91 PBS also containing 2% Evans blue dye. Mice were sacrificed 1.5 
hours after antigen challenge, ears were removed and Evans blue dye extracted and 
quantified. Evans blue dye extravasated into ear tissue is proportional to anaphylaxis 
intensity as it is indicative of the increase in vascular permeability characteristic of 
anaphylaxis. it is clear from Figure 7.3A, that maximal anaphylactic responses are reached 
when ears are sensitised. with 10 gg of wild type anti-NP IgE. The apparent reduced intensity 
of anaphylaxis seen following injection of 20 gg compared to 10 gg wild type anti-NP IgE is 
not statistically significant (p = 0.34). 
Figure 7.313 shows the results from a single mouse; its left ear was sensitised with 
wild type anti-NP IgE and its right ear with PBS. Challenge was made intravenously 48 
hours later, and 1.5 hours subsequently to this the mouse was sacrificed and its ears removed 
(see inset photo of ears immediately before removal). It is clear from this representative 
mouse that no transfer of anti-NP IgE occurs between ears as the right ear is completely clear 
of Evans blue extravasation, except for a small spot at the site of needle damage from PBS 
injection. 
1 Since the time of writing this Thesis, Zhu et al. (March 2005) have reported the use of hFccRI(x Tg 
mice for PCA experiments using a variation of the method described in this Chapter. 
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Figure 7.3: (A) Titration of \N lid type anti-NP IgE In Nssive cutaneous anaphylaxis in ears of 
hFcERI Tg mice. Mouse ears were sensitised with different (indicated) amounts of wild typc 
anti-NP IgE in left ear and PBS in the right ear. Intravenous antigen challenge was performed 
48 hours later with NIP(5)BSA and Evans blue dye. (B) Evans blue dye extravasation in the 
ears of one mouse. This mouse was sensitised in the left ear with wild type anti-NP IgE and 
in the right ear with PBS. Challenge was made with NIP(5)BSA 48 hours later-, this plot 
shows that no transfer of anti-NP IgE occurs between the two ears of one mouse (the bille 
spot on the right ear of the photographed mouse is a result of needle clarnage to ear from 
injecfion of PBS). 
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7.6 Anaphylaxis triggered by cross-linking of wild type and R334S anti-NP IgE- 
FcF, Rl complexes 
Intensity of anaphylaxis was then compared between the ears of (six) mice sensitised 
in one (left) ear with 20 ýLg of wild type anti-NP IgE and the other (right) ear with 20 pg of 
R334S anti-NP IgE. Challenge with 100 ýtg NIP(5)BSA in PBS containing 2% Evans blue 
dye, was made either 48 or 96 hours later (three mice per timepoint). Challenge was followed 
1.5 hours later with sacrifice, ear removal and quantification of extravasated Evans blue dye. 
Results for comparison of wild type to R334S anti-NP IgE (Figure 7.4) indicate that at both 
the 48 and 96 hour timepoints, anaphylaxis intensity is statistically significantly less when 
ears are sensitised with R334S anti-NP IgE compared to wild type anti-NP IgE (p = 0.021 and 
0.002 between wild type and R334S anti-NP IgE for 48 and 96 hours respectively). 
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Figure 7.4: Passive cutaneous anaphylaxis in ears of hFcr-RI Tg mice. Two sets of 3 mice 
were used. All 6 mice were sensitised with 20 pg of wild type anti-NP IgE in their left ear, 
and 20 ýtg of R334S anti-NP IgE in their right ear. Three mice were challenged intravenously 
with 100 ýjg of NIP(5)BSA in PBS containing 2% Evans blue dye, 48 hours after 
sensitisation, and the remaining three mice received the same challenge, 96 hours after 
sensitisation. Challenge in each case was followed 1.5 hours later with sacrifice and ear 
removal. Ears were cut to identical sizes and Evans blue dye extracted and quantified by 
absorbance at 620 nm in a spectrophotometer. * indicates a statistically significant difference 
in anphylaxis intensity between wild type and R334S anti-NP IgE at 48 and 96 hours of p 
0.021 and 0.002 respectively. 
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7.7 Rate of wild tvve and R334S anti-NP IgE clearance from ear dermis 
it was possible that the reduced anaphylaxis intensity in ears sensitised. with R334S 
anti-NP IgE resulted from there being less R334S compared to wild type anti-NP IgE in the 
ears at all time points of antigen challenge, due to the reduced affinity of binding of R334S 
anti-NP IgE, potentially allowing a faster rate of clearance from the ear. A control 
experiment was therefore performed in which the rate of both wild type and R334S anti-NP 
IgE clearance out of the ear tissue was measured. Twenty mice were divided into two groups 
of ten, and of the first group nine were each sensitised in both ears with 14 gg wild type anti- 
NP IgE. The remaining mouse was sensitised in both ears with PBS. Of the second group of 
ten mice, nine were each sensitised in both ears with 14 gg R334S anti-NP IgE, and the tenth 
mouse in both ears with PBS. Three mice from each IgE-sensitised group were sacrificed at 
24,48 and 96 hours after sensitisation (in the absence of antigen challenge and Evans blue 
dye injection). The single mouse from each group sensitised with PBS was sacrificed at 24 
hours. Both ears from each mouse were removed immediately following sacrifice. 
The IgE injections, sacrifice and ear removal for this experiment were performed by 
S6bastien Fleury at the Pasteur Institute, Lille and sent to London on dry ice for my extraction 
and quantification of IgE. All ears were subject to the same procedure for extraction of IgE, 
as described in section 2.3.3. Each individual ear extract was then tested in each of two 
different ELISAs for quantification of the presence of human IgE. The first ELISA involved 
a sandwich of anti-NP IgE between NEP(5)BSA (to which the IgE binds via its F(ab')2 region) 
and a polyclonal HRP-conjugated anti-IgE (reference 17 in Table 2.2). The second ELISA 
involved a sandwich of anti-NP IgE between the anti-IgE antibody 4.15 (reference 16 in 
Table 2.2) and the same polyclonal HRP-conjugated anti-IgE mentioned above. The ELISAs 
were first both confirmed to detect wild type and R334S anti-NP IgE equally (results not 
shown). The results in Figures 7.5 A and B indicate that there is no statistically significant 
difference in the amount of wild type compared to R334S anti-NP IgE present in the ear 
dermis at the time points indicated, as judged by either ELISA, suggesting that heir clearance 
from the ear tissue occurs at similar rates. 
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A ELISA 1: Coating antibody = 4.15 (anti-IgE) 
Detection antibody =P 0295 (HRP-anti-IgE) 
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Figure 7.5: Rate of clearance of wild type versus R334S anti-NP IgE out of mouse ears after 
intradermal injection. Nine mice each received intradermal injection of 14 gg wild type anti- 
NP IgE in both ears and another nine mice each received intradermal injection of 14 gg of 
R334S anti-NP IgE in both ears. Mice were sacrificed in groups of three, at 24,48 or 96 
hours after sensitisation, and anti-NP IgE was extracted from ear tissue and quantified. (A): 
Quantification of wild type and R334S anti-NP IgE in 4.15 ELISA; (B): Quantification of 
wild type and R334S anti-NP IgE from same extracts used in A, but on NIP(5)BSA ELISA. 
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7.8 Discussion 
The results of experiments described in this chapter were unexpected. As discussed 
in Chapter 1, the high affinity of the IgE: FcF-RI interaction is proposed to confer upon IgE the 
ability to sensitise FccRI-expressing mast cells in tissues for long periods of time. Therefore, 
it was originally expected that at early time points after sensitisation of mouse ear tissue with 
either wild type or R334S anti-NP IgE, the intensity of anaphylaxis mediated upon 
multivalent antigen (NIP(5)BSA) challenge would be similar for both. It was expected that 
the lower affinity, R334S IgE would be cleared at a faster rate from the ear tissue than wild 
type IgE, and that this would correlate with a faster rate of reduction in anaphylaxis intensity 
upon antigen challenge as a function of time following sensitisation, compared to tissue 
sensitised with wild type IgE. 
Instead, what has been found from experiments described in this chapter is firstly, 
that wild type and R334S IgE appear to be cleared from the ear tissue at equivalent rates (at 
least within the time points tested). Secondly, despite there being equal amounts of IgE 
present in the ear tissue at each time point at which antigen challenge was made, the intensity 
of anaphylaxis mediated through mast cells sensitised with R334S IgE is consistently lower 
than the intensity of anaphylaxis mediated when mast cells are sensitised with wild type IgE. 
The equivalent rates of wild type and R334S IgE diffusion out of the ear tissue is likely to be 
due to the dense, poorly vascularised nature of mouse ear tissue, restricting diffusion of the 
IgE, and allowing re-binding to IgE receptors. These results provide a different and 
surprising rationale for the proposal that tumour-specific IgE might be more effective than 
IgG-subclasses for the immunotherapeutic treatment of cancer, as discussed below. 
Furthermore, these results have unexpected but extremely important therapeutic implications 
for allergy and asthma, and these are discussed first. 
The IgE-FcF-RI interaction plays a central role in allergic immune responses and 
represents an important molecular target for therapeutic intervention. However, despite the 
availability of the crystal structure of both IgE-Fc and an IgE-FcF-3-4 fragment in complex 
with FccRloc, no therapeutic agent able to effectively abolish the interaction is widely 
available. The main reason for this is that such a blocking agent is required to bind IgE or 
FccRI with a minimum affinity of - 1010 M-1 (equivalent to that between IgE and FcF-RI) to 
have a chance of effectively competing with IgE for receptor binding. However, these results 
suggest that it is not in fact necessary to abolish the interaction between IgE and FcF-Rl, as a 
reduction in affinity of only 33-fold has significant effects in vivo. 
Results shown in Figure 7.5 suggest that despite the lower affinity of R334S IgE for 
FcF-RI, it is retained as well as wild type IgE in the ear tissue. It is therefore unlikely that the 
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difference in anaphylaxis intensity seen in Figure 7.4 reflects the presence of different 
amounts of each IgE in the ear at the time of antigen challenge. Further support for the idea 
that reduced anaphylaxis is a consequence of reduced IgE-FcFRI interaction affinity and not 
differences in IgE levels in the ear at the time of antigen challenge, comes from the fact that 
these results reflect the compiled data from a minimum of three mice per condition at each 
time point, and that a large excess of IgE has been used for sensitisation. 
There was insufficient time in the course of this work to investigate the mechanism 
behind these results. However, one potential mechanism by which antigen cross-linking of an 
IgE bound to FcERI with reduced affinity may lead to a cellular response of reduced intensity 
is kinetic proof-reading by FcF-Rl. Kinetic proof-reading is known to be a mechanism used by 
T cells to discriminate between 'self', and 'non-self' (McKeithan, 1995). However, it has 
also been shown that IgE bound to FcF-RI on RBL-21-13 cells has the capacity to kinetically 
discriminate between antigens of different affinity, such that ligands with lower affinity for 
IgE show progressive inefficiency in the phosphorylation of downstream signalling 
components, to the extent that a complete response is prevented (Torigoe et al., 1998). It is 
thought that low affinity multivalent antigens are unable to maintain FcERI aggregation for 
sufficient time for responses to go to completion. It may be that a similar kinetic proof- 
reading process applies to FcF-RI, whereby a lower affinity IgE causes FcERI aggregates to 
dissociate before signalling is complete, leading to a reduced final cellular response. This is 
supported by data in Table 7.1, which is used in section 7.4 to determine that the half-life of 
R334S IgE binding to FcF-Rl is approximately 14 times shorter than binding of wild type IgE 
to FcERI. Therefore, it is possible that R334S IgE may bind FcERI for insufficient time for an 
FcF-Rl signalling response to go to completion, when that 'complete' response is likely to take 
a minimum of 20 minutes, as exemplified by a wheal and flare reaction (Cass and Anderson, 
1968). 
One way of achieving a reduction in IgE affinity for FcF-Rl may be to prevent the 
engagement of one of the two sub-sites of interaction between IgE and FcF_RI. This is implied 
by data in Hunt et al., 2005, in which abolition of the inter-heavy chain disulphide bond of an 
FcF, 3-4 fragment permitted the determination of the binding kinetics of a single sub-site 
within a fully folded CO domain, and showed it to be in the order of 105_106 M_ 1. The 
reduction in affinity, compared to a wild type IgE Fcc3-4 fragment, comes predominantly 
from an increased off-rate. This may confer upon IgE a suitably low binding affinity for it to 
mediate reduced cellular responses similar to R334S IgE. The fact that a conformational 
change in IgE is required for it to bind FcCRI through both its sub-sites suggests that an 
inhibitor that prevented this conformational change may have the potential to reduce the 
ability of IgE to cause allergic reactions. 
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The central role of IgE (through its interaction with FcF'RI) in allergy has recently 
been demonstrated through the ability of a therapeutic anti-IgE antibody, Omalizumab 
(Jardieu et al., 1999; Chang et al., 2000), to abrogate the symptoms of both allergy and 
asthma (for a review see Holgate et al., 2005). Omalizumab is a humanised monoclonal IgG 
antibody, which binds the CF-3 domains (receptor-binding region) of IgE with sufficiently 
high affinity (1.5 x 10'0 M-) for it to efficiently block the interaction between free IgE and 
FcF-Rl. In addition, it is unable to bind receptor-bound IgE and therefore does not cause 
cellular activation by cross-linking of FcFRI by itself. Some of its action may also be 
mediated through direct interaction with membrane IgE on B cells, with the effect of a 
reduction in the levels of secreted IgE (Sutton et al., 2000). This success of Omalizumab 
highlights what an excellent target the IgE-FcF_RI interaction is, for treatment of allergy. 
Despite its success, Omalizumab is unlikely to become a widely available treatment 
for allergy suffers due to the expense involved in the production of such a large biological 
molecule, and its need for repeated intravenous administration (Heaney and Robinson, 2005). 
The development of a small molecule inhibitor of the conformational change required for the 
binding of both sites in IgE to FcF_RIcc would therefore be a worthwhile investment. The 
availability of the crystal structures of IgE-Fc, an IgE-Fce3-4 fragment and the latter in 
complex with soluble FcFRI(x makes the structure-based design of such an inhibitor possible. 
Results of experiments described in this Chapter are now considered in the context of 
the immunotherapeutic treatment of cancer with tumour-specific IgE antibodies. The results 
suggest that it is through the high affinity with which IgE binds to FcP_Rl, that it is able to 
trigger such a powerful immune response. The corollary might therefore be that the lower 
affinity binding of IgG subclasses to FcyR leads to a cellular response of lower relative 
intensity (upon antigen-induced receptor cross-linking). Of course, the cell types to which an 
antibody binds and activates are dependent on the cellular distribution of its specific Fc 
receptors, and thus the nature of the immune response triggered depends upon the properties 
of that cell type. However, the results described in this Chapter imply that immunotherapy 
for cancer with IgE may mediate immune responses that can cause tumour cell death at lower 
doses than tumour-specific antibodies of isotypes which bind to Fc receptors with lower 
affinity. Treatment of cancer with lower doses of tumour-specific IgE is likely to reduce the 
potential for unwanted side effects. Further support for the theory that only low doses of 
tumour-specific IgE would be required for effective tumour cell killing, is the well-known 
sensitivity of cellular activation in response to FcrRI cross-linking with antigen (Metzger, 
1992). 
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This apparent correlation between the affinity of IgE for FcFRl, and the intensity of 
the cellular response mediated, n-dght explain the more efficient killing of tumour cells seen in 
in vivo models by tumour-specific antibodies of the IgE isotype, compared to IgG (Gould et 
al., 1999; Karagiannis et al., 2003). In these models, PBMC were used as effector cells, and 
therefore included cell types expressing FcyR but not FcFRI (e. g., NK cells), in addition to 
those cell types expressing FcyR and FcF-RI (e. g., monocytes). The greater efficacy of IgE 
over IgG in these models may therefore reflect the activation of fewer FcERI-expressing cells 
mediating an anti-tumour immune response of greater intensity and efficacy, rather than the 
collective anti-turnour activity mediated by IgGl-dependent activation of greater number of 
cells (each expressing higher levels of FcyR), each responding with lower intensity. 
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CHAPTER 8: 
Final Discussion 
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8.1 IgE in immunotherain of cancer? 
In this Thesis, MOvl8 IgE has been used to assess the proposal that tumour-specific 
antibodies of the IgE isotype might be able to initiate an immune response able to eradicate 
turnour cells. MOvl8 IgE is a human-mouse chimaeric IgE antibody specific for the tumour 
antigen associated with ovarian carcinoma, Folate Binding Protein (FBP). The human 
ovarian carcinoma cell line, IGROVI, was used as the FBP-expressing turnour-target cell 
population in the study of IgE-mediated killing in vitro (B6nard et al., 1985). IGROV I cells 
are proposed to provide a suitable target for ADCC by FBP-specific antibodies, due to their 
high level of FBP expression and the high affinity with which FBP is bound by MOvl8 IgE 
and MOvl8 IgG (- 109 M-1) (Coney et al., 1994; Gould et al., 1999). These turnour-antigen 
properties are known to confer upon turnour cells, susceptibility to antibody-mediated killing. 
Although FBP is functionally associated with signalling molecules in the cell 
membrane (Miotti et al., 2000), the cross-linking (by whole, bivalent antibody) of FBP 
expressed by IGROVI cells is not sufficient to initiate signalling responses which negatively 
affect cell viability (as shown in Chapter 3 of this Thesis, and also in Coney et al., 1994 and 
Gould et al., 1999). This might be a disadvantage of FBP-specific anti-cancer antibodies, as 
tumour cell killing mediated through the tumour antigen, independently of the antibody Fc 
region, is an important determinant of anti-cancer antibody efficacy (Tutt et al., 1998). 
However, it is important to note that the specificity of an anti-cancer antibody of the IgE (or 
indeed any) isotype is interchangeable, and MOv 18 IgE merely serves as a model to prove the 
principle that an anti-cancer antibody with an Fc region of the IgE isotype, will recruit an 
immune response effectively able to mediate tumour cell death, in vitro and / or in vivo. 
Therefore, the lack of Fc-independent activity of Mov 18 IgE in work described in this Thesis 
is in fact advantageous. 
A novel three-colour flow cytornetric antibody-dependent cytotoxicity / phagocytosis 
assay was designed and set-up, as described in Chapter 4. The main benefit of this killing 
assay is its ability to quantify those tumour cells that have been killed by cytotoxicity in 
addition to those that are phagocytosed by effectors during the course of the assay. This 
ADCCP assay was used to assess the capacity of monocytes and eosinophils to act as 
M008-mediated effector cells of IGROVI tumour cell killing. The effector to target cell 
ratio, time period of effector and target cell incubation with MOv 18 IgE, and concentration of 
MOv 18 IgE which gave the highest level of IGROV I turnour cell killing by U937 monocytes 
were determined. As such, U937 monocytes were able to mediate turnour cell death in the 
presence of MOvl8 IgE, which was significantly higher than in the presence of control 
antibody, anfi-NP IgE. Tumour cell killing was also observed when primary monocytes were 
used in equivalent assays, in place of U937 monocytes. 
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Although MOvI8 IgE-dependent primary monocyte-mediated killing of IGROVI 
tumour cells is low, this ability of primary monocytes to kill IGROVI turnour cells in a 
MOvI8 IgE-dependent manner was particularly impressive in light of the following reasons. 
Firstly, as reported previously (Reischl et al., 1996; Karagiannis et al., 2003) and 
demonstrated in Chapter 3 of this Thesis, only around one third of peripheral blood 
monocytes express FcFRL of which a proportion may already be occupied with endogenous 
IgE, preventing MOvI8 IgE binding. Secondly, the population of monocytes used were only 
70 - 80 % pure, and as such, used at an actual effector to target ratio of potentially as low as 
0.7: 1 (when mixed at a ratio of 1: 1). Thirdly, the time-period for which effector and target 
cells were incubated together with MOvl8 IgE was only 2.5 hours. Therefore, the level of 
tumour cell killing by primary monocytes may be significantly improved by optimisation of 
these parameters. 
Using the nude mouse model described in Chapter 6 of this Thesis, a similar 
population of primary monocytes was unable to improve the survival of turnour-bearing nude 
mice; potential explanations for this are discussed in section 6.5. In the future, the ability of 
monocytes to mediate MOvI8 IgE-dependent turnour cell killing in this model will be 
assessed by comparison of monocyte-depleted and reconstituted PBMC, to whole PBMC. 
However, HUA-bearing nude mice treated with U937 monocytes plus MOvI8 IgE did 
survive longer than control mice. This may reflect the enhanced capacity of these cells to 
survive in these mice due to the fact that they are a transformed cell line. Alternatively, as the 
clone of U937 monocytes used for experiments described in this Thesis appear to bind IgE 
only via CD23 and not FcF_RI, these results may reflect the greater efficacy of CD23 over 
FcF_Rl, in IgE-dependent activation of monocytes for turnour cell killing in vivo. 
Supporting a role for CD23 expressed by U937 monocytes in killing of HUA tumour 
cells in nude mice, is the observation by Dr. Sophia Karagiannis (personal communication) 
that HUA turnour-bearing nude mice treated with IL-4-stimulated U937 monocytes plus 
MOvl8 IgE survived longer than equivalent mice treated with unstimulated U937 monocytes 
plus MOvl8 IgE. Stimulation of monocytes with IL-4 is known to upregulate expression of 
CD23. This potential involvement of CD23 in mediating IgE-dependent tumour cell killing in 
vivo is significant, as associated with monocyte migration into tissue (or tumours) is their 
maturation into macrophages, a process which involves an upregulation in CD23 expression; 
tissue-dwelling macrophages may then be activated by ILA which stimulates further 
expression of CD23 (Gordon, 2003). 
Also shown in Chapter 5, was the ability of a pure population of peripheral blood 
eosinophils to effectively mediate IGROVI tumour cell killing. This is the first report of IgE- 
dependent tumour cell killing by freshly purified human peripheral blood eosinophils in vitro. 
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Previously, a number of mouse models of cancer have shown eosinophil-dependent tumour 
cell killing (Tepper et al., 1989; Tepper et al., 1992; Reali et al., 2001; Mattes et al., 2004) in 
response to IL-4. As discussed in section 1.1.1, eosinophils are commonly found to infiltrate 
human turnours. Together, these results suggest that it might be possible to manipulate these 
eosinophils in human patients; mast cells located in and around the tumour area would 
become sensitised with turnour-specific IgE following treatment, and cross-linking of FcF-Rl- 
bound IgE by turnour antigen would lead to mast cell degranulation, involving the release of 
IL-4 and IL-5. The inflammation associated with mast cell and subsequent eosinophil 
activation might then lead to recruitment of additional eosinophils and other effector cell 
types, including basophils, monocytes and T cells and an enhancement of the anti-tumour 
inflammatory response. In addition, IL-4 treatment of eosinophils may drive their 
differentiation and expansion into 'Th2-cytokine' producers (Pericle et al., 1994; Chen et al., 
2004); the effect of this would be further IL-4 production, and positive feedback. 
Unfortunately, like primary monocytes, purified human eosinophils were unable to 
mediate the improved survival of nude mice, as described in Chapter 6 of this thesis. As 
discussed in section 6.6, these negative results may relate to the failure of primary monocytes 
and eosinophils to survive in the mice for sufficient time to mediate an anti-tumour effector 
function. The in vivo survival of eosinophils may have been improved by co-injection of IL- 
5. The role of eosinophils in mediating killing of HUA tumour cells in the nude mouse model 
is currently being determined by Dr. S. Karagiannis, by assessing the ability of a population 
of eosinophil-supplemented PBMC plus MOv 18 IgE, compared to whole PBMC plus MOv 18 
IgE, in mediating the improved survival of HUA-tumour-bearing nude mice. 
In contrast to IgE, neither monocytes (U937 and primary) nor eosinophils were able 
to kill tumour cells in a MOvI8 IgGl-dependent manner, within the parameters used in 
experiments described in this Thesis. A suitable positive control is now required to confirm 
these results. Although it is possible that given the right conditions e. g., a greater effector to 
target ratio and increased duration of incubation of effector and target cells with MOvI8 
IgGl, that MOvI8 IgGl-dependent killing of IGROVI tumour cell targets may be increased, 
results of experiments described in this Thesis suggest that IgE is a more sensitive trigger than 
IgG for initiating ADCC of tumour cell targets. Similarly, treatment of HUA-bearing nude 
mice with PBMC plus MOvI8 IgE but not MOvI8 IgGl, was able to confer a survival 
advantage (Karagiannis et al., 2003). Tumour-bearing mice treated with human PBMC in 
combination with MOvl8 IgE survived for a mean of 40±17 days compared to 26±11 days 
for mice treated with PBMC alone, and 21±7 days for mice treated with PBMC and MOvl8 
IgG. This ability of PBMC plus MOvl8 IgE, but not MOvl8 IgG, to mediate improved 
survival of nude mice replicates (in a different system) those results obtained in Gould et al., 
Chapter 8 175 
1999, where MOvI8 IgE was more effective than MOvI8 IgG (in combination with PBMQ 
in prolonging inhibition of growth of a subcutaneously growing (IGROVI) ovarian cancer 
xenograft in SCID mice. These results provide further support for the ability of tumour- 
specific IgE to mediate a more effective anti-tumour immune response than IgG against 
tumour cells in vivo. 
One disadvantage of the nude mouse xenograft model described in Chapter 6 (and 
discussed above), is that the IgE-mediated anti-tumour immune response is limited to those 
human cellular effector cells injected, and by the duration for which these cells survive in the 
mice. Injected human effector cells included either PBMC (which lack eosinophils), an 
enriched population of monocytes, or a pure population of eosinophils. Therefore mast cells, 
the primary mediators of an allergic immune response, have been excluded. These 
experiments are therefore likely to underestimate the beneficial effects of treatment of cancer 
with MOvl8 IgE. The corollary, however, is that this model also does not provide an 
accurate assessment of the potential that treatment with MOv 18 IgE might cause anaphylactic 
shock. Therefore, two new, more physiological models were set up, each using an 
immunocompetent host, the 'humanised' hFcF-Rlcc transgenic mouse and the WAG rat. This 
involved the optimisation of the growth of the syngeneic FBP-expresssing tumour cell lines, 
C26tFR and CC53ltFR, to cause death of the animals within a suitable time frame. The 
ability of MOvl8 IgE to mediate beneficial effects on the survival of C26tFR turnour-bearing 
hFccRI Tg mice, and or CC53ltFR tumour-bearing WAG rats, can now be assessed. 
Furthermore, any toxicity that might be associated with MOvl8 IgE therapy can be studied. 
More detailed suggestions for preliminary experiments have been made in Chapter 6; in brief, 
the suggested experiments were intended to address both the efficacy of MOvl8 IgE 
treatment in mediating the improved survival of turnour-bearing animals, in addition to 
assessing the potential of MOv 18 IgE therapy in causing anaphylactic shock. 
Tumour-bearing WAG rats treated with MOv 18 IgE that show a survival advantage, 
could be studied for the presence of turnour-specific CD4' or CD8' T cells, and serum 
turnour-specific antibodies of different isoytpes, as a sign of the generation of an active anti- 
tumour immune response. As discussed in section 1.4.3, the acquisition of anti-tumour 
immunity by treatment with MOvl8 IgE has been proved in principle, in experiments 
described by Reali et al., 2001. Presentation of turnour-antigen is likely to be enhanced by 
treatment of turnours with IgE, in part due to the inflammatory environment created by 
activation of innate immune responses at the tumour site, but also due to the known role of 
both FccRI (expressed by Langerhans cells in tissues) and CD23 (on macrophages and B 
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cells) in antigen presentation. In addition CD23 expression on macrophages would be 
upregulated in response to IL-4, potentially amplifying presentation of tumour antigen further. 
Alongside in vivo studies of MOvI8 IgE activity, future work on this project should 
include further in vitro studies to determine the mechanisms by which each effector cell type 
mediates tumour cell killing, beyond simply stating 'cytotoxicity' or 'phagocytosis'. 
Tumour-cell killing mechanisms may include the secretion of oxidative metabolites, nitric 
oxide or cytokines such as TNF-cc. Furthermore, it is necessary to determine which IgE 
receptor it is, FcF-Rl and / or CD23, through which killing is triggered with each cell type, to 
be sure that at least one of these receptors is involved in mediating tumour-cell death, and to 
exclude a role for a third IgE receptor (e. g., F-BP, briefly introduced in section 1.3.8). It would 
also be useful to determine the capacity of both mast cells and basophils, primary mediators 
of the allergic response, to act as MOvI8 IgE-dependent effectors of tumour cell killing in 
vitro. Furthermore, the capacity of different cell type combinations, e. g., basophils and 
monocytes, to mediate MOv 18 IgE-dependent tumour cell killing, could also be studied. 
Experiments described in this Thesis, provide support, further to that provided by 
Gould et al., 1999 and Karagiannis et al., 2003, for the proposal that tumour-specific IgE 
antibodies might be efficaciously used for the immunotherapy of cancer. Results of 
experiments described in this thesis suggest that IgE receptor-expressing cells, including 
monocytes and eosinophils (which infiltrate tumours), may be conferred with turnouricidal 
activity when activated with a tumour-specific IgE antibody. Harnessing this arm of the 
immune system and re-directing it towards tumour cells, may result in the successful 
induction of a passive immune response against turnours of solid tissues. Treatment of cancer 
with tumour-specific monoclonal antibodies allows for the specific killing of tumour cells 
with minimal cross-reactivity with normal cells; this is in great contrast to the unwanted cell 
killing occurring with traditional chemotherapy and radiation therapy. Manipulation of the 
predominantly tissue-based IgE-mediated immune response by use of tumour-specific 
antibodies of the IgE isotype may improve the success of monoclonal antibody therapy for the 
treatment of solid turnours, as long as the side effects can be shown to be preferable to the 
cancer itself. 
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8.2 Imolications of the high affinity interaction between IgE and FcERI 
As discussed in Chapter I of this Thesis, the high affinity with which IgE binds FcF-Rl 
is proposed to be responsible for the ability of IgE to tenaciously bind FcERI-expressing mast 
cells in tissues, and basophils in blood. In this way, the allergen-specific IgE produced by B 
cells of allergic individuals is able to sensitise these cell types, leaving the individual 
essentially permanently primed to make an immediate response upon allergen challenge. In 
Chapter 7 of this Thesis, experiments were performed to see if IgE could be made less 
anaphylactogenic by reducing its affinity for FcF_RI; it was expected that the lower affinity of 
R334S IgE for FcF_RI would cause it to diffuse out of the fissue faster, correlating with a 
reduction in anaphylaxis upon antigen challenge. To this end, Dr. Jianguo Shi cloned and 
expressed a human anti-NP IgE which was mutated in both its CO domains (an arginine for 
serine substitution at position 334, R334S), to give it a 33-fold reduced affinity FcF_Rl, 
compared to wild type IgE. 'Humanised' FcFRI transgenic mice (which bind human IgE) 
were then sensitised in one ear with wild type IgE, and in the other with R334S IgE, for 
binding to resident mast cells; mice received intravenous antigen challenge at fimepoints 
thereafter. 
These experiments show that despite there being identical amounts of wild type and 
R334S anti-NP IgE in the ears of these mice, the intensity of anaphylaxis occurring in mouse 
ears sensitised with R334S anti-NP IgE was consistently lower than in those sensitised with 
wild type IgE. These results suggest that the intensity of the (mast cell) response, mediated 
by cross-linking of FcFRI at the cell surface, is proportional to the affinity of the lgE+cF_RI 
interaction. These are particularly interesting results, which support the proposal that IgE 
might be more successfully used than IgG in immunotherapy of cancer. The IgE-receptor- 
expressing cells found in and around tumour areas might be triggered to kill tumour cells by 
sensitisation with relatively less antibody (IgE) than would be required for another antibody 
isotype (IgG), which binds its Fc receptors with lower affinity. 
It is interesting to note that studies are currently underway to enhance the affinity of 
IgG binding to FcyRIII, relative to FcyRII, the rationale for this work, is that if tumour- 
specific antibodies of the IgG isotypc could be manipulated to bind preferentially to the 
stimulatory receptor FcyRlll over FcyRIlb, then they may be able to trigger effector cells 
expressing both these FcyR, to mediate more effective tumour cell killing responses (reviewed 
in Weiner and Carter, 2005). Clynes er al., 2000, have used mouse models to demonstrate the 
benefits of reducing FcyRllb involvement in IgG-mediated anti-tumour immune responses. 
These studies assessed the efficacy of Rituximab and Trastuzurnab in enhancing the survival 
of lumour-bearing mice either deficient, or not, in FcyRllb, Results showed a survival 
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advantage in mice treated with either anti-cancer antibody, in FcyRII-deficient mice, over 
wild type controls. Interestingly, it was thought that the increased effector cell activity was 
contributed primarily by monocytes (which express both FcyRII and FcyRIII), highlighting 
the importance of monocyte manipulation in antibody-mediated tumour cell killing, a cell 
type which may be more successfully manipulated using IgE. 
These results also have unexpected, but highly significant implications for the design 
of a therapeutic agent for the treatment of allergy and asthma. The lgE-FcERI interaction 
represents a fundamental therapeutic target for inhibition of the allergic immune response. 
The beneficial effects of inhibiting the interaction between IgE and FcF-Rl, have recently been 
demonstrated with the therapeutic anti-IgE antibody Omalizumab, by its ability to abolish the 
symptoms of allergy and asthma. However, a major barrier to the successful production of 
such a therapeutic agent has been the requirement for it to compete with the extremely high 
affinity of the interaction between IgE and FcFRl. Moreover, it must do so with such efficacy 
that even a small number of FcF-RI do not become occupied with IgE; the formation of FcCRI 
dimers has been shown to be sufficient for mast cell activation (Segal, 1977). Work described 
in Chapter 7 of this Thesis has shown that it may not in fact be necessary to completely block 
IgE binding to FcFRI, but only to reduce the affinity of the interaction by approximately 33- 
fold to achieve a reduction in the intensity of IgE-mediated immune responses in vivo. As 
discussed in Chapter 7, the design of a small molecule allosteric inhibitor of IgE may be one 
way by which the affinity of the interaction can be suitably decreased. The advantage of a 
small molecule allosteric inhibitor compared to the therapeutic antibody, Omalizumab, is that 
it would be cheaper to produce and also able to be administered orally or topically; it could 
therefore be widely available to all allergy sufferers. 
It would be interesting to determine the mechanism by which IgE binding to Fcrr-RI 
with lower affinity leads to anaphylactic responses of reduced intensity. The faster off-rate of 
R334S compared to wild type IgE from FccRIcc (shown in Table 7.1) suggests that in the 
tissue R334S anti-NP IgE might be associating, dissociating and re-associating faster than 
wild type anti-NP IgE does with FcF-RI; this may be responsible for the reduced intensity of 
anaphylaxis through a kinetic proof reading mechanism (as speculated in section 7.8). If this 
were the case, the reduced intensity of anaphylaxis could be explained by an inability of 
R334S anti-NP IgE to hold together the FcFRl aggregate for sufficient time for the response 
to go to completion (full degranulation of the mast cell) (Torigoe et al., 1997 and 1998). 
In vitro experiments could be used to determine whether or not a 'kinetic 
proofreading' mechanism is the reason for the reduced intensity of anaphylactic responses 
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seen when mast cells are sensitised with lower affinity IgE. One method that might be used to 
test this, is to use either a cell line expressing human FccRI (e. g., RBL cells transfected with 
human FcF_Rl a-chain) or bone marrow derived mast cells from hFcF_Rl Tg mice, to compare 
hexosaminidase release following aggregation of an equal number of FcFRl at the cell surface 
with R334S compared to wild type IgE. Alternatively, following aggregation of (an equal 
number of) FcF_Rl by either R334S or wild type IgE, the various components of the 
downstream signalling pathway could be immunoprecipitated, and their phosphorylation 
status compared. Experiments of this type are currently being performed by Dr. James Hunt, 
to test the kinetic proofreading hypothesis. 
If indeed the reduced intensity of anaphylaxis triggered by a lower-affinity IgE 
(R334S) was based on a mechanism of kinetic proofreading, another potential way of 
manipulating this mechanism as a therapy for allergy and asthma, may be to treat patients 
with a low affinity IgE (such as R334S IgE) with an irrelevant specificity, such that it will 
persist in the tissue and quickly associate and dissociate from FcF_Rl on mast cells faster than 
wild type allergen-specific IgE. The effect of this may be the 'hoarding' of Lyn kinase, 
preventing wild type IgE signalling responses from going to completion in response to 
allergen challenge. One disadvantage of such treatment however, is likely to be an 
upregulation of FcF_RI on the cells in response to the higher serum IgE levels. 
8.3 Final comment 
In section 1.5 of Chapter 1, the aims of this Thesis were indicated as being two-fold: 
> To assess the efficacy of M008 IgE in triggering immune responses against 
turnours, both in vitro and in vivo. 
> To address how the affinity of the IgE-FcF-Rl interaction impacts on the intensity of 
IgE-mediated immune responses in vivo. 
Both of these aims have been accomplished. As a result, this Thesis illustrates that 
tumour-specific IgE antibodies might be successfully used to harness an immune response, 
typically encountered towards innocuous antigens in allergic individuals, to instead kill 
turnour cells in cancer patients. 
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